Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:panobinostat
go back to main search page
Accession:CHEBI:85990 term browser browse the term
Definition:A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Synonyms:exact_synonym: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
 related_synonym: Formula=C21H23N3O2;   InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+;   InChIKey=FPOHNWQLNRZRFC-ZHACJKMWSA-N;   LBH 589;   LBH589;   SMILES=Cc1[nH]c2ccccc2c1CCNCc1ccc(\\C=C\\C(=O)NO)cc1
 alt_id: MESH:C496932
 xref: CAS:404950-80-7;   Drug_Central:4682;   KEGG:D10319
 xref_mesh: MESH:C496932
 xref: PMID:25305451;   PMID:25377157;   PMID:25410127;   PMID:25458954;   PMID:25572329;   PMID:25608569;   PMID:25612941;   PMID:25628765;   PMID:25710456;   PMID:25802326;   PMID:25837990;   PMID:25870990;   PMID:25904215;   PMID:25939707;   PMID:25944617;   PMID:26000292;   PMID:26030093;   PMID:26051506;   Reaxys:12257756;   Wikipedia:Panobinostat
 cyclic_relationship: is_conjugate_base_of CHEBI:85992


show annotations for term's descendants           Sort by:
panobinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2ml1 alpha-2-macroglobulin-like 1 decreases expression ISO Panobinostat results in decreased expression of OVOS2 mRNA CTD PMID:26272509 NCBI chr 4:163,501,210...163,543,419
Ensembl chr 4:163,501,585...163,543,506 		JBrowse link
G Abat 4-aminobutyrate aminotransferase increases expression
multiple interactions 		ISO panobinostat results in increased expression of ABAT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474 		JBrowse link
G Abca5 ATP binding cassette subfamily A member 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA
panobinostat results in decreased expression of ABCA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:95,739,610...95,808,633
Ensembl chr10:95,739,610...95,808,424 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA CTD PMID:27188386 NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493 		JBrowse link
G Abhd14a abhydrolase domain containing 14A decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:115,957,853...115,965,697
Ensembl chr 8:115,957,858...115,965,697 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA CTD PMID:21791302 NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846 		JBrowse link
G Acad11 acyl-CoA dehydrogenase family, member 11 increases expression ISO panobinostat results in increased expression of ACAD11 mRNA CTD PMID:26272509 NCBI chr 8:113,560,142...113,625,346
Ensembl chr 8:113,560,196...113,625,352 		JBrowse link
G Ackr3 atypical chemokine receptor 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ACKR3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214 		JBrowse link
G Acp3 acid phosphatase 3 increases expression
multiple interactions 		ISO Panobinostat results in increased expression of ACP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:113,784,372...113,833,033
Ensembl chr 8:113,785,032...113,833,033 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA
panobinostat results in increased expression of ACSL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023 		JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 increases expression ISO panobinostat results in increased expression of ACSM3 mRNA CTD PMID:26272509 NCBI chr 1:183,564,652...183,591,328
Ensembl chr 1:183,564,635...183,591,437 		JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression ISO Panobinostat results in decreased expression of ACTA2 mRNA CTD PMID:30481203 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Ada adenosine deaminase multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA
panobinostat results in decreased expression of ADA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293 		JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552 		JBrowse link
G Adam22 ADAM metallopeptidase domain 22 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA
panobinostat results in decreased expression of ADAM22 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:26,670,984...26,925,843
Ensembl chr 4:26,671,112...26,925,843 		JBrowse link
G Adam28 ADAM metallopeptidase domain 28 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA
panobinostat results in increased expression of ADAM28 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:50,184,286...50,250,605
Ensembl chr15:50,127,516...50,250,526 		JBrowse link
G Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA
panobinostat results in increased expression of ADAMTS15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:37,566,064...37,589,446
Ensembl chr 8:37,566,065...37,589,446 		JBrowse link
G Adamts17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA CTD PMID:27188386 NCBI chr 1:129,856,062...130,178,430
Ensembl chr 1:129,856,074...130,176,844 		JBrowse link
G Adamts19 ADAM metallopeptidase with thrombospondin type 1 motif, 19 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA
panobinostat results in increased expression of ADAMTS19 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:54,545,357...54,729,184
Ensembl chr18:54,545,357...54,729,181 		JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ADCYAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383 		JBrowse link
G Adcyap1r1 ADCYAP receptor type I multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA
panobinostat results in increased expression of ADCYAP1R1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:85,924,171...85,972,973
Ensembl chr 4:85,924,100...85,972,973 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA
panobinostat results in decreased expression of ADGRG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124 		JBrowse link
G Adgrg6 adhesion G protein-coupled receptor G6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA CTD PMID:27188386 NCBI chr 1:10,633,004...10,774,685
Ensembl chr 1:10,631,829...10,774,023 		JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ADGRL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:26,690,891...27,458,132
Ensembl chr14:26,722,194...27,280,418 		JBrowse link
G Adgrv1 adhesion G protein-coupled receptor V1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA
panobinostat results in decreased expression of ADGRV1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:13,067,149...13,647,407
Ensembl chr 2:13,067,150...13,647,372 		JBrowse link
G Adra2a adrenoceptor alpha 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA CTD PMID:27188386 NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871 		JBrowse link
G Afap1l1 actin filament associated protein 1-like 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of AFAP1L1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:55,183,786...55,244,174
Ensembl chr18:57,454,121...57,514,480 		JBrowse link
G Ahnak AHNAK nucleoprotein increases expression
multiple interactions 		ISO panobinostat results in increased expression of AHNAK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675 		JBrowse link
G Ajap1 adherens junctions associated protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA
panobinostat results in increased expression of AJAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:169,190,477...169,302,938
Ensembl chr 5:169,190,477...169,304,515 		JBrowse link
G Akap12 A-kinase anchoring protein 12 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA
panobinostat results in decreased expression of AKAP12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:43,135,515...43,225,245
Ensembl chr 1:43,199,008...43,225,557 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein CTD PMID:18445700 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Alcam activated leukocyte cell adhesion molecule increases expression
multiple interactions 		ISO panobinostat results in increased expression of ALCAM mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876 		JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ALDH1A2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883 		JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777 		JBrowse link
G Aldh1l2 aldehyde dehydrogenase 1 family, member L2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398 		JBrowse link
G Alkal2 ALK and LTK ligand 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA
panobinostat results in increased expression of ALKAL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:53,223,204...53,232,794
Ensembl chr 6:53,223,341...53,233,011 		JBrowse link
G Alx1 ALX homeobox 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ALX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:40,044,185...40,063,778
Ensembl chr 7:40,033,676...40,063,778 		JBrowse link
G Amer2 APC membrane recruitment protein 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of AMER2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:34,525,352...34,535,660
Ensembl chr15:38,701,657...38,705,633 		JBrowse link
G Amigo2 adhesion molecule with Ig like domain 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA
panobinostat results in increased expression of AMIGO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218 		JBrowse link
G Ang angiogenin multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA CTD PMID:27188386 NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106 		JBrowse link
G Angpt1 angiopoietin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA
panobinostat results in increased expression of ANGPT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696 		JBrowse link
G Angpt2 angiopoietin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA
panobinostat results in increased expression of ANGPT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239 		JBrowse link
G Ankh ANKH inorganic pyrophosphate transport regulator multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA
panobinostat results in increased expression of ANKH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699 		JBrowse link
G Ankrd1 ankyrin repeat domain 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA
panobinostat results in increased expression of ANKRD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:243,228,460...243,237,014
Ensembl chr 1:243,228,448...243,263,751 		JBrowse link
G Ankrd22 ankyrin repeat domain 22 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA CTD PMID:27188386 NCBI chr 1:241,052,235...241,083,737
Ensembl chr 1:241,052,237...241,105,559 		JBrowse link
G Anks1b ankyrin repeat and sterile alpha motif domain containing 1B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA CTD PMID:27188386 NCBI chr 7:26,200,649...27,366,552
Ensembl chr 7:26,201,240...27,364,943 		JBrowse link
G Ano3 anoctamin 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA CTD PMID:27188386 NCBI chr 3:117,690,242...118,004,695
Ensembl chr 3:117,692,103...118,004,675 		JBrowse link
G Anxa1 annexin A1 increases expression ISO panobinostat results in increased expression of ANXA1 mRNA CTD PMID:26272509 NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831 		JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631 		JBrowse link
G Anxa3 annexin A3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA
panobinostat results in increased expression of ANXA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:13,031,675...13,085,678
Ensembl chr14:13,023,762...13,085,849 		JBrowse link
G Anxa9 annexin A9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA CTD PMID:27188386 NCBI chr 2:185,562,174...185,572,560
Ensembl chr 2:185,562,174...185,572,560 		JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of AOX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980 		JBrowse link
G Ap1m2 adaptor related protein complex 1 subunit mu 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA
panobinostat results in increased expression of AP1M2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:28,114,748...28,132,767
Ensembl chr 8:28,114,748...28,132,642 		JBrowse link
G Ap5s1 adaptor related protein complex 5 subunit sigma 1 decreases expression ISO Panobinostat results in decreased expression of AP5S1 mRNA CTD PMID:33770205 NCBI chr 3:118,429,618...118,432,929
Ensembl chr 3:138,882,634...138,888,899 		JBrowse link
G Apela apelin receptor early endogenous ligand increases expression ISO Panobinostat results in increased expression of APELA mRNA CTD PMID:26272509 NCBI chr16:29,460,855...29,469,962
Ensembl chr16:29,460,812...29,469,955 		JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ARAP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:50,921,323...51,120,972
Ensembl chr14:50,921,713...51,120,962 		JBrowse link
G Arfgef3 ARFGEF family member 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA
panobinostat results in decreased expression of ARFGEF3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:15,058,574...15,223,742
Ensembl chr 1:15,058,579...15,223,742 		JBrowse link
G Arhgap15 Rho GTPase activating protein 15 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA
panobinostat results in decreased expression of ARHGAP15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:48,382,945...49,002,213
Ensembl chr 3:48,382,904...49,011,378 		JBrowse link
G Arhgap18 Rho GTPase activating protein 18 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA
panobinostat results in increased expression of ARHGAP18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:20,222,948...20,456,827
Ensembl chr 1:20,222,954...20,456,670 		JBrowse link
G Arhgap24 Rho GTPase activating protein 24 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA CTD PMID:27188386 NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950 		JBrowse link
G Arhgap31 Rho GTPase activating protein 31 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA] CTD PMID:26733615 NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076 		JBrowse link
G Arhgap5 Rho GTPase activating protein 5 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ARHGAP5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636 		JBrowse link
G Arhgap6 Rho GTPase activating protein 6 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ARHGAP6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:28,525,912...29,062,344
Ensembl chr  X:28,525,917...29,061,244 		JBrowse link
G Arid2 AT-rich interaction domain 2 affects expression
multiple interactions 		ISO panobinostat affects the expression of ARID2 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARID2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA] 		CTD PMID:26733615 NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:129,324,137...129,443,187 		JBrowse link
G Arid5b AT-rich interaction domain 5B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA
panobinostat results in increased expression of ARID5B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686 		JBrowse link
G Armh4 armadillo-like helical domain containing 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA
panobinostat results in decreased expression of ARMH4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:22,975,895...23,076,986
Ensembl chr15:25,455,297...25,556,534 		JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ARNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997 		JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859 		JBrowse link
G Arx aristaless related homeobox decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ARX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:62,010,097...62,022,009
Ensembl chr  X:62,010,097...62,022,002 		JBrowse link
G As3mt arsenite methyltransferase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA CTD PMID:21791302 NCBI chr 1:255,536,879...255,569,245
Ensembl chr 1:255,537,109...255,569,249 		JBrowse link
G Asb9 ankyrin repeat and SOCS box-containing 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA CTD PMID:27188386 NCBI chr  X:33,588,484...33,633,285
Ensembl chr  X:33,588,484...33,624,397 		JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA CTD PMID:27188386 NCBI chr 7:23,790,642...23,793,509
Ensembl chr 7:23,790,360...23,798,231 		JBrowse link
G Asic1 acid sensing ion channel subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA CTD PMID:27188386 NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:132,698,723...132,707,832 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions 		ISO panobinostat results in increased expression of ASNS mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050 		JBrowse link
G Ass1 argininosuccinate synthase 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ASS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627 		JBrowse link
G Astn1 astrotactin 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:73,070,754...73,388,902
Ensembl chr13:73,071,267...73,388,895 		JBrowse link
G Astn2 astrotactin 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ASTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:83,772,988...84,759,439
Ensembl chr 5:83,773,633...84,759,485 		JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO panobinostat results in increased expression of ATF3 mRNA CTD PMID:26272509 NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750 		JBrowse link
G Atp13a4 ATPase 13A4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA CTD PMID:27188386 NCBI chr11:84,727,014...84,864,747
Ensembl chr11:84,731,041...84,864,747 		JBrowse link
G Atp23 ATP23 metallopeptidase and ATP synthase assembly factor homolog increases expression
multiple interactions 		ISO panobinostat results in increased expression of ATP23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:64,600,100...64,615,240
Ensembl chr 7:64,600,100...64,615,392 		JBrowse link
G Atp2c2 ATPase secretory pathway Ca2+ transporting 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA
panobinostat results in increased expression of ATP2C2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:64,662,729...64,719,998
Ensembl chr19:64,662,715...64,719,996 		JBrowse link
G Atp6v0a2 ATPase H+ transporting V0 subunit a2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA
panobinostat results in decreased expression of ATP6V0A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:37,608,211...37,640,860
Ensembl chr12:37,472,813...37,640,860 		JBrowse link
G Atp6v0a4 ATPase H+ transporting V0 subunit a4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA
panobinostat results in increased expression of ATP6V0A4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:67,727,145...67,809,092
Ensembl chr 4:67,727,145...67,809,092 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA
panobinostat results in increased expression of ATP6V0D2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:38,133,158...38,182,245 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
panobinostat results in increased expression of ATP8B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027 		JBrowse link
G Atp8b3 ATPase phospholipid transporting 8B3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA
panobinostat results in increased expression of ATP8B3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:9,175,544...9,195,449
Ensembl chr 7:9,826,275...9,846,195 		JBrowse link
G Atp9a ATPase phospholipid transporting 9A (putative) multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA
panobinostat results in decreased expression of ATP9A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:177,779,203...177,886,431
Ensembl chr 3:177,779,203...178,023,661 		JBrowse link
G Axin2 axin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA
panobinostat results in increased expression of AXIN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:94,393,379...94,426,579
Ensembl chr10:94,395,909...94,426,575 		JBrowse link
G B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA
panobinostat results in increased expression of B3GNT7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:94,404,197...94,408,148
Ensembl chr 9:94,404,135...94,408,147 		JBrowse link
G Bace2 beta-secretase 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of BACE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:50,176,852...50,258,948
Ensembl chr11:50,176,621...50,259,008 		JBrowse link
G Bag2 BAG cochaperone 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
panobinostat results in increased expression of BAG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752 		JBrowse link
G Bag5 BAG cochaperone 5 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA CTD PMID:21791302 NCBI chr 6:136,589,623...136,593,278
Ensembl chr 6:136,584,741...136,598,492 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions 		ISO panobinostat results in increased expression of BAMBI mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:58,816,438...58,821,003
Ensembl chr17:58,816,442...58,821,247 		JBrowse link
G Batf3 basic leucine zipper ATF-like transcription factor 3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA CTD PMID:21791302 NCBI chr13:105,220,782...105,232,365
Ensembl chr13:105,220,390...105,232,369 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat] CTD PMID:18445700 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Baz1a bromodomain adjacent to zinc finger domain, 1A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA
panobinostat results in increased expression of BAZ1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:78,124,872...78,247,672
Ensembl chr 6:78,124,872...78,247,648 		JBrowse link
G Bcl11a BCL11 transcription factor A increases expression
multiple interactions 		ISO panobinostat results in increased expression of BCL11A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:102,230,147...102,325,289
Ensembl chr14:102,231,113...102,325,623 		JBrowse link
G Bcl2 BCL2, apoptosis regulator affects expression
decreases expression
multiple interactions 		ISO panobinostat affects the expression of BCL2 mRNA
panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA] 		CTD PMID:24435446 PMID:26272509 PMID:26733615 PMID:27188386 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
decreases expression
increases expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein]
panobinostat results in decreased expression of BCL2L11 mRNA
panobinostat results in increased expression of BCL2L11 protein 		CTD PMID:24435446 PMID:26272509 PMID:27188386 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Begain brain-enriched guanylate kinase-associated multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA
panobinostat results in decreased expression of BEGAIN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:133,708,010...133,744,264
Ensembl chr 6:133,708,007...133,744,526 		JBrowse link
G Best4 bestrophin 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA
panobinostat results in decreased expression of BEST4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,858,774...135,865,624
Ensembl chr 5:135,860,018...135,863,707 		JBrowse link
G Bex5l1 brain expressed X-linked 5 like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA
panobinostat results in increased expression of BEX5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:119,181,370...119,202,904 JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression
multiple interactions 		ISO panobinostat results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783 		JBrowse link
G Bhlhe41 basic helix-loop-helix family, member e41 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA CTD PMID:21791302 NCBI chr 4:180,565,003...180,569,415
Ensembl chr 4:180,565,003...180,569,355 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO Panobinostat results in decreased expression of BIRC5 mRNA CTD PMID:30481203 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Bmal2 basic helix-loop-helix ARNT like 2 multiple interactions ISO [Cisplatin co-treated with Panobinostat] affects the expression of BMAL2 mRNA CTD PMID:21791302 NCBI chr 4:181,429,097...181,478,384
Ensembl chr 4:181,430,159...181,478,382 		JBrowse link
G Bmf Bcl2 modifying factor increases expression ISO Panobinostat results in increased expression of BMF mRNA CTD PMID:33770205 NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258 		JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA
panobinostat results in increased expression of BMP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760 		JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA
panobinostat results in increased expression of BMP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172 		JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
panobinostat results in increased expression of BMP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189 		JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA
panobinostat results in increased expression of BMP7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137 		JBrowse link
G Bmper BMP-binding endothelial regulator multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA
panobinostat results in increased expression of BMPER mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359 		JBrowse link
G Bmpr1b bone morphogenetic protein receptor type 1B multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of BMPR1B mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BMPR1B mRNA] CTD PMID:26733615 NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311 		JBrowse link
G Bnc2 basonuclin zinc finger protein 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of BNC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:103,724,934...104,061,890
Ensembl chr 5:103,724,934...104,125,428 		JBrowse link
G Bnipl BCL2 interacting protein like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA
panobinostat results in increased expression of BNIPL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:185,507,591...185,519,415
Ensembl chr 2:185,507,593...185,517,582 		JBrowse link
G Boc BOC cell adhesion associated, oncogene regulated multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA
panobinostat results in increased expression of BOC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:69,628,703...69,704,009
Ensembl chr11:69,628,660...69,704,004 		JBrowse link
G Bri3bp Bri3 binding protein increases expression ISO panobinostat results in increased expression of BRI3BP mRNA CTD PMID:26272509 NCBI chr12:31,176,742...31,188,563
Ensembl chr12:36,838,098...36,849,919 		JBrowse link
G Brinp1 BMP/retinoic acid inducible neural specific 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of BRINP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:87,363,621...87,565,580
Ensembl chr 5:87,364,050...87,508,256 		JBrowse link
G Brip1 BRCA1 interacting DNA helicase 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA CTD PMID:27188386 NCBI chr10:71,402,035...71,528,083
Ensembl chr10:71,401,151...71,575,206 		JBrowse link
G Bspry B-box and SPRY domain containing increases expression
multiple interactions 		ISO panobinostat results in increased expression of BSPRY mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:80,942,974...80,965,157
Ensembl chr 5:80,942,979...80,988,154 		JBrowse link
G C11h3orf52 similar to human chromosome 3 open reading frame 52 increases expression
multiple interactions 		ISO panobinostat results in increased expression of C3ORF52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:55,166,986...55,192,273
Ensembl chr11:68,629,570...68,654,868 		JBrowse link
G C13h1orf53 similar to human chromosome 1 open reading frame 53 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA
panobinostat results in decreased expression of C1ORF53 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:50,413,785...50,418,974
Ensembl chr13:52,965,244...52,970,607 		JBrowse link
G C19h16orf87 similar to human chromosome 16 open reading frame 87 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA CTD PMID:27188386 NCBI chr19:21,626,390...21,653,869
Ensembl chr19:37,799,799...37,827,452 		JBrowse link
G C1galt1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA
panobinostat results in increased expression of C1GALT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:36,894,440...36,932,434
Ensembl chr 4:36,894,488...36,932,441 		JBrowse link
G C1h19orf33 similar to human chromosome 19 open reading frame 33 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA
Panobinostat results in increased expression of C19ORF33 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:93,677,305...93,678,141
Ensembl chr 1:93,677,305...93,678,141 		JBrowse link
G C1qtnf4 C1q and TNF related 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA
panobinostat results in decreased expression of C1QTNF4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:97,310,220...97,328,818
Ensembl chr 3:97,327,670...97,342,587 		JBrowse link
G C2cd2 C2 calcium-dependent domain containing 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA
panobinostat results in decreased expression of C2CD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016 		JBrowse link
G C2h3orf33 similar to human chromosome 3 open reading frame 33 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of C3ORF33 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:150,522,758...150,554,007
Ensembl chr 2:150,530,231...150,554,055 		JBrowse link
G C3 complement C3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of C3 mRNA CTD PMID:21791302 NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339 		JBrowse link
G C3h11orf96 similar to human chromosome 11 open reading frame 96 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA
panobinostat results in increased expression of C11ORF96 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:100,351,199...100,378,346 		JBrowse link
G C4h2orf68 similar to human chromosome 2 open reading frame 68 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:104,402,553...104,408,317
Ensembl chr 4:105,960,751...105,966,508 		JBrowse link
G C5h8orf34 similar to human chromosome 8 open reading frame 34 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA
panobinostat results in increased expression of C8ORF34 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:7,237,968...7,777,119
Ensembl chr 5:12,021,007...12,559,772 		JBrowse link
G C7h12orf56 similar to human chromosome 12 open reading frame 56 increases expression
multiple interactions 		ISO panobinostat results in increased expression of C12ORF56 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:59,055,283...59,106,900
Ensembl chr 7:59,056,310...59,106,407 		JBrowse link
G C8h11orf52 similar to human chromosome 11 open reading frame 52 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA CTD PMID:27188386 NCBI chr 8:59,977,717...59,984,706
Ensembl chr 8:59,976,623...59,990,901 		JBrowse link
G C9h6orf141 similar to human chromosome 6 open reading frame 141 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of C6ORF141 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:20,024,916...20,029,094
Ensembl chr 9:27,521,466...27,525,644 		JBrowse link
G Ca12 carbonic anhydrase 12 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CA12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465 		JBrowse link
G Ca13 carbonic anhydrase 13 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA CTD PMID:27188386 NCBI chr 2:88,649,643...88,680,763
Ensembl chr 2:88,649,625...88,680,763 		JBrowse link
G Ca4 carbonic anhydrase 4 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916 		JBrowse link
G Ca8 carbonic anhydrase 8 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:26,102,767...26,199,819
Ensembl chr 5:26,102,813...26,199,796 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CACNA2D1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:19,902,324...20,330,287
Ensembl chr 4:19,905,764...20,330,147 		JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CACNB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:82,473,097...82,818,564
Ensembl chr17:82,473,129...82,818,564 		JBrowse link
G Cadm4 cell adhesion molecule 4 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CADM4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:80,075,163...80,097,423
Ensembl chr 1:89,202,554...89,225,345 		JBrowse link
G Calb2 calbindin 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CALB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:55,023,849...55,050,858
Ensembl chr19:55,023,838...55,057,952 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases expression
multiple interactions 		ISO panobinostat results in increased expression of CALCA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529 		JBrowse link
G Capn6 calpain 6 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CAPN6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:112,177,467...112,202,178
Ensembl chr  X:112,177,467...112,202,178 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [resveratrol co-treated with panobinostat] results in increased cleavage of CASP3 protein CTD PMID:22923501 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp8 caspase 8 multiple interactions
increases expression 		ISO [Cisplatin co-treated with Panobinostat] affects the expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [Panobinostat co-treated with Vorinostat] results in increased cleavage of CASP8 protein; [Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein; CASP8 protein affects the susceptibility to [Resveratrol co-treated with Panobinostat]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein]
panobinostat results in increased expression of CASP8 mRNA 		CTD PMID:21791302 PMID:22923501 PMID:26272509 PMID:27188386 NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO [resveratrol co-treated with panobinostat] results in increased cleavage of CASP9 protein CTD PMID:22923501 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cblc Cbl proto-oncogene C increases expression
multiple interactions 		ISO panobinostat results in increased expression of CBLC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:88,567,930...88,584,709
Ensembl chr 1:88,567,932...88,584,709 		JBrowse link
G Cc2d2a coiled-coil and C2 domain containing 2A multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CC2D2A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CC2D2A mRNA] CTD PMID:26733615 NCBI chr14:71,563,835...71,648,352
Ensembl chr14:71,563,835...71,648,331 		JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:58,963,196...58,992,962
Ensembl chr 4:58,962,908...58,992,975 		JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,404,526...100,411,112
Ensembl chr 6:106,134,333...106,144,441 		JBrowse link
G Ccdc69 coiled-coil domain containing 69 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA
panobinostat results in increased expression of CCDC69 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:39,673,984...39,701,080
Ensembl chr10:39,673,985...39,700,579 		JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CCKBR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745 		JBrowse link
G Ccl26 C-C motif chemokine ligand 26 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CCL26 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:26,745,972...26,750,924 JBrowse link
G Ccn3 cellular communication network factor 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA CTD PMID:27188386 NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581 		JBrowse link
G Ccng2 cyclin G2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206 		JBrowse link
G Ccnt2 cyclin T2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CCNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:41,804,007...41,845,641
Ensembl chr13:41,804,046...41,844,488 		JBrowse link
G Cd200 Cd200 molecule multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CD200 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CD200 mRNA] CTD PMID:26733615 NCBI chr11:68,916,200...68,943,570
Ensembl chr11:68,916,224...68,943,569 		JBrowse link
G Cd24 CD24 molecule multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA
panobinostat results in increased expression of CD24 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785 		JBrowse link
G Cd274 CD274 molecule increases expression ISO Panobinostat results in increased expression of CD274 protein CTD PMID:26775640 NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951 		JBrowse link
G Cd44 CD44 molecule increases expression
multiple interactions 		ISO panobinostat results in increased expression of CD44 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424 		JBrowse link
G Cd52 CD52 molecule increases expression
multiple interactions 		ISO panobinostat results in increased expression of CD52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086 		JBrowse link
G Cd55 CD55 molecule (Cromer blood group) multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA
panobinostat results in increased expression of CD55 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107 		JBrowse link
G Cd74 CD74 molecule multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA
panobinostat results in increased expression of CD74 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410 		JBrowse link
G Cd9 CD9 molecule multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
panobinostat results in increased expression of CD9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444 		JBrowse link
G Cdc42ep3 CDC42 effector protein 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA
panobinostat results in decreased expression of CDC42EP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:21,461,762...21,508,540 		JBrowse link
G Cdc42ep5 CDC42 effector protein 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA
panobinostat results in increased expression of CDC42EP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:70,035,921...70,038,990 JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
panobinostat results in increased expression of CDH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh10 cadherin 10 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA
panobinostat results in increased expression of CDH10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:70,355,521...70,577,880
Ensembl chr 2:70,357,217...70,578,332 		JBrowse link
G Cdh18 cadherin 18 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CDH18 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:74,548,681...75,550,720
Ensembl chr 2:75,075,595...75,550,720 		JBrowse link
G Cdh2 cadherin 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA
panobinostat results in decreased expression of CDH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288 		JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:51,303,414...51,353,900
Ensembl chr19:51,300,083...51,354,257 		JBrowse link
G Cdh8 cadherin 8 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CDH8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:5,494,552...5,901,950
Ensembl chr19:5,500,221...5,902,627 		JBrowse link
G Cdk19 cyclin-dependent kinase 19 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA CTD PMID:27188386 NCBI chr20:45,324,911...45,465,121
Ensembl chr20:45,324,862...45,465,121 		JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 decreases expression ISO Panobinostat results in decreased expression of CDK5R1 mRNA CTD PMID:33770205 NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
increases expression 		ISO [(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of CDK6 protein; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA
panobinostat results in increased expression of CDK6 mRNA 		CTD PMID:24435446 PMID:26272509 PMID:27188386 NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO panobinostat results in increased expression of CDKN1A protein CTD PMID:18445700 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression ISO panobinostat results in increased expression of CDKN1B protein CTD PMID:18445700 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cdon cell adhesion associated, oncogene regulated increases expression
multiple interactions 		ISO panobinostat results in increased expression of CDON mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA
panobinostat results in increased expression of CEBPB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression
multiple interactions 		ISO panobinostat results in increased expression of CEBPD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824 		JBrowse link
G Celf5 CUGBP, Elav-like family member 5 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,876,564...8,901,069 		JBrowse link
G Cep85l centrosomal protein 85-like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
panobinostat results in increased expression of CEP85L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:33,111,114...33,282,182
Ensembl chr20:33,115,438...33,282,238 		JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression
multiple interactions 		ISO Panobinostat results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:75,919,129...75,962,786
Ensembl chr11:75,919,142...75,962,785 		JBrowse link
G Cfap95 cilia and flagella associated protein 95 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA CTD PMID:27188386 NCBI chr 1:230,558,329...230,669,479
Ensembl chr 1:230,558,331...230,669,479 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA CTD PMID:27188386 NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434 		JBrowse link
G Cgnl1 cingulin-like 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CGNL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:81,154,169...81,305,598
Ensembl chr 8:81,140,091...81,305,747 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO panobinostat results in increased expression of CHAC1 mRNA CTD PMID:26272509 NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361 		JBrowse link
G Chga chromogranin A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA
panobinostat results in increased expression of CHGA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237 		JBrowse link
G Chodl chondrolectin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
panobinostat results in increased expression of CHODL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:31,141,030...31,163,342
Ensembl chr11:31,141,021...31,163,334 		JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA
panobinostat results in increased expression of CHRM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304 		JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA CTD PMID:27188386 NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:64,297,755...64,311,412 		JBrowse link
G Chst15 carbohydrate sulfotransferase 15 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CHST15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444 		JBrowse link
G Chst4 carbohydrate sulfotransferase 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA
panobinostat results in increased expression of CHST4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:54,900,914...54,911,735
Ensembl chr19:54,882,719...54,916,648 		JBrowse link
G Chsy1 chondroitin sulfate synthase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA
panobinostat results in increased expression of CHSY1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:129,100,088...129,161,167
Ensembl chr 1:129,100,041...129,161,081 		JBrowse link
G Cimap3 ciliary microtubule associated protein 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA CTD PMID:27188386 NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:196,163,275...196,181,604 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA
panobinostat results in increased expression of CITED2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782 		JBrowse link
G Cldn1 claudin 1 increases expression ISO panobinostat results in increased expression of CLDN1 mRNA CTD PMID:26272509 NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529 		JBrowse link
G Cldn23 claudin 23 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CLDN23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:63,117,045...63,118,769
Ensembl chr16:63,116,781...63,118,957 		JBrowse link
G Cldn4 claudin 4 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CLDN4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958 		JBrowse link
G Cldn6 claudin 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA
panobinostat results in increased expression of CLDN6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581 		JBrowse link
G Cldn7 claudin 7 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CLDN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905 		JBrowse link
G Clgn calmegin decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CLGN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325 		JBrowse link
G Clic6 chloride intracellular channel 6 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CLIC6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:45,223,715...45,266,261
Ensembl chr11:45,223,669...45,267,344 		JBrowse link
G Clp1 cleavage factor polyribonucleotide kinase subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA CTD PMID:27188386 NCBI chr 3:90,213,461...90,217,165
Ensembl chr 3:90,213,465...90,217,538 		JBrowse link
G Clstn2 calsyntenin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA
panobinostat results in increased expression of CLSTN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:106,899,894...107,516,402
Ensembl chr 8:106,899,894...107,040,053 		JBrowse link
G Cltrn collectrin, amino acid transport regulator multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA
panobinostat results in decreased expression of CLTRN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:33,993,825...34,027,124
Ensembl chr  X:33,993,825...34,027,181 		JBrowse link
G Clu clusterin increases expression
multiple interactions 		ISO panobinostat results in increased expression of CLU mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860 		JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:40,722,843...40,971,730
Ensembl chr  X:40,722,996...40,965,604 		JBrowse link
G Cnmd chondromodulin increases expression
multiple interactions 		ISO panobinostat results in increased expression of CNMD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:61,450,617...61,475,382
Ensembl chr15:61,450,450...61,475,350 		JBrowse link
G Cnot4 CCR4-NOT transcription complex, subunit 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA CTD PMID:27188386 NCBI chr 4:64,679,903...64,781,432
Ensembl chr 4:64,679,904...64,738,083 		JBrowse link
G Cnrip1 cannabinoid receptor interacting protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA
panobinostat results in increased expression of CNRIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:95,664,435...95,707,062
Ensembl chr14:95,664,774...95,694,371 		JBrowse link
G Cntn1 contactin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA
panobinostat results in increased expression of CNTN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391 		JBrowse link
G Cntn2 contactin 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:46,497,269...46,528,112
Ensembl chr13:46,499,396...46,528,027 		JBrowse link
G Cobl cordon-bleu WH2 repeat protein multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA
panobinostat results in increased expression of COBL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:91,041,721...91,274,272
Ensembl chr14:91,041,721...91,274,257 		JBrowse link
G Cobll1 cordon-bleu WH2 repeat protein-like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA
panobinostat results in increased expression of COBLL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:70,161,369...70,324,844
Ensembl chr 3:70,161,372...70,323,460 		JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression ISO panobinostat results in increased expression of COL11A1 mRNA CTD PMID:27188386 NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264 		JBrowse link
G Col14a1 collagen type XIV alpha 1 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA
panobinostat results in increased expression of COL14A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA CTD PMID:27188386 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
panobinostat results in increased expression of COL1A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995 		JBrowse link
G Col23a1 collagen type XXIII alpha 1 chain increases expression
multiple interactions 		ISO panobinostat results in increased expression of COL23A1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:36,050,327...36,337,279
Ensembl chr10:36,050,259...36,337,897 		JBrowse link
G Col5a2 collagen type V alpha 2 chain increases expression ISO panobinostat results in increased expression of COL5A2 mRNA CTD PMID:26272509 NCBI chr 9:54,940,768...55,090,151
Ensembl chr 9:54,940,764...55,090,150 		JBrowse link
G Col5a3 collagen type V alpha 3 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA
panobinostat results in increased expression of COL5A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:27,580,768...27,626,002
Ensembl chr 8:27,580,768...27,626,122 		JBrowse link
G Col6a1 collagen type VI alpha 1 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA
panobinostat results in increased expression of COL6A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA
panobinostat results in increased expression of COL6A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990 		JBrowse link
G Col9a3 collagen type IX alpha 3 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA
panobinostat results in increased expression of COL9A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:188,089,337...188,112,034
Ensembl chr 3:188,089,403...188,112,270 		JBrowse link
G Colec12 collectin sub-family member 12 increases expression
multiple interactions 		ISO panobinostat results in increased expression of COLEC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297 		JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:67,073,551...67,178,194
Ensembl chr13:67,073,551...67,178,194 		JBrowse link
G Comtd1 catechol-O-methyltransferase domain containing 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of COMTD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:2,509,121...2,512,232
Ensembl chr15:2,509,032...2,512,232 		JBrowse link
G Coro2a coronin 2A increases expression
multiple interactions 		ISO panobinostat results in increased expression of CORO2A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:65,623,823...65,654,602 		JBrowse link
G Cpe carboxypeptidase E increases expression
multiple interactions 		ISO panobinostat results in increased expression of CPE mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524 		JBrowse link
G Cped1 cadherin-like and PC-esterase domain containing 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CPED1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:51,482,497...51,755,440
Ensembl chr 4:51,482,545...51,755,442 		JBrowse link
G Cpne4 copine 4 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CPNE4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:114,056,152...114,531,855
Ensembl chr 8:113,993,703...114,531,855 		JBrowse link
G Cpxm2 carboxypeptidase X (M14 family), member 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CPXM2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,266,930...196,377,350
Ensembl chr 1:196,266,930...196,377,347 		JBrowse link
G Cr1l complement C3b/C4b receptor 1 like increases expression
multiple interactions 		ISO panobinostat results in increased expression of CR1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:109,138,132...109,189,068
Ensembl chr13:109,103,235...109,188,869 		JBrowse link
G Cr2 complement C3d receptor 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:109,207,034...109,244,980
Ensembl chr13:109,213,867...109,244,552 		JBrowse link
G Crabp1 cellular retinoic acid binding protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA CTD PMID:27188386 NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:64,047,060...64,055,470 		JBrowse link
G Crabp2 cellular retinoic acid binding protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
panobinostat results in increased expression of CRABP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:175,707,312...175,728,385 		JBrowse link
G Crip1 cysteine rich protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA CTD PMID:27188386 NCBI chr 6:138,047,801...138,055,672
Ensembl chr 6:138,047,801...138,055,672 		JBrowse link
G Cripto cripto, EGF-CFC family member increases expression ISO Panobinostat results in increased expression of CRIPTO mRNA CTD PMID:26272509 NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948 		JBrowse link
G Crispld1 cysteine-rich secretory protein LCCL domain containing 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CRISPLD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:6,050,970...6,098,265
Ensembl chr 5:6,051,891...6,098,265 		JBrowse link
G Cryba1 crystallin, beta A1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA
panobinostat results in decreased expression of CRYBA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:63,106,465...63,113,020
Ensembl chr10:63,106,475...63,112,817 		JBrowse link
G Cryba4 crystallin, beta A4 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:50,039,148...50,053,636
Ensembl chr12:50,047,049...50,053,634 		JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA
panobinostat results in increased expression of CRYBG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:47,425,030...47,496,918
Ensembl chr20:49,007,929...49,204,047 		JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA CTD PMID:27188386 NCBI chr14:113,219...118,808
Ensembl chr14:113,225...118,117 		JBrowse link
G Cspg5 chondroitin sulfate proteoglycan 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA
panobinostat results in decreased expression of CSPG5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:119,098,932...119,113,191
Ensembl chr 8:119,098,925...119,143,907 		JBrowse link
G Csrnp3 cysteine and serine rich nuclear protein 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA CTD PMID:27188386 NCBI chr 3:70,906,587...71,102,596
Ensembl chr 3:70,906,380...71,094,009 		JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA CTD PMID:27188386 NCBI chr 7:72,007,372...72,017,654
Ensembl chr 7:72,007,372...72,017,654 		JBrowse link
G Ctnnd2 catenin delta 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA
panobinostat results in decreased expression of CTNND2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:82,879,469...83,727,409
Ensembl chr 2:82,879,469...83,727,409 		JBrowse link
G Cul3 cullin 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of CUL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:89,040,987...89,118,775
Ensembl chr 9:89,040,987...89,118,427 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA
panobinostat results in increased expression of CX3CL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA
panobinostat results in increased expression of CXCL12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627 		JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA
panobinostat results in increased expression of CXCL14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of CXCR4 mRNA CTD PMID:21791302 NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459 		JBrowse link
G Cxxc5 CXXC finger protein 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA
panobinostat results in increased expression of CXXC5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA
panobinostat results in increased expression of CYP1A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyren cell cycle regulator of NHEJ decreases expression ISO panobinostat results in decreased expression of CYREN mRNA CTD PMID:26272509 NCBI chr 4:64,514,477...64,519,896
Ensembl chr 4:64,514,477...64,518,742 		JBrowse link
G Cyria CYFIP related Rac1 interactor A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA
Panobinostat results in increased expression of CYRIA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860 		JBrowse link
G Dab1 DAB adaptor protein 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA
panobinostat results in decreased expression of DAB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:123,621,510...124,742,585
Ensembl chr 5:124,369,415...124,742,584 		JBrowse link
G Dach2 dachshund family transcription factor 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DACH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:82,644,374...83,210,181
Ensembl chr  X:82,644,128...83,210,000 		JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA
panobinostat results in increased expression of DACT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053 		JBrowse link
G Dazl deleted in azoospermia-like multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
panobinostat results in decreased expression of DAZL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:18,193,363...18,210,100
Ensembl chr 9:18,193,363...18,210,100 		JBrowse link
G Dcaf12l2 DDB1 and CUL4 associated factor 12-like 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA
panobinostat results in decreased expression of DCAF12L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:123,293,761...123,296,550
Ensembl chr  X:128,167,040...128,169,829 		JBrowse link
G Dcaf4 DDB1 and CUL4 associated factor 4 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DCAF4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:108,885,932...108,912,110 		JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA
panobinostat results in increased expression of DCC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541 		JBrowse link
G Dclk1 doublecortin-like kinase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA
panobinostat results in increased expression of DCLK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:141,571,983...141,861,090 		JBrowse link
G Dclk2 doublecortin-like kinase 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA
panobinostat results in decreased expression of DCLK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:174,506,660...174,636,353
Ensembl chr 2:174,506,660...174,636,192 		JBrowse link
G Dcun1d4 defective in cullin neddylation 1 domain containing 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA CTD PMID:27188386 NCBI chr14:35,006,792...35,087,285
Ensembl chr14:35,006,792...35,088,520 		JBrowse link
G Dennd1a DENN domain containing 1A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA
panobinostat results in decreased expression of DENND1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:41,974,502...42,461,816
Ensembl chr 3:41,974,502...42,461,886 		JBrowse link
G Dennd1b DENN domain containing 1B multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA
panobinostat results in decreased expression of DENND1B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:53,096,717...53,324,372
Ensembl chr13:53,092,261...53,324,369 		JBrowse link
G Dennd2a DENN domain containing 2A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA
panobinostat results in decreased expression of DENND2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:69,199,814...69,299,128
Ensembl chr 4:69,199,814...69,298,984 		JBrowse link
G Dennd4a DENN domain containing 4A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA
panobinostat results in increased expression of DENND4A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:74,218,131...74,331,543
Ensembl chr 8:74,218,191...74,331,542 		JBrowse link
G Depdc1b DEP domain containing 1B decreases expression ISO panobinostat results in decreased expression of DEPDC1B mRNA CTD PMID:26272509 NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:41,624,922...41,697,202 		JBrowse link
G Depdc7 DEP domain containing 7 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:111,554,701...111,575,979
Ensembl chr 3:111,554,706...111,575,979 		JBrowse link
G Deptor DEP domain containing MTOR-interacting protein increases expression
multiple interactions 		ISO panobinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DHRS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653 		JBrowse link
G Diaph2 diaphanous-related formin 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:96,700,535...97,528,080
Ensembl chr  X:96,700,726...97,528,080 		JBrowse link
G Dipk1c divergent protein kinase domain 1C decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:80,362,854...80,384,774
Ensembl chr18:80,362,982...80,386,551 		JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein increases expression
multiple interactions 		ISO panobinostat results in increased expression of DLC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819 		JBrowse link
G Dlk1 delta like non-canonical Notch ligand 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of DLK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529 		JBrowse link
G Dlx3 distal-less homeobox 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DLX3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:80,561,335...80,566,730
Ensembl chr10:80,561,335...80,566,711 		JBrowse link
G Dlx6 distal-less homeobox 6 decreases expression ISO panobinostat results in decreased expression of DLX6 mRNA CTD PMID:26272509 NCBI chr 4:35,951,005...35,956,354
Ensembl chr 4:35,951,005...35,956,354 		JBrowse link
G Dmrta2 DMRT-like family A2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA
panobinostat results in increased expression of DMRTA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:130,034,473...130,040,283
Ensembl chr 5:130,034,473...130,040,222 		JBrowse link
G Dmxl1 Dmx-like 1 increases expression ISO Panobinostat results in increased expression of DMXL1 mRNA CTD PMID:33770205 NCBI chr18:45,179,505...45,349,999
Ensembl chr18:45,179,551...45,356,406 		JBrowse link
G Dner delta/notch-like EGF repeat containing multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA CTD PMID:27188386 NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568 		JBrowse link
G Dock5 dedicator of cytokinesis 5 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DOCK5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:46,155,124...46,334,127
Ensembl chr15:46,155,125...46,334,042 		JBrowse link
G Dock9 dedicator of cytokinesis 9 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DOCK9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:105,018,341...105,289,799
Ensembl chr15:105,024,912...105,289,799 		JBrowse link
G Dok5 docking protein 5 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA CTD PMID:27188386 NCBI chr 3:179,934,419...180,071,334
Ensembl chr 3:179,934,552...180,071,333 		JBrowse link
G Dppa5 developmental pluripotency associated 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA
panobinostat results in increased expression of DPPA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:88,095,627...88,097,936
Ensembl chr 1:14,260,684...14,261,146 		JBrowse link
G Dsc2 desmocollin 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DSC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,725,466...11,757,466 		JBrowse link
G Dst dystonin decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of DST mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533 		JBrowse link
G Dtwd1 DTW domain containing 1 decreases expression ISO Panobinostat results in decreased expression of DTWD1 mRNA CTD PMID:33770205 NCBI chr 3:133,845,768...133,859,965
Ensembl chr 3:133,841,935...133,860,316 		JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression
multiple interactions 		ISO panobinostat results in increased expression of DUSP10 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304 		JBrowse link
G Dusp23 dual specificity phosphatase 23 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of DUSP23 mRNA CTD PMID:21791302 NCBI chr13:87,630,245...87,632,400
Ensembl chr13:87,630,245...87,632,400 		JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of DUSP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700 		JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA
panobinostat results in increased expression of DUSP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417 		JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA
panobinostat results in increased expression of DYNC1I1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:34,819,313...35,132,647
Ensembl chr 4:34,819,430...35,142,319 		JBrowse link
G Dyrk3 dual specificity tyrosine phosphorylation regulated kinase 3 increases expression ISO Panobinostat results in increased expression of DYRK3 mRNA CTD PMID:33770205 NCBI chr13:45,146,383...45,157,082
Ensembl chr13:45,146,384...45,157,249 		JBrowse link
G E2f2 E2F transcription factor 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA
panobinostat results in decreased expression of E2F2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087 		JBrowse link
G Eaf2 ELL associated factor 2 increases expression ISO Panobinostat results in increased expression of EAF2 mRNA CTD PMID:33770205 NCBI chr11:77,465,585...77,509,993
Ensembl chr11:77,406,020...77,509,993 		JBrowse link
G Ebf1 EBF transcription factor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA
panobinostat results in increased expression of EBF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702 		JBrowse link
G Ebi3 Epstein-Barr virus induced 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA CTD PMID:27188386 NCBI chr 9:861,441...874,731
Ensembl chr 9:870,792...874,973 		JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA
panobinostat results in decreased expression of ECPAS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:78,398,449...78,509,077
Ensembl chr 5:78,398,718...78,512,908 		JBrowse link
G Edn1 endothelin 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of EDN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Ednra endothelin receptor type A increases expression
multiple interactions 		ISO panobinostat results in increased expression of EDNRA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
panobinostat results in increased expression of EDNRB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765 		JBrowse link
G Efna1 ephrin A1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
panobinostat results in increased expression of EFNA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726 		JBrowse link
G Efna5 ephrin A5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA
panobinostat results in decreased expression of EFNA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:109,763,786...110,042,396
Ensembl chr 9:109,767,252...110,042,348 		JBrowse link
G Egf epidermal growth factor decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of EGF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egfl8 EGF-like-domain, multiple 8 increases expression ISO panobinostat results in increased expression of EGFL8 mRNA CTD PMID:26272509 NCBI chr20:4,137,531...4,140,632
Ensembl chr20:4,138,053...4,141,681 		JBrowse link
G Eif3m eukaryotic translation initiation factor 3, subunit M decreases expression ISO panobinostat results in decreased expression of EIF3M mRNA CTD PMID:26272509 NCBI chr 3:111,879,589...111,897,193
Ensembl chr 3:111,870,925...111,897,193 		JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:133,709,802...133,858,398
Ensembl chr 4:133,625,768...133,885,647 		JBrowse link
G Elf1 E74 like ETS transcription factor 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ELF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:61,354,026...61,395,762
Ensembl chr15:61,330,877...61,395,758 		JBrowse link
G Elf3 E74 like ETS transcription factor 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ELF3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:49,242,265...49,247,102
Ensembl chr13:49,242,267...49,247,380 		JBrowse link
G Elf5 E74 like ETS transcription factor 5 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:110,264,460...110,291,926
Ensembl chr 3:110,252,797...110,291,926 		JBrowse link
G Elk3 ETS transcription factor ELK3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ELK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:29,655,676...29,718,163
Ensembl chr 7:29,655,693...29,691,661 		JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:63,194,539...63,251,526
Ensembl chr 8:63,137,295...63,251,322 		JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,750,350...23,790,601 		JBrowse link
G Elp4 elongator acetyltransferase complex subunit 4 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ELP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:112,617,020...112,839,963
Ensembl chr 3:112,617,035...112,839,963 		JBrowse link
G Emilin3 elastin microfibril interfacer 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of EMILIN3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:169,978,488...169,984,718
Ensembl chr 3:169,978,672...169,984,488 		JBrowse link
G Emp1 epithelial membrane protein 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of EMP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365 		JBrowse link
G Enox1 ecto-NOX disulfide-thiol exchanger 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA CTD PMID:27188386 NCBI chr15:58,924,519...59,488,919
Ensembl chr15:59,215,018...59,488,918 		JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA
panobinostat results in increased expression of ENPP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957 		JBrowse link
G Eogt EGF domain specific O-linked N-acetylglucosamine transferase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA
panobinostat results in increased expression of EOGT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:131,275,587...131,313,243
Ensembl chr 4:131,276,573...131,311,926 		JBrowse link
G Epas1 endothelial PAS domain protein 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of EPAS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729 		JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:116,502,864...116,707,274
Ensembl chr 9:116,462,807...116,707,274 		JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 increases expression
multiple interactions 		ISO panobinostat results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:33,221,705...33,321,400
Ensembl chr13:33,223,589...33,321,133 		JBrowse link
G Epcam epithelial cell adhesion molecule multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA
panobinostat results in increased expression of EPCAM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702 		JBrowse link
G Epha1 Eph receptor A1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA CTD PMID:27188386 NCBI chr 4:72,213,022...72,227,543
Ensembl chr 4:72,213,037...72,227,474 		JBrowse link
G Epha3 Eph receptor A3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA
panobinostat results in increased expression of EPHA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425 		JBrowse link
G Epha4 Eph receptor A4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA
panobinostat results in decreased expression of EPHA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755 		JBrowse link
G Epha7 Eph receptor A7 increases expression
multiple interactions 		ISO panobinostat results in increased expression of EPHA7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:47,771,776...47,925,189
Ensembl chr 5:47,771,865...47,925,058 		JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:154,179,065...154,360,459
Ensembl chr 5:154,179,065...154,360,615 		JBrowse link
G Epn3 epsin 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA CTD PMID:27188386 NCBI chr10:79,935,857...79,946,121
Ensembl chr10:79,935,857...79,944,235 		JBrowse link
G Eps8l2 EPS8 signaling adaptor L2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA CTD PMID:27188386 NCBI chr 1:205,875,825...205,901,109
Ensembl chr 1:205,875,801...205,901,101 		JBrowse link
G Epsti1 epithelial stromal interaction 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA
panobinostat results in increased expression of EPSTI1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:59,692,712...59,791,376
Ensembl chr15:59,693,142...59,791,380 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA
panobinostat results in decreased expression of ERAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:5,666,436...5,740,056 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
panobinostat results in increased expression of ERBB3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120 		JBrowse link
G Erp27 endoplasmic reticulum protein 27 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA
panobinostat results in increased expression of ERP27 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,535,845...171,552,848
Ensembl chr 4:171,535,847...171,553,072 		JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ESRP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:29,224,831...29,279,381
Ensembl chr 5:29,225,360...29,279,278 		JBrowse link
G Esrp2 epithelial splicing regulatory protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA
panobinostat results in increased expression of ESRP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:50,944,401...50,951,919
Ensembl chr19:50,944,401...50,951,568 		JBrowse link
G Etnk1 ethanolamine kinase 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ETNK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:177,857,001...177,901,278
Ensembl chr 4:177,856,960...177,924,721 		JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions 		ISO panobinostat results in increased expression of ETS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021 		JBrowse link
G Etv1 ETS variant transcription factor 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA
panobinostat results in decreased expression of ETV1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:61,317,429...61,408,959 		JBrowse link
G Ext1 exostosin glycosyltransferase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA
panobinostat results in decreased expression of EXT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:86,265,651...86,544,488
Ensembl chr 7:86,259,900...86,544,567 		JBrowse link
G Ezr ezrin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA
panobinostat results in increased expression of EZR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:49,373,035...49,416,573 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA
panobinostat results in increased expression of F2RL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954 		JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA
panobinostat results in decreased expression of F2RL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:28,706,501...28,712,473 		JBrowse link
G Fabp3 fatty acid binding protein 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA
panobinostat results in increased expression of FABP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881 		JBrowse link
G Fam110b family with sequence similarity 110, member B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA CTD PMID:27188386 NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:23,586,867...23,799,583 		JBrowse link
G Fam124a family with sequence similarity 124 member A decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of FAM124A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:40,975,789...41,031,069
Ensembl chr15:40,975,877...41,029,628 		JBrowse link
G Fam13c family with sequence similarity 13, member C multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA
panobinostat results in increased expression of FAM13C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:18,064,706...18,186,888
Ensembl chr20:18,064,706...18,286,674 		JBrowse link
G Fam149a family with sequence similarity 149, member A decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of FAM149A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:53,587,841...53,647,072
Ensembl chr16:53,587,841...53,647,072 		JBrowse link
G Fam163a family with sequence similarity 163, member A affects expression
multiple interactions 		ISO panobinostat affects the expression of FAM163A mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAM163A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAM163A mRNA] 		CTD PMID:26733615 NCBI chr13:68,262,867...68,341,323
Ensembl chr13:70,813,134...70,891,316 		JBrowse link
G Fam168a family with sequence similarity 168, member A decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of FAM168A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:164,469,447...164,615,542
Ensembl chr 1:164,469,471...164,615,506 		JBrowse link
G Fam241a family with sequence similarity 241 member A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA CTD PMID:27188386 NCBI chr 2:219,019,025...219,049,648
Ensembl chr 2:219,018,241...219,049,770 		JBrowse link
G Fam43a family with sequence similarity 43, member A increases expression
multiple interactions 		ISO panobinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297 		JBrowse link
G Fam89a family with sequence similarity 89, member A increases expression
multiple interactions 		ISO panobinostat results in increased expression of FAM89A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:69,607,391...69,620,019
Ensembl chr19:69,607,391...69,620,019 		JBrowse link
G Fank1 fibronectin type III and ankyrin repeat domains 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA
panobinostat results in decreased expression of FANK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:188,577,512...188,685,501
Ensembl chr 1:198,007,547...198,115,561 		JBrowse link
G Fat3 FAT atypical cadherin 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of FAT3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:20,972,840...21,555,679
Ensembl chr 8:20,972,840...21,555,240 		JBrowse link
G Faxc failed axon connections homolog, metaxin like GST domain containing affects expression
multiple interactions 		ISO panobinostat affects the expression of FAXC mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAXC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAXC mRNA] 		CTD PMID:26733615 NCBI chr 5:40,277,167...40,336,503
Ensembl chr 5:40,277,135...40,344,076 		JBrowse link
G Fbln7 fibulin 7 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of FBLN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:136,564,825...136,601,205
Ensembl chr 3:136,564,917...136,601,198 		JBrowse link
G Fbn1 fibrillin 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA
panobinostat results in decreased expression of FBN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:133,007,693...133,204,277
Ensembl chr 3:133,008,361...133,204,283 		JBrowse link
G Fbxl13 F-box and leucine-rich repeat protein 13 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA CTD PMID:27188386 NCBI chr 4:14,307,032...14,505,491
Ensembl chr 4:14,307,096...14,499,585 		JBrowse link
G Fbxo2 F-box protein 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FBXO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:163,875,757...163,881,508 		JBrowse link
G Fbxo8 F-box protein 8 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FBXO8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FBXO8 mRNA] CTD PMID:26733615 NCBI chr16:33,665,305...33,711,215
Ensembl chr16:38,676,014...38,721,906 		JBrowse link
G Fbxo9 f-box protein 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA CTD PMID:27188386 NCBI chr 8:87,838,787...87,864,362
Ensembl chr 8:87,838,789...87,864,504 		JBrowse link
G Fermt1 FERM domain containing kindlin 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FERMT1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:140,624,434...140,666,419
Ensembl chr 3:140,624,434...140,666,419 		JBrowse link
G Fez1 fasciculation and elongation protein zeta 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA
panobinostat results in decreased expression of FEZ1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:44,733,300...44,784,097 		JBrowse link
G Fezf2 Fez family zinc finger 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA
panobinostat results in decreased expression of FEZF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:15,199,045...15,207,982
Ensembl chr15:15,204,193...15,207,982 		JBrowse link
G Fgd5 FYVE, RhoGEF and PH domain containing 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA
panobinostat results in increased expression of FGD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:126,054,201...126,151,698
Ensembl chr 4:126,054,210...126,151,697 		JBrowse link
G Fgf18 fibroblast growth factor 18 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA CTD PMID:27188386 NCBI chr10:18,210,240...18,241,929
Ensembl chr10:18,210,512...18,240,933 		JBrowse link
G Fgf19 fibroblast growth factor 19 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FGF19 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267 		JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of FGF8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605 		JBrowse link
G Fgf9 fibroblast growth factor 9 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of FGF9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926 		JBrowse link
G Fgfbp3 fibroblast growth factor binding protein 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FGFBP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:234,644,023...234,646,028
Ensembl chr 1:244,056,307...244,065,654 		JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA
panobinostat results in increased expression of FGFR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209 		JBrowse link
G Fhod3 formin homology 2 domain containing 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA
panobinostat results in decreased expression of FHOD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:16,267,830...16,700,508
Ensembl chr18:16,267,977...16,700,508 		JBrowse link
G Fign fidgetin, microtubule severing factor affects expression
multiple interactions 		ISO panobinostat affects the expression of FIGN mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FIGN mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FIGN mRNA] 		CTD PMID:26733615 NCBI chr 3:69,045,918...69,169,148
Ensembl chr 3:69,045,050...69,169,988 		JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression ISO panobinostat results in decreased expression of FJX1 mRNA CTD PMID:26272509 NCBI chr 3:109,229,223...109,231,324
Ensembl chr 3:109,227,170...109,232,479 		JBrowse link
G Flnb filamin B increases expression ISO panobinostat results in increased expression of FLNB mRNA CTD PMID:26272509 NCBI chr15:19,392,212...19,525,278
Ensembl chr15:19,392,216...19,525,209 		JBrowse link
G Flrt2 fibronectin leucine rich transmembrane protein 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA
panobinostat results in decreased expression of FLRT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004 		JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
panobinostat results in increased expression of FLT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750 		JBrowse link
G Fndc5 fibronectin type III domain containing 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA
panobinostat results in decreased expression of FNDC5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:146,765,951...146,775,611
Ensembl chr 5:146,751,416...146,778,540 		JBrowse link
G Foxc1 forkhead box C1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FOXC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:32,840,119...32,844,100
Ensembl chr17:32,805,858...32,844,347 		JBrowse link
G Foxc2 forkhead box C2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FOXC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977 		JBrowse link
G Foxd3 forkhead box D3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:119,450,532...119,452,898
Ensembl chr 5:119,450,394...119,452,786 		JBrowse link
G Foxh1 forkhead box H1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FOXH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:110,268,608...110,272,105
Ensembl chr 7:110,268,612...110,270,692 		JBrowse link
G Foxo1 forkhead box O1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of FOXO1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419 		JBrowse link
G Fras1 Fraser extracellular matrix complex subunit 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of FRAS1 mRNA CTD PMID:21791302 NCBI chr14:13,095,370...13,506,895
Ensembl chr14:13,095,370...13,504,664 		JBrowse link
G Frem1 Fras1 related extracellular matrix 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA
panobinostat results in increased expression of FREM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:102,367,201...102,515,464
Ensembl chr 5:102,367,201...102,515,404 		JBrowse link
G Frrs1l ferric-chelate reductase 1-like multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA
panobinostat results in decreased expression of FRRS1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:76,451,101...76,485,319
Ensembl chr 5:76,451,101...76,485,316 		JBrowse link
G Frzb frizzled-related protein multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA
panobinostat results in decreased expression of FRZB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:85,739,162...85,772,168
Ensembl chr 3:85,739,165...85,772,096 		JBrowse link
G Fut4 fucosyltransferase 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA
panobinostat results in increased expression of FUT4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436 		JBrowse link
G Fut9 fucosyltransferase 9 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA
panobinostat results in decreased expression of FUT9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:44,148,371...44,361,209
Ensembl chr 5:44,146,152...44,362,823 		JBrowse link
G Fzd10 frizzled class receptor 10 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA
panobinostat results in increased expression of FZD10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:33,734,364...33,737,559
Ensembl chr12:33,734,364...33,741,646 		JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA
panobinostat results in decreased expression of FZD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:88,061,988...88,063,898
Ensembl chr10:88,061,667...88,065,396 		JBrowse link
G Fzd3 frizzled class receptor 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA
panobinostat results in decreased expression of FZD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:43,596,962...43,664,047
Ensembl chr15:43,596,965...43,663,960 		JBrowse link
G Fzd5 frizzled class receptor 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA
panobinostat results in decreased expression of FZD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612 		JBrowse link
G Fzd7 frizzled class receptor 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA
panobinostat results in increased expression of FZD7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585 		JBrowse link
G Fzd8 frizzled class receptor 8 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA CTD PMID:27188386 NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961 		JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA
panobinostat results in increased expression of GABRB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:27,438,127...27,657,680
Ensembl chr10:27,438,238...27,655,171 		JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
panobinostat results in increased expression of GABRB3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:117,602,772...117,838,230
Ensembl chr 1:117,431,842...117,836,725 		JBrowse link
G Gabrp gamma-aminobutyric acid type A receptor subunit pi multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA CTD PMID:27188386 NCBI chr10:18,647,243...18,673,806
Ensembl chr10:18,647,243...18,673,727 		JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA
panobinostat results in increased expression of GAD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759 		JBrowse link
G Gad2 glutamate decarboxylase 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA CTD PMID:27188386 NCBI chr17:89,671,718...89,734,246
Ensembl chr17:89,671,716...89,941,089 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; Panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45A mRNA]; SRT2183 promotes the reaction [Panobinostat results in increased expression of GADD45A mRNA]
panobinostat results in increased expression of GADD45A mRNA 		CTD PMID:23681230 PMID:26272509 PMID:27188386 NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions 		ISO panobinostat results in increased expression of GADD45B mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma multiple interactions
increases expression 		ISO GADD45G protein affects the susceptibility to [SRT2183 co-treated with panobinostat]; panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [resveratrol results in increased expression of GADD45G mRNA]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45G mRNA]; resveratrol promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]; SRT2183 promotes the reaction [panobinostat results in increased expression of GADD45G mRNA] CTD PMID:23681230 NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369 		JBrowse link
G Galnt18 polypeptide N-acetylgalactosaminyltransferase 18 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA
panobinostat results in increased expression of GALNT18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:175,027,832...175,338,883
Ensembl chr 1:175,027,839...175,338,883 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
panobinostat results in increased expression of GALNT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:71,150,559...71,187,321
Ensembl chr 3:71,150,571...71,174,323 		JBrowse link
G Gap43 growth associated protein 43 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA
panobinostat results in increased expression of GAP43 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797 		JBrowse link
G Garin1b golgi associated RAB2 interactor 1B decreases expression ISO Panobinostat results in decreased expression of GARIN1B mRNA CTD PMID:26272509 NCBI chr 4:58,880,537...58,903,966
Ensembl chr 4:58,880,594...58,903,961 		JBrowse link
G Gas7 growth arrest specific 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA
panobinostat results in increased expression of GAS7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:52,651,690...52,882,244
Ensembl chr10:52,651,690...52,882,244 		JBrowse link
G Gata2 GATA binding protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA
panobinostat results in increased expression of GATA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055 		JBrowse link
G Gata3 GATA binding protein 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
panobinostat results in increased expression of GATA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670 		JBrowse link
G Gata4 GATA binding protein 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA
panobinostat results in decreased expression of GATA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:41,635,572...41,707,252
Ensembl chr15:41,635,572...41,681,609 		JBrowse link
G Gata6 GATA binding protein 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA CTD PMID:27188386 NCBI chr18:2,460,909...2,492,322
Ensembl chr18:2,458,253...2,492,322 		JBrowse link
G Gbx2 gastrulation brain homeobox 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of GBX2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:97,957,304...97,959,883
Ensembl chr 9:97,957,304...97,959,883 		JBrowse link
G Gchfr GTP cyclohydrolase I feedback regulator increases expression
multiple interactions 		ISO panobinostat results in increased expression of GCHFR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926 		JBrowse link
G Gdf10 growth differentiation factor 10 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA CTD PMID:27188386 NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,243,317...9,256,794 		JBrowse link
G Gja3 gap junction protein, alpha 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of GJA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:35,296,946...35,322,405
Ensembl chr15:35,295,523...35,322,809 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA CTD PMID:27188386 NCBI chr15:35,375,977...35,393,817
Ensembl chr15:35,375,692...35,393,877 		JBrowse link
G Gje1 gap junction protein, epsilon 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GJE1 mRNA CTD PMID:21791302 NCBI chr 1:10,905,890...10,911,800
Ensembl chr 1:10,905,890...10,908,305 		JBrowse link
G Gkap1 G kinase anchoring protein 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA
panobinostat results in decreased expression of GKAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:6,389,377...6,429,091
Ensembl chr17:6,389,377...6,438,279 		JBrowse link
G Glb1l galactosidase, beta 1-like multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GLB1L mRNA CTD PMID:21791302 NCBI chr 9:84,141,993...84,154,176
Ensembl chr 9:84,143,841...84,154,176 		JBrowse link
G Glcci1 glucocorticoid induced 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GLCCI1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:36,307,956...36,635,614
Ensembl chr 4:37,529,364...37,599,802
Ensembl chr 4:37,529,364...37,599,802 		JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:235,389,567...235,809,416
Ensembl chr 1:235,392,651...235,809,221 		JBrowse link
G Glrx2 glutaredoxin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA
panobinostat results in increased expression of GLRX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:58,032,199...58,055,061
Ensembl chr13:58,032,401...58,043,150 		JBrowse link
G Gls glutaminase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA
panobinostat results in increased expression of GLS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:56,836,584...56,908,861 		JBrowse link
G Gnas GNAS complex locus multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA
panobinostat results in increased expression of GNAS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536 		JBrowse link
G Gng11 G protein subunit gamma 11 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA
panobinostat results in increased expression of GNG11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:32,977,681...32,983,121
Ensembl chr 4:32,977,664...32,984,438 		JBrowse link
G Gng8 G protein subunit gamma 8 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA
panobinostat results in decreased expression of GNG8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:86,692,609...86,696,463
Ensembl chr 1:86,692,642...86,696,408 		JBrowse link
G Gnl3l G protein nucleolar 3 like multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA CTD PMID:21791302 NCBI chr  X:23,404,324...23,437,501
Ensembl chr  X:23,404,324...23,439,315 		JBrowse link
G Gpc3 glypican 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GPC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:136,789,770...137,157,598
Ensembl chr  X:136,789,770...137,157,639 		JBrowse link
G Gpc4 glypican 4 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GPC4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:136,565,536...136,676,142
Ensembl chr  X:136,565,591...136,676,057 		JBrowse link
G Gpc6 glypican 6 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA
panobinostat results in decreased expression of GPC6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:100,437,415...101,435,038
Ensembl chr15:100,437,943...101,435,027 		JBrowse link
G Gpd1l glycerol-3-phosphate dehydrogenase 1 like increases expression
multiple interactions 		ISO panobinostat results in increased expression of GPD1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:123,469,282...123,498,948
Ensembl chr 8:123,466,667...123,498,908 		JBrowse link
G Gpr173 G-protein coupled receptor 173 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GPR173 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:24,925,634...24,950,485
Ensembl chr  X:24,922,704...24,950,887 		JBrowse link
G Gpr183 G protein-coupled receptor 183 decreases expression ISO Panobinostat results in decreased expression of GPR183 mRNA CTD PMID:33770205 NCBI chr15:105,445,129...105,457,192
Ensembl chr15:105,437,561...105,466,977 		JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GPR27 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:133,884,894...133,886,027
Ensembl chr 4:133,883,234...133,904,093 		JBrowse link
G Gpr37 G protein-coupled receptor 37 increases expression
multiple interactions 		ISO panobinostat results in increased expression of GPR37 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:55,104,355...55,126,420
Ensembl chr 4:55,104,365...55,126,494 		JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions 		ISO panobinostat results in increased expression of GREM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089 		JBrowse link
G Grhl1 grainyhead-like transcription factor 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA CTD PMID:27188386 NCBI chr 6:46,935,947...46,986,126
Ensembl chr 6:46,935,967...46,980,264 		JBrowse link
G Grhl2 grainyhead-like transcription factor 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA CTD PMID:27188386 NCBI chr 7:70,280,360...70,415,277
Ensembl chr 7:70,285,310...70,415,274 		JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of GRHL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:153,057,760...153,089,890
Ensembl chr 5:153,057,760...153,089,890 		JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA CTD PMID:27188386 NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309 		JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:125,103,975...125,369,690
Ensembl chr  X:125,103,782...125,369,679 		JBrowse link
G Grik3 glutamate ionotropic receptor kainate type subunit 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of GRIK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:143,052,442...143,268,873
Ensembl chr 5:143,052,442...143,268,873 		JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA CTD PMID:27188386 NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378 		JBrowse link
G Grm3 glutamate metabotropic receptor 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA
panobinostat results in decreased expression of GRM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:25,319,218...25,600,721
Ensembl chr 4:25,319,942...25,564,764 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA1 mRNA CTD PMID:21791302 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA2 mRNA CTD PMID:21791302 NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092 		JBrowse link
G Gsta5 glutathione S-transferase alpha 5 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA5 mRNA CTD PMID:21791302 NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765 		JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of GUCY1A1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of GUCY1A1 mRNA] CTD PMID:26733615 NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737 		JBrowse link
G Gypc glycophorin C increases expression
multiple interactions 		ISO panobinostat results in increased expression of GYPC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:24,434,921...24,467,592
Ensembl chr18:24,434,922...24,440,053 		JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression 		ISO manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]]; Panobinostat promotes the reaction [SRT2183 results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein] CTD PMID:22923501 PMID:23681230 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G H2bc12 H2B clustered histone 12 decreases expression
multiple interactions 		ISO Panobinostat results in decreased expression of H2BC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816 		JBrowse link
G H3f4 H3.4 histone, cluster member increases acetylation ISO Panobinostat results in increased acetylation of H3-4 protein CTD PMID:19215824 NCBI chr10:44,240,282...44,240,842 JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of HACD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:81,992,284...82,014,676
Ensembl chr17:81,992,292...82,014,592 		JBrowse link
G Hand1 heart and neural crest derivatives expressed 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA CTD PMID:27188386 NCBI chr10:42,507,117...42,509,684
Ensembl chr10:42,507,122...42,509,684 		JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
panobinostat results in increased expression of HAPLN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:22,366,967...22,431,709
Ensembl chr 2:22,366,967...22,429,098 		JBrowse link
G Has2 hyaluronan synthase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA
panobinostat results in increased expression of HAS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535 		JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA CTD PMID:27188386 NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935 		JBrowse link
G Hdac8 histone deacetylase 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA
panobinostat results in increased expression of HDAC8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:71,425,240...71,632,865
Ensembl chr  X:71,394,928...71,632,865 		JBrowse link
G Hdac9 histone deacetylase 9 decreases expression ISO Panobinostat results in decreased expression of HDAC9 mRNA CTD PMID:30481203 NCBI chr 6:56,489,472...57,351,654
Ensembl chr 6:56,490,988...57,351,835 		JBrowse link
G Heg1 heart development protein with EGF-like domains 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA
panobinostat results in decreased expression of HEG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:80,512,096...80,600,150
Ensembl chr11:80,512,096...80,600,092 		JBrowse link
G Hes2 hes family bHLH transcription factor 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of HES2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:167,947,948...167,964,660
Ensembl chr 5:167,949,918...167,955,601 		JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of HES5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021 		JBrowse link
G Hesx1 HESX homeobox 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of HESX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:2,198,589...2,200,694
Ensembl chr16:2,198,589...2,200,694 		JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
panobinostat results in increased expression of HEY2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:28,641,100...28,651,187
Ensembl chr 1:28,641,057...28,651,187 		JBrowse link
G Hhip Hedgehog-interacting protein multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA CTD PMID:27188386 NCBI chr19:44,768,038...44,856,878
Ensembl chr19:44,767,536...44,862,795 		JBrowse link
G Hip1 huntingtin interacting protein 1 increases expression ISO Panobinostat results in increased expression of HIP1 mRNA CTD PMID:33770205 NCBI chr12:26,769,868...26,904,367
Ensembl chr12:26,769,961...26,904,296 		JBrowse link
G Hk1 hexokinase 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of HK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814 		JBrowse link
G Hmces 5-hydroxymethylcytosine binding, ES cell specific increases expression ISO Panobinostat results in increased expression of HMCES mRNA CTD PMID:33770205 NCBI chr 4:121,950,129...121,972,937
Ensembl chr 4:121,950,840...121,972,891 		JBrowse link
G Hmgcll1 3-hydroxy-3-methylglutaryl-CoA lyase like 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of HMGCLL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,757,301...76,887,300
Ensembl chr 8:85,637,958...85,767,740 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA
panobinostat results in increased expression of HMOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hmx2 H6 family homeobox 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA CTD PMID:27188386 NCBI chr 1:195,749,284...195,758,347
Ensembl chr 1:195,749,284...195,756,945 		JBrowse link
G Hnmt histamine N-methyltransferase increases expression
multiple interactions 		ISO panobinostat results in increased expression of HNMT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:26,978,274...27,010,291
Ensembl chr 3:26,977,933...27,010,482 		JBrowse link
G Hnrnpr heterogeneous nuclear ribonucleoprotein R multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA CTD PMID:27188386 NCBI chr 5:153,826,482...153,872,272
Ensembl chr 5:153,826,692...153,858,344 		JBrowse link
G Homez homeobox and leucine zipper encoding multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA CTD PMID:27188386 NCBI chr15:32,292,897...32,309,564
Ensembl chr15:32,291,048...32,321,319 		JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA CTD PMID:27188386 NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209 		JBrowse link
G Hpdl 4-hydroxyphenylpyruvate dioxygenase-like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA
panobinostat results in increased expression of HPDL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,523,258...135,524,864
Ensembl chr 5:135,523,262...135,535,704 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA CTD PMID:27188386 NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831 		JBrowse link
G Hps1 HPS1, biogenesis of lysosomal organelles complex 3 subunit 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA
panobinostat results in increased expression of HPS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:251,500,427...251,526,529
Ensembl chr 1:251,500,427...251,526,739 		JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression
multiple interactions 		ISO panobinostat results in increased expression of HRK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:44,048,402...44,070,561
Ensembl chr12:44,048,402...44,070,561 		JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions 		ISO panobinostat results in increased expression of HSPA4L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:125,668,236...125,720,986 		JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ICAM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Id4 inhibitor of DNA binding 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA
panobinostat results in increased expression of ID4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:16,595,724...16,598,293
Ensembl chr17:16,595,724...16,598,492 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
panobinostat results in increased expression of IDH3A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:63,867,882...63,887,223
Ensembl chr 8:63,867,820...63,887,223 		JBrowse link
G Ier3 immediate early response 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of IER3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377 		JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA
panobinostat results in increased expression of IFI30 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:18,709,570...18,713,635
Ensembl chr16:18,709,563...18,715,711 		JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 increases expression
multiple interactions 		ISO Panobinostat results in increased expression of IFITM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776 		JBrowse link
G Ifnar2 interferon alpha and beta receptor subunit 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of IFNAR2 mRNA CTD PMID:21791302 NCBI chr11:44,099,574...44,131,941
Ensembl chr11:44,099,753...44,131,937 		JBrowse link
G Ift25 intraflagellar transport 25 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA
Panobinostat results in decreased expression of IFT25 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:127,264,450...127,291,225
Ensembl chr 5:127,264,498...127,291,225 		JBrowse link
G Igdcc3 immunoglobulin superfamily, DCC subclass, member 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of IGDCC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:74,556,348...74,603,136
Ensembl chr 8:74,556,348...74,603,136 		JBrowse link
G Igf2 insulin-like growth factor 2 increases expression ISO panobinostat results in increased expression of IGF2 mRNA CTD PMID:26272509 NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases expression ISO panobinostat results in decreased expression of IGFBP3 mRNA CTD PMID:26272509 NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944 		JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA
panobinostat results in increased expression of IGFBP7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:31,091,681...31,151,623
Ensembl chr14:31,091,347...31,151,620 		JBrowse link
G Igsf21 immunoglobin superfamily, member 21 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA CTD PMID:27188386 NCBI chr 5:157,570,964...157,795,290
Ensembl chr 5:157,570,964...157,795,290 		JBrowse link
G Il17rd interleukin 17 receptor D decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:2,235,172...2,489,827
Ensembl chr16:2,235,169...2,301,850 		JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of IL1RAPL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:55,322,779...56,827,486
Ensembl chr  X:55,328,964...56,826,613 		JBrowse link
G Il20rb interleukin 20 receptor subunit beta increases expression
multiple interactions 		ISO panobinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:109,858,108...109,896,066
Ensembl chr 8:109,854,012...109,889,363 		JBrowse link
G Il27ra interleukin 27 receptor subunit alpha increases expression
multiple interactions 		ISO panobinostat results in increased expression of IL27RA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:41,014,730...41,026,740
Ensembl chr19:41,014,730...41,026,760 		JBrowse link
G Il3ra interleukin 3 receptor subunit alpha multiple interactions
increases expression 		ISO [Cisplatin co-treated with panobinostat] affects the expression of IL3RA mRNA
Panobinostat results in increased expression of IL3RA mRNA 		CTD PMID:21791302 PMID:33770205 NCBI chr12:21,431,848...21,437,336
Ensembl chr12:21,431,848...21,437,250 		JBrowse link
G Inf2 inverted formin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA
panobinostat results in increased expression of INF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:137,470,259...137,497,039
Ensembl chr 6:137,470,286...137,497,039 		JBrowse link
G Inhbe inhibin subunit beta E multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA
panobinostat results in increased expression of INHBE mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519 		JBrowse link
G Inpp4b inositol polyphosphate-4-phosphatase type II B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA CTD PMID:27188386 NCBI chr19:42,824,710...43,575,039
Ensembl chr19:42,829,871...43,185,091 		JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA CTD PMID:27188386 NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589 		JBrowse link
G Inpp5f inositol polyphosphate-5-phosphatase F increases expression ISO Panobinostat results in increased expression of INPP5F mRNA CTD PMID:33770205 NCBI chr 1:192,620,891...192,700,681
Ensembl chr 1:192,620,891...192,700,681 		JBrowse link
G Insc INSC, spindle orientation adaptor protein increases expression
multiple interactions 		ISO panobinostat results in increased expression of INSC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:178,427,360...178,534,827
Ensembl chr 1:178,427,423...178,535,047 		JBrowse link
G Iqca1 IQ motif containing with AAA domain 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRC11 mRNA
Panobinostat results in increased expression of DRC11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:90,626,735...90,742,563
Ensembl chr 9:98,073,887...98,190,066 		JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA
panobinostat results in increased expression of IQGAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043 		JBrowse link
G Irf6 interferon regulatory factor 6 increases expression
multiple interactions 		ISO panobinostat results in increased expression of IRF6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:107,200,876...107,220,083
Ensembl chr13:107,200,731...107,220,049 		JBrowse link
G Irx1 iroquois homeobox 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA
panobinostat results in increased expression of IRX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:33,123,122...33,128,951
Ensembl chr 1:33,123,122...33,128,951 		JBrowse link
G Irx2 iroquois homeobox 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA
panobinostat results in increased expression of IRX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:32,489,512...32,494,930
Ensembl chr 1:32,489,512...32,494,930 		JBrowse link
G Irx3 iroquois homeobox 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA
panobinostat results in increased expression of IRX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:31,384,803...31,388,241
Ensembl chr19:31,384,833...31,388,238 		JBrowse link
G Isl1 ISL LIM homeobox 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA CTD PMID:27188386 NCBI chr 2:49,813,618...49,823,442
Ensembl chr 2:49,813,618...49,823,442 		JBrowse link
G Itga8 integrin subunit alpha 8 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ITGA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:80,213,139...80,410,633
Ensembl chr17:80,213,143...80,410,633 		JBrowse link
G Itga9 integrin subunit alpha 9 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ITGA9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:127,185,244...127,493,296
Ensembl chr 8:127,169,226...127,493,296 		JBrowse link
G Itgb5 integrin subunit beta 5 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ITGB5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:80,333,588...80,449,373
Ensembl chr11:80,333,590...80,449,373 		JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA
Panobinostat results in increased expression of ITIH5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:73,161,886...73,261,930
Ensembl chr17:73,161,611...73,262,496 		JBrowse link
G Itm2a integral membrane protein 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA CTD PMID:27188386 NCBI chr  X:76,559,183...76,565,144
Ensembl chr  X:76,559,181...76,565,437 		JBrowse link
G Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA
panobinostat results in increased expression of ITPR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:180,759,325...181,165,361
Ensembl chr 4:180,760,442...181,164,763 		JBrowse link
G Jade2 jade family PHD finger 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of JADE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:36,576,187...36,625,129
Ensembl chr10:36,576,187...36,623,532 		JBrowse link
G Jarid2 jumonji and AT-rich interaction domain containing 2 increases expression ISO Panobinostat results in increased expression of JARID2 mRNA CTD PMID:33770205 NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,983,217...20,161,970 		JBrowse link
G Jazf1 JAZF zinc finger 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of JAZF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:83,210,054...83,513,790
Ensembl chr 4:83,210,058...83,513,644 		JBrowse link
G Jcad junctional cadherin 5 associated increases expression
multiple interactions 		ISO panobinostat results in increased expression of JCAD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:57,784,634...57,826,213
Ensembl chr17:57,784,634...57,826,183 		JBrowse link
G Jdp2 Jun dimerization protein 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of JDP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:110,988,927...111,033,392
Ensembl chr 6:110,992,806...111,033,392 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO panobinostat results in increased expression of JUN mRNA CTD PMID:26272509 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Kank4 KN motif and ankyrin repeat domains 4 increases expression
multiple interactions 		ISO panobinostat results in increased expression of KANK4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:118,517,971...118,581,002 		JBrowse link
G Kat2b lysine acetyltransferase 2B multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA
panobinostat results in decreased expression of KAT2B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616 		JBrowse link
G Kat6a lysine acetyltransferase 6A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA CTD PMID:27188386 NCBI chr16:75,787,411...75,868,584
Ensembl chr16:75,787,411...75,866,099 		JBrowse link
G Kat7 lysine acetyltransferase 7 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA
panobinostat results in decreased expression of KAT7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:80,718,335...80,752,387
Ensembl chr10:80,718,335...80,752,387 		JBrowse link
G Kbtbd11 kelch repeat and BTB domain containing 11 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of KBTBD11 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:81,318,596...81,340,334
Ensembl chr16:81,313,093...81,340,390 		JBrowse link
G Kcna7 potassium voltage-gated channel subfamily A member 7 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KCNA7 mRNA CTD PMID:21791302 NCBI chr 1:105,022,549...105,028,041
Ensembl chr 1:105,022,549...105,028,041 		JBrowse link
G Kcnc1 potassium voltage-gated channel subfamily C member 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA
panobinostat results in decreased expression of KCNC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:106,039,247...106,081,034
Ensembl chr 1:106,039,237...106,081,033 		JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
panobinostat results in decreased expression of KCND2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522 		JBrowse link
G Kcng1 potassium voltage-gated channel modifier subfamily G member 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of KCNG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:177,379,593...177,412,986
Ensembl chr 3:177,392,031...177,411,507 		JBrowse link
G Kcnh5 potassium voltage-gated channel subfamily H member 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA
panobinostat results in decreased expression of KCNH5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:99,350,947...99,643,856
Ensembl chr 6:99,360,302...99,643,856 		JBrowse link
G Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA
panobinostat results in decreased expression of KCNJ13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:95,509,228...95,528,400
Ensembl chr 9:95,510,877...95,520,817 		JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA CTD PMID:27188386 NCBI chr 3:60,353,990...60,518,110
Ensembl chr 3:60,354,146...60,518,104 		JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA CTD PMID:27188386 NCBI chr19:70,856,985...70,895,053
Ensembl chr19:70,856,985...70,895,051 		JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA
panobinostat results in decreased expression of KCNK10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:123,419,778...123,555,820
Ensembl chr 6:123,423,950...123,555,614 		JBrowse link
G Kcnmb4 potassium calcium-activated channel subfamily M regulatory beta subunit 4 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KCNMB4 mRNA CTD PMID:21791302 NCBI chr 7:53,952,150...54,005,101
Ensembl chr 7:53,949,881...54,005,281 		JBrowse link
G Kcnn3 potassium calcium-activated channel subfamily N member 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA
panobinostat results in decreased expression of KCNN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:177,227,276...177,378,849
Ensembl chr 2:177,234,327...177,379,693 		JBrowse link
G Kcnv1 potassium voltage-gated channel modifier subfamily V member 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA CTD PMID:27188386 NCBI chr 7:78,145,319...78,153,794
Ensembl chr 7:78,145,319...78,153,816 		JBrowse link
G Kctd1 potassium channel tetramerization domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA
panobinostat results in increased expression of KCTD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:6,396,947...6,591,026
Ensembl chr18:6,396,947...6,515,191 		JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA
panobinostat results in increased expression of KCTD12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:86,214,786...86,220,725
Ensembl chr15:86,214,840...86,224,539 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA CTD PMID:27188386 NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192 		JBrowse link
G Kiaa0040 KIAA0040 ortholog multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA
panobinostat results in increased expression of KIAA0040 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:74,807,959...74,845,530
Ensembl chr13:74,807,982...74,845,530 		JBrowse link
G Kiaa1549 KIAA1549 homolog decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of KIAA1549 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:67,807,635...67,935,303
Ensembl chr 4:67,811,803...67,935,360 		JBrowse link
G Kiaa1755 KIAA1755 ortholog increases expression
multiple interactions 		ISO panobinostat results in increased expression of KIAA1755 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:167,270,476...167,305,337
Ensembl chr 3:167,192,612...167,304,240 		JBrowse link
G Kif13a kinesin family member 13A decreases expression ISO panobinostat results in decreased expression of KIF13A mRNA CTD PMID:26272509 NCBI chr17:17,972,227...18,154,763
Ensembl chr17:17,972,325...18,154,760 		JBrowse link
G Kif28 kinesin family member 28 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA CTD PMID:27188386 NCBI chr13:93,959,492...94,014,255
Ensembl chr13:93,959,492...94,014,255 		JBrowse link
G Kif5c kinesin family member 5C multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KIF5C mRNA CTD PMID:21791302 NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:54,441,310...54,594,813 		JBrowse link
G Kifap3 kinesin-associated protein 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of KIFAP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:78,660,849...78,797,821
Ensembl chr13:78,660,871...78,797,820 		JBrowse link
G Kiss1r KISS1 receptor multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA CTD PMID:27188386 NCBI chr 7:10,435,766...10,439,424
Ensembl chr 7:10,435,766...10,439,424 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase increases expression
multiple interactions 		ISO panobinostat results in increased expression of KIT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812 		JBrowse link
G Kitlg KIT ligand increases expression
multiple interactions 		ISO panobinostat results in increased expression of KITLG mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793 		JBrowse link
G Kiz kizuna centrosomal protein decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of KIZ mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:154,730,873...154,838,410
Ensembl chr 3:154,730,634...154,838,410 		JBrowse link
G Klf15 KLF transcription factor 15 increases expression
multiple interactions 		ISO panobinostat results in increased expression of KLF15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:124,522,909...124,542,373 		JBrowse link
G Klf4 KLF transcription factor 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA CTD PMID:27188386 NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592 		JBrowse link
G Klf5 KLF transcription factor 5 increases expression
multiple interactions 		ISO panobinostat results in increased expression of KLF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262 		JBrowse link
G Klf6 KLF transcription factor 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA
panobinostat results in increased expression of KLF6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601 		JBrowse link
G Klhl14 kelch-like family member 14 increases expression ISO panobinostat results in increased expression of KLHL14 mRNA CTD PMID:26272509 NCBI chr18:13,079,159...13,192,728
Ensembl chr18:13,079,159...13,193,557 		JBrowse link
G Klk10 kallikrein related-peptidase 10 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA CTD PMID:21791302 NCBI chr 1:103,371,638...103,375,918
Ensembl chr 1:103,371,638...103,375,918 		JBrowse link
G Klk8 kallikrein related-peptidase 8 multiple interactions
increases expression 		ISO [Cisplatin co-treated with Panobinostat] affects the expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA
panobinostat results in increased expression of KLK8 mRNA 		CTD PMID:21791302 PMID:26272509 PMID:27188386 NCBI chr 1:103,388,352...103,395,195
Ensembl chr 1:103,388,352...103,395,195 		JBrowse link
G Klrg2 killer cell lectin like receptor G2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of KLRG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:68,314,347...68,341,759
Ensembl chr 4:68,330,660...68,341,043 		JBrowse link
G Kremen1 kringle containing transmembrane protein 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of KREMEN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:84,295,931...84,361,534
Ensembl chr14:84,297,700...84,361,614 		JBrowse link
G Krt18 keratin 18 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
panobinostat results in increased expression of KRT18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848 		JBrowse link
G Krt19 keratin 19 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA CTD PMID:27188386 NCBI chr10:85,576,235...85,580,952
Ensembl chr10:85,576,235...85,580,952 		JBrowse link
G Krt8 keratin 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA
panobinostat results in increased expression of KRT8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403 		JBrowse link
G L1cam L1 cell adhesion molecule multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA
panobinostat results in increased expression of L1CAM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:156,748,597...156,775,116
Ensembl chr  X:156,748,597...156,775,077 		JBrowse link
G L1td1 LINE-1 type transposase domain containing 1 increases expression ISO panobinostat results in increased expression of L1TD1 mRNA CTD PMID:26272509 NCBI chr 5:118,488,688...118,501,591
Ensembl chr 5:118,488,688...118,501,591 		JBrowse link
G Lacc1 laccase domain containing 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LACC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:58,799,477...58,816,840
Ensembl chr15:58,786,637...58,816,840 		JBrowse link
G Lactb lactamase, beta increases expression
multiple interactions 		ISO panobinostat results in increased expression of LACTB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,452,679...76,469,986
Ensembl chr 8:76,452,349...76,468,716 		JBrowse link
G Lama2 laminin subunit alpha 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LAMA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:19,492,126...20,140,056
Ensembl chr 1:19,244,599...20,140,056 		JBrowse link
G Lama4 laminin subunit alpha 4 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LAMA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:43,946,898...44,087,972
Ensembl chr20:43,946,898...44,087,972 		JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LAMC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102 		JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LAMP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:122,038,734...122,087,745
Ensembl chr  X:121,922,187...122,087,675 		JBrowse link
G Layn layilin increases expression
multiple interactions 		ISO panobinostat results in increased expression of LAYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:60,261,325...60,280,797
Ensembl chr 8:60,263,456...60,281,418 		JBrowse link
G Lctl lactase-like decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:73,506,096...73,534,668
Ensembl chr 8:73,513,634...73,534,668 		JBrowse link
G Ldhd lactate dehydrogenase D increases expression
multiple interactions 		ISO panobinostat results in increased expression of LDHD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:56,492,827...56,497,695
Ensembl chr19:56,482,924...56,509,197 		JBrowse link
G Lemd1 LEM domain containing 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA CTD PMID:27188386 NCBI chr13:46,183,860...46,250,105
Ensembl chr13:46,218,085...46,250,562 		JBrowse link
G Lgals1 galectin 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA CTD PMID:27188386 NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800 		JBrowse link
G Lgals3 galectin 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LGALS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737 		JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:139,276,810...139,474,740
Ensembl chr 2:139,276,789...139,474,737 		JBrowse link
G Lhx2 LIM homeobox 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA
panobinostat results in decreased expression of LHX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645 		JBrowse link
G Lhx8 LIM homeobox 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA
panobinostat results in increased expression of LHX8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:245,904,712...245,929,376
Ensembl chr 2:245,904,712...245,929,376 		JBrowse link
G Lifr LIF receptor subunit alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA
panobinostat results in increased expression of LIFR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:57,951,787...58,020,357
Ensembl chr 2:57,952,975...58,020,364 		JBrowse link
G Lim2 lens intrinsic membrane protein 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA CTD PMID:27188386 NCBI chr 1:102,974,188...102,980,358
Ensembl chr 1:102,974,188...102,980,358 		JBrowse link
G Limch1 LIM and calponin homology domains 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LIMCH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:41,466,433...41,779,477
Ensembl chr14:41,466,433...41,778,837 		JBrowse link
G Lin28b lin-28 homolog B multiple interactions
affects expression
decreases expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LIN28B mRNA]; (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of LIN28B protein]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LIN28B mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of LIN28B protein]
panobinostat affects the expression of LIN28B mRNA
panobinostat results in decreased expression of LIN28B protein 		CTD PMID:26733615 NCBI chr20:50,447,700...50,547,135
Ensembl chr20:50,450,971...50,541,968 		JBrowse link
G Lingo2 leucine rich repeat and Ig domain containing 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LINGO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:50,370,744...51,687,252
Ensembl chr 5:55,156,997...56,489,155 		JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LIX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:58,128,961...58,187,554
Ensembl chr 1:66,802,272...66,860,627 		JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:61,778,971...61,800,960
Ensembl chr18:61,772,917...61,800,820 		JBrowse link
G Lmf1 lipase maturation factor 1 increases expression ISO panobinostat results in increased expression of LMF1 mRNA CTD PMID:26272509 NCBI chr10:15,094,432...15,188,665
Ensembl chr10:15,098,138...15,188,664 		JBrowse link
G Lmo2 LIM domain only 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA
panobinostat results in decreased expression of LMO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:110,810,162...110,832,895
Ensembl chr 3:110,809,912...110,833,075 		JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:172,965,951...173,025,156 		JBrowse link
G Lmo7 LIM domain 7 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA CTD PMID:27188386 NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551 		JBrowse link
G Lnx1 ligand of numb-protein X 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA
panobinostat results in increased expression of LNX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:33,868,517...33,971,217
Ensembl chr14:33,868,571...33,971,217 		JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LPAR6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:54,826,110...54,827,919
Ensembl chr15:54,823,717...54,978,783 		JBrowse link
G Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LRIG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:128,687,723...128,788,219
Ensembl chr 4:128,687,723...128,788,219 		JBrowse link
G Lrp12 LDL receptor related protein 12 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LRP12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:72,825,979...72,897,308
Ensembl chr 7:72,825,979...72,897,171 		JBrowse link
G Lrp2 LDL receptor related protein 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA
panobinostat results in decreased expression of LRP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535 		JBrowse link
G Lrp8 LDL receptor related protein 8 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA CTD PMID:27188386 NCBI chr 5:127,792,236...127,864,207
Ensembl chr 5:127,792,299...127,864,207 		JBrowse link
G Lrrc17 leucine rich repeat containing 17 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA
panobinostat results in increased expression of LRRC17 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048 		JBrowse link
G Lrrc3b leucine rich repeat containing 3B multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA
panobinostat results in decreased expression of LRRC3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:12,404,309...12,481,618
Ensembl chr15:12,336,369...12,481,866 		JBrowse link
G Lrrc55 leucine rich repeat containing 55 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of LRRC55 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:90,676,547...90,687,392
Ensembl chr 3:90,680,160...90,685,280 		JBrowse link
G Lrrc8b leucine rich repeat containing 8 VRAC subunit B multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA
panobinostat results in decreased expression of LRRC8B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:4,655,273...4,721,648
Ensembl chr14:4,655,273...4,721,076 		JBrowse link
G Lrrc8e leucine rich repeat containing 8 VRAC subunit E multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA
panobinostat results in increased expression of LRRC8E mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:7,376,103...7,387,250
Ensembl chr12:7,380,585...7,387,249 		JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA CTD PMID:27188386 NCBI chr 9:99,039,590...99,167,805
Ensembl chr 9:99,039,614...99,167,779 		JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 multiple interactions
affects expression
increases expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRN3 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRN3 mRNA]
panobinostat affects the expression of LRRN3 mRNA
panobinostat results in increased expression of LRRN3 mRNA 		CTD PMID:26272509 PMID:26733615 PMID:27188386 NCBI chr 6:64,216,164...64,247,293
Ensembl chr 6:64,215,878...64,247,614 		JBrowse link
G Lrrn4 leucine rich repeat neuronal 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA CTD PMID:27188386 NCBI chr 3:140,592,303...140,603,986
Ensembl chr 3:140,592,076...140,605,574 		JBrowse link
G Lrrtm1 leucine rich repeat transmembrane neuronal 1 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRTM1 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRTM1 mRNA]
panobinostat affects the expression of LRRTM1 mRNA 		CTD PMID:26733615 PMID:27188386 NCBI chr 4:111,246,213...111,295,638
Ensembl chr 4:111,235,054...111,276,818 		JBrowse link
G Ly75 lymphocyte antigen 75 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LY75 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878 		JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions 		ISO panobinostat results in increased expression of LYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:21,437,127...21,553,097
Ensembl chr 5:21,437,084...21,554,461 		JBrowse link
G Lypd3 Ly6/Plaur domain containing 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LYPD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:80,226,449...80,230,901
Ensembl chr 1:89,354,335...89,358,810 		JBrowse link
G Lysmd2 LysM domain containing 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LYSMD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,259,443...85,274,876
Ensembl chr 8:85,259,410...85,275,241 		JBrowse link
G Lyzl6 lysozyme-like 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA
panobinostat results in increased expression of LYZL6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:89,044,375...89,049,210
Ensembl chr10:89,044,375...89,049,210 		JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of LZTS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:25,309,502...25,364,942
Ensembl chr16:25,309,507...25,364,940 		JBrowse link
G Mab21l2 mab-21 like 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:174,244,538...174,247,620
Ensembl chr 2:174,238,828...174,252,064 		JBrowse link
G Macc1 MET transcriptional regulator MACC1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
panobinostat results in increased expression of MACC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:146,495,544...146,574,254
Ensembl chr 6:146,495,861...146,574,260 		JBrowse link
G Macrod2 mono-ADP ribosylhydrolase 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of MACROD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:148,173,821...150,191,077
Ensembl chr 3:148,173,829...150,188,058 		JBrowse link
G Macroh2a1 macroH2A.1 histone multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
Panobinostat results in decreased expression of MACROH2A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:8,484,340...8,547,268
Ensembl chr17:8,484,246...8,547,257 		JBrowse link
G Mafb MAF bZIP transcription factor B increases expression ISO panobinostat results in increased expression of MAFB mRNA CTD PMID:26272509 NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975 		JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA
panobinostat results in increased expression of MAGI2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:15,278,518...16,762,427
Ensembl chr 4:15,278,518...16,762,199 		JBrowse link
G Mak male germ cell-associated kinase multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA
panobinostat results in decreased expression of MAK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:23,889,417...23,936,857
Ensembl chr17:23,889,516...23,936,855 		JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,745,165...33,928,584 		JBrowse link
G Maneal mannosidase, endo-alpha-like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA
panobinostat results in increased expression of MANEAL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:137,115,154...137,122,299
Ensembl chr 5:142,400,213...142,407,027 		JBrowse link
G Map2 microtubule-associated protein 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MAP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721 		JBrowse link
G Map6 microtubule-associated protein 6 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA
panobinostat results in decreased expression of MAP6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:162,980,339...163,046,548
Ensembl chr 1:162,980,181...163,046,548 		JBrowse link
G Map7d2 MAP7 domain containing 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA CTD PMID:27188386 NCBI chr  X:39,181,091...39,296,814
Ensembl chr  X:39,181,091...39,296,695 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein CTD PMID:18445700 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100 		JBrowse link
G Mapk13 mitogen activated protein kinase 13 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA
panobinostat results in increased expression of MAPK13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:6,836,979...6,847,197
Ensembl chr20:6,837,013...6,847,191 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein CTD PMID:18445700 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mat1a methionine adenosyltransferase 1A multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of MAT1A mRNA CTD PMID:21791302 NCBI chr16:17,017,168...17,035,368
Ensembl chr16:17,016,030...17,035,367 		JBrowse link
G Mbnl3 muscleblind-like splicing regulator 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MBNL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:135,526,256...135,621,499
Ensembl chr  X:135,532,494...135,621,976 		JBrowse link
G Mboat1 membrane bound O-acyltransferase domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA
panobinostat results in increased expression of MBOAT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,540,041...34,653,698 		JBrowse link
G Mcc MCC regulator of WNT signaling pathway multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA
panobinostat results in increased expression of MCC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:37,042,350...37,517,114
Ensembl chr18:37,049,253...37,517,076 		JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:237,596,544...237,705,770
Ensembl chr 2:237,626,302...237,705,769 		JBrowse link
G Mcub mitochondrial calcium uniporter dominant negative subunit beta decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of MCUB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:221,153,525...221,223,814
Ensembl chr 2:221,153,525...221,223,814 		JBrowse link
G Mdfic MyoD family inhibitor domain containing multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA
panobinostat results in increased expression of MDFIC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:44,938,301...45,018,157
Ensembl chr 4:44,938,480...45,018,156 		JBrowse link
G Me3 malic enzyme 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA
panobinostat results in decreased expression of ME3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:152,946,595...153,148,026
Ensembl chr 1:152,946,628...153,148,026 		JBrowse link
G Mecom MDS1 and EVI1 complex locus decreases expression ISO panobinostat results in decreased expression of MECOM mRNA CTD PMID:26272509 NCBI chr 2:114,837,815...115,393,052
Ensembl chr 2:114,837,840...115,393,038 		JBrowse link
G Med13l mediator complex subunit 13L increases expression
multiple interactions 		ISO panobinostat results in increased expression of MED13L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:37,807,596...38,004,886
Ensembl chr12:43,468,556...43,665,819 		JBrowse link
G Mef2c myocyte enhancer factor 2C increases expression
multiple interactions 		ISO panobinostat results in increased expression of MEF2C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:15,708,732...15,871,639
Ensembl chr 2:15,708,924...15,871,640 		JBrowse link
G Meis2 Meis homeobox 2 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MEIS2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MEIS2 mRNA] CTD PMID:26733615 NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751 		JBrowse link
G Meox1 mesenchyme homeobox 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA
panobinostat results in increased expression of MEOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976 		JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA
panobinostat results in increased expression of METRNL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135 		JBrowse link
G Mettl21a methyltransferase 21A, HSPA lysine multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA CTD PMID:27188386 NCBI chr 9:73,400,223...73,484,677
Ensembl chr 9:73,471,813...73,481,339 		JBrowse link
G Mfap3l microfibril associated protein 3 like multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA
panobinostat results in decreased expression of MFAP3L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:34,422,490...34,465,544
Ensembl chr16:34,426,696...34,441,709 		JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA
panobinostat results in decreased expression of MFNG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:112,191,288...112,209,129
Ensembl chr 7:112,161,071...112,209,129 		JBrowse link
G Mgat3 beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of MGAT3 mRNA CTD PMID:21791302 NCBI chr 7:113,614,011...113,640,201
Ensembl chr 7:113,598,059...113,643,481 		JBrowse link
G Mia MIA SH3 domain containing increases expression
multiple interactions 		ISO panobinostat results in increased expression of MIA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:91,601,326...91,603,019
Ensembl chr 1:91,601,327...91,603,019 		JBrowse link
G Miat myocardial infarction associated transcript decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of MIAT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:50,075,026...50,090,259 JBrowse link
G Micall1 MICAL-like 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MICALL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:112,557,192...112,587,618
Ensembl chr 7:112,557,192...112,587,618 		JBrowse link
G Micb MHC class I polypeptide-related sequence B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA
Panobinostat results in increased expression of MICB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:87,623,826...87,640,872 		JBrowse link
G Mid1ip1 MID1 interacting protein 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MID1IP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:14,733,539...14,735,859
Ensembl chr  X:14,732,830...14,739,079 		JBrowse link
G Mmp14 matrix metallopeptidase 14 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MMP14 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893 		JBrowse link
G Mnx1 motor neuron and pancreas homeobox 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of MNX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:6,541,645...6,546,604
Ensembl chr 4:6,541,645...6,546,604 		JBrowse link
G Mpped2 metallophosphoesterase domain containing 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA
panobinostat results in decreased expression of MPPED2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:93,180,895...93,355,605
Ensembl chr 3:113,635,407...113,811,783 		JBrowse link
G Mpz myelin protein zero increases expression
multiple interactions 		ISO panobinostat results in increased expression of MPZ mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:86,103,290...86,109,156
Ensembl chr13:86,103,290...86,109,155 		JBrowse link
G Msl1 MSL complex subunit 1 affects expression
multiple interactions
decreases expression 		ISO panobinostat affects the expression of MSL1 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MSL1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MSL1 mRNA]
Panobinostat results in decreased expression of MSL1 mRNA 		CTD PMID:26733615 PMID:33770205 NCBI chr10:84,251,362...84,263,384
Ensembl chr10:84,251,642...84,261,971 		JBrowse link
G Msx1 msh homeobox 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA
panobinostat results in increased expression of MSX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:77,185,802...77,189,735
Ensembl chr14:77,185,802...77,189,735 		JBrowse link
G Msx2 msh homeobox 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA
panobinostat results in increased expression of MSX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945 		JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 increases expression
multiple interactions 		ISO Panobinostat results in increased expression of MTARC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:98,894,347...98,928,754
Ensembl chr13:98,897,108...98,928,781 		JBrowse link
G Mthfd2l methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like increases expression
multiple interactions 		ISO panobinostat results in increased expression of MTHFD2L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:17,374,139...17,455,508
Ensembl chr14:17,374,144...17,454,322 		JBrowse link
G Muc15 mucin 15, cell surface associated increases expression
multiple interactions 		ISO panobinostat results in increased expression of MUC15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:117,749,161...117,761,466
Ensembl chr 3:117,749,324...117,762,101 		JBrowse link
G Muc3a mucin 3A, cell surface associated multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA CTD PMID:27188386 NCBI chr12:25,082,728...25,091,494
Ensembl chr12:25,082,837...25,097,265 		JBrowse link
G Muc4 mucin 4, cell surface associated multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA
panobinostat results in increased expression of MUC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:81,513,321...81,575,200 JBrowse link
G Mustn1 musculoskeletal, embryonic nuclear protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA CTD PMID:27188386 NCBI chr16:6,079,355...6,081,608
Ensembl chr16:6,079,277...6,081,586 		JBrowse link
G Mvb12a multivesicular body subunit 12A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA
panobinostat results in decreased expression of MVB12A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:18,286,231...18,291,096
Ensembl chr16:18,286,231...18,292,583 		JBrowse link
G Mxra7 matrix remodeling associated 7 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA
panobinostat results in decreased expression of MXRA7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:102,501,848...102,530,231
Ensembl chr10:102,489,604...102,530,231 		JBrowse link
G Mybl1 MYB proto-oncogene like 1 increases expression ISO Panobinostat results in increased expression of MYBL1 mRNA CTD PMID:33770205 NCBI chr 5:14,365,768...14,401,012
Ensembl chr 5:14,365,768...14,399,588 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat results in decreased expression of MYC protein]; [panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of MYC protein; panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]; panobinostat promotes the reaction [SRT2183 results in decreased expression of MYC protein] CTD PMID:23681230 PMID:24435446 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Mycn MYCN proto-oncogene, bHLH transcription factor multiple interactions
decreases expression
increases expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of MYCN protein]; [(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; Panobinostat inhibits the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein]
panobinostat results in decreased expression of MYCN protein
panobinostat results in increased expression of MYCN mRNA 		CTD PMID:26272509 PMID:26733615 PMID:27188386 NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508 		JBrowse link
G Myct1 myc target 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA CTD PMID:27188386 NCBI chr 1:44,423,478...44,434,751
Ensembl chr 1:44,423,544...44,436,992 		JBrowse link
G Myf5 myogenic factor 5 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA CTD PMID:27188386 NCBI chr 7:44,689,407...44,692,638
Ensembl chr 7:44,689,407...44,692,638 		JBrowse link
G Mylip myosin regulatory light chain interacting protein multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA
panobinostat results in increased expression of MYLIP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471 		JBrowse link
G Mylk myosin light chain kinase multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA
panobinostat results in decreased expression of MYLK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659 		JBrowse link
G Myo1d myosin ID multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA
panobinostat results in increased expression of MYO1D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958 		JBrowse link
G Myo1e myosin IE increases expression ISO Panobinostat results in increased expression of MYO1E mRNA CTD PMID:33770205 NCBI chr 8:79,768,828...79,961,048
Ensembl chr 8:79,753,596...79,961,045 		JBrowse link
G Myo5b myosin Vb multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA CTD PMID:27188386 NCBI chr18:70,313,717...70,613,918
Ensembl chr18:70,311,990...70,613,918 		JBrowse link
G Myocd myocardin increases expression
multiple interactions 		ISO panobinostat results in increased expression of MYOCD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819 		JBrowse link
G Myof myoferlin increases expression
multiple interactions 		ISO panobinostat results in increased expression of MYOF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768 		JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of NABP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:57,570,326...57,625,926
Ensembl chr 9:57,618,505...57,626,052 		JBrowse link
G Nalf1 NALCN channel auxiliary factor 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA
Panobinostat results in decreased expression of NALF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:86,415,540...86,938,150
Ensembl chr16:86,415,488...86,938,150 		JBrowse link
G Nanog Nanog homeobox increases expression
multiple interactions 		ISO panobinostat results in increased expression of NANOG mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061 		JBrowse link
G Nanos1 nanos C2HC-type zinc finger 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA
panobinostat results in decreased expression of NANOS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:269,883,536...269,895,417 		JBrowse link
G Nans N-acetylneuraminate synthase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA
panobinostat results in increased expression of NANS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:65,575,970...65,593,164
Ensembl chr 5:65,576,015...65,610,547 		JBrowse link
G Nav1 neuron navigator 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA
panobinostat results in decreased expression of NAV1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:49,418,755...49,671,117
Ensembl chr13:49,418,755...49,671,004 		JBrowse link
G Nav3 neuron navigator 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA
panobinostat results in increased expression of NAV3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893 		JBrowse link
G Ncald neurocalcin delta multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA
panobinostat results in decreased expression of NCALD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,417,683...70,849,763
Ensembl chr 7:70,419,433...70,849,482 		JBrowse link
G Ncoa7 nuclear receptor coactivator 7 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA
panobinostat results in decreased expression of NCOA7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:28,674,614...28,835,891
Ensembl chr 1:28,675,426...28,835,886 		JBrowse link
G Ndp norrin cystine knot growth factor NDP multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA
panobinostat results in decreased expression of NDP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:8,379,569...8,404,019
Ensembl chr  X:8,379,569...8,406,802 		JBrowse link
G Ndufb1 NADH:ubiquinone oxidoreductase subunit B1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of NDUFB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:121,115,649...121,124,055
Ensembl chr 6:126,880,537...126,888,864 		JBrowse link
G Nefl neurofilament light chain increases expression
multiple interactions 		ISO panobinostat results in increased expression of NEFL mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515 		JBrowse link
G Nefm neurofilament medium chain multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA
panobinostat results in increased expression of NEFM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163 		JBrowse link
G Negr1 neuronal growth regulator 1 increases expression ISO panobinostat results in increased expression of NEGR1 mRNA CTD PMID:27188386 NCBI chr 2:248,283,164...249,015,538
Ensembl chr 2:248,283,353...249,018,410 		JBrowse link
G Nell1 neural EGFL like 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of NELL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:108,845,462...109,709,858
Ensembl chr 1:108,845,462...109,709,858 		JBrowse link
G Nell2 neural EGFL like 2 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of NELL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917 		JBrowse link
G Neu1 neuraminidase 1 increases expression ISO Panobinostat results in increased expression of NEU1 mRNA CTD PMID:33770205 NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,902,120...3,906,383 		JBrowse link
G Neurl3 neuralized E3 ubiquitin protein ligase 3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of LINCR mRNA CTD PMID:21791302 NCBI chr 9:45,990,373...45,998,470
Ensembl chr 9:45,990,375...45,998,535 		JBrowse link
G Nexmif neurite extension and migration factor multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA
panobinostat results in decreased expression of NEXMIF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:73,153,786...73,284,943
Ensembl chr  X:73,153,786...73,178,639 		JBrowse link
G Nf1 neurofibromin 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of NF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:64,803,986...65,037,086
Ensembl chr10:64,804,266...65,034,946 		JBrowse link
G Nfasc neurofascin multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA
panobinostat results in decreased expression of NFASC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:46,549,369...46,735,989
Ensembl chr13:46,549,369...46,736,139 		JBrowse link
G Nfatc4 nuclear factor of activated T-cells 4 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of NFATC4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:33,256,912...33,284,522
Ensembl chr15:33,274,153...33,285,582 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of NFE2L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nfib nuclear factor I/B increases expression
multiple interactions 		ISO panobinostat results in increased expression of NFIB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:101,805,168...102,020,618
Ensembl chr 5:101,805,168...102,019,945 		JBrowse link
G Nfic nuclear factor I/C multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NFIC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NFIC mRNA] CTD PMID:26733615 NCBI chr 7:8,928,423...8,963,455
Ensembl chr 7:8,904,117...8,963,409 		JBrowse link
G Ngef neuronal guanine nucleotide exchange factor increases expression
multiple interactions 		ISO panobinostat results in increased expression of NGEF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:95,594,823...95,692,381
Ensembl chr 9:95,594,823...95,692,251 		JBrowse link
G Ngfr nerve growth factor receptor increases expression
multiple interactions 		ISO panobinostat results in increased expression of NGFR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305 		JBrowse link
G Nhsl2 NHS-like 2 affects expression
multiple interactions 		ISO panobinostat affects the expression of NHSL2 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NHSL2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NHSL2 mRNA] 		CTD PMID:26733615 NCBI chr  X:71,009,940...71,249,427
Ensembl chr  X:71,009,949...71,241,289 		JBrowse link
G Nipal2 NIPA-like domain containing 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of NIPAL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:67,659,628...67,771,105
Ensembl chr 7:67,659,628...67,769,959 		JBrowse link
G Nkain3 Sodium/potassium transporting ATPase interacting 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA
Panobinostat results in decreased expression of NKAIN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:38,410,576...39,106,910
Ensembl chr 5:38,386,841...39,106,385 		JBrowse link
G Nkd1 NKD inhibitor of WNT signaling pathway 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of NKD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:34,649,803...34,722,846 JBrowse link
G Nlgn1 neuroligin 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of NLGN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:110,184,987...111,110,316
Ensembl chr 2:110,186,573...110,909,984 		JBrowse link
G Nlrp1a NLR family, pyrin domain containing 1A multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of NLRP1 mRNA CTD PMID:21791302 NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880 		JBrowse link
G Nme8 NME/NM23 family member 8 increases expression
multiple interactions 		ISO panobinostat results in increased expression of NME8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:49,932,861...50,000,610
Ensembl chr17:49,932,860...50,000,608 		JBrowse link
G Nmi N-myc (and STAT) interactor increases expression
multiple interactions 		ISO panobinostat results in increased expression of NMI mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:56,824,778...56,848,891
Ensembl chr 3:56,811,314...56,848,717 		JBrowse link
G Nmnat2 nicotinamide nucleotide adenylyltransferase 2 multiple interactions
increases expression 		ISO [Cisplatin co-treated with Panobinostat] affects the expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA
panobinostat results in increased expression of NMNAT2 mRNA 		CTD PMID:21791302 PMID:26272509 PMID:27188386 NCBI chr13:67,655,794...67,831,609
Ensembl chr13:67,655,807...67,831,608 		JBrowse link
G Noct nocturnin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA
panobinostat results in increased expression of NOCT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:137,422,074...137,442,282
Ensembl chr 2:137,422,074...137,442,282 		JBrowse link
G Nog noggin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPY19L2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERLEC1P1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM200B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM226B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BW4P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00515 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503-AS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF785 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF93 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN16-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOBEC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRC11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVMER61-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00472 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1LC3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGCKA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VHRT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF165 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF600 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA
panobinostat results in increased expression of NOG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103 		JBrowse link
G Nol4 nucleolar protein 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA
panobinostat results in decreased expression of NOL4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:14,207,303...14,569,697
Ensembl chr18:14,207,303...14,569,677 		JBrowse link
G Npffr2 neuropeptide FF receptor 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA
panobinostat results in increased expression of NPFFR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:18,513,120...18,558,074
Ensembl chr14:18,797,234...18,842,186 		JBrowse link
G Npnt nephronectin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA
panobinostat results in increased expression of NPNT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:224,065,191...224,133,435 		JBrowse link
G Npr3 natriuretic peptide receptor 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA
panobinostat results in increased expression of NPR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:62,592,557...62,660,497
Ensembl chr 2:62,597,668...62,660,066 		JBrowse link
G Npy neuropeptide Y multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA
panobinostat results in increased expression of NPY mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310 		JBrowse link
G Npy1r neuropeptide Y receptor Y1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA
panobinostat results in decreased expression of NPY1R mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387 		JBrowse link
G Npy2r neuropeptide Y receptor Y2 multiple interactions
affects expression
decreases expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of NPY2R mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NPY2R mRNA]
panobinostat affects the expression of NPY2R mRNA
panobinostat results in decreased expression of NPY2R mRNA 		CTD PMID:26272509 PMID:26733615 PMID:27188386 NCBI chr 2:170,200,027...170,210,286
Ensembl chr 2:170,200,027...170,210,448 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA
panobinostat results in increased expression of NQO1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA
panobinostat results in increased expression of NQO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:31,114,825...31,144,062
Ensembl chr17:31,114,529...31,143,662 		JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA
panobinostat results in increased expression of NR2F1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924 		JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA
panobinostat results in decreased expression of NR2F2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:133,420,227...133,431,975 		JBrowse link
G Nrg1 neuregulin 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA
panobinostat results in decreased expression of NRG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849 		JBrowse link
G Nrip1 nuclear receptor interacting protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA
panobinostat results in increased expression of NRIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:28,382,835...28,466,483
Ensembl chr11:28,378,878...28,467,353 		JBrowse link
G Nrip3 nuclear receptor interacting protein 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA
panobinostat results in decreased expression of NRIP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:173,224,532...173,249,829
Ensembl chr 1:173,224,532...173,251,769 		JBrowse link
G Nrk Nik related kinase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA CTD PMID:27188386 NCBI chr  X:107,159,154...107,256,417
Ensembl chr  X:107,159,233...107,256,417 		JBrowse link
G Nrp1 neuropilin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA
panobinostat results in increased expression of NRP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702 		JBrowse link
G Nrp2 neuropilin 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA CTD PMID:27188386 NCBI chr 9:71,616,602...71,731,869
Ensembl chr 9:71,616,657...71,731,871 		JBrowse link
G Nrros negative regulator of reactive oxygen species decreases expression ISO Panobinostat results in decreased expression of NRROS mRNA CTD PMID:33770205 NCBI chr11:82,133,608...82,151,160
Ensembl chr11:82,133,144...82,151,308 		JBrowse link
G Nrxn2 neurexin 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA CTD PMID:27188386 NCBI chr 1:213,155,673...213,271,526
Ensembl chr 1:213,155,673...213,271,526 		JBrowse link
G Nsd2 nuclear receptor binding SET domain protein 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA
panobinostat results in decreased expression of NSD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:81,057,727...81,135,866
Ensembl chr14:81,057,727...81,123,027 		JBrowse link
G Nsmaf neutral sphingomyelinase activation associated factor multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NSMAF mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NSMAF mRNA] CTD PMID:26733615 NCBI chr 5:24,315,319...24,378,346
Ensembl chr 5:24,315,319...24,375,355 		JBrowse link
G Ntn4 netrin 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA
panobinostat results in decreased expression of NTN4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:30,073,637...30,187,407
Ensembl chr 7:30,073,333...30,188,309 		JBrowse link
G Nuak2 NUAK family kinase 2 decreases expression ISO panobinostat results in decreased expression of NUAK2 mRNA CTD PMID:26272509 NCBI chr13:46,305,744...46,322,755
Ensembl chr13:46,305,975...46,322,748 		JBrowse link
G Nudt4 nudix hydrolase 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA
panobinostat results in increased expression of NUDT4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:32,074,978...32,091,491
Ensembl chr 7:32,075,002...32,091,491 		JBrowse link
G Nwd2 NACHT and WD repeat domain containing 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA
panobinostat results in increased expression of NWD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:44,833,623...45,024,962
Ensembl chr14:44,834,856...45,024,047 		JBrowse link
G Oat ornithine aminotransferase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA
panobinostat results in increased expression of OAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754 		JBrowse link
G Ola1 Obg-like ATPase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA
panobinostat results in decreased expression of OLA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:78,374,440...78,493,401
Ensembl chr 3:78,374,441...78,492,012 		JBrowse link
G Olfm3 olfactomedin 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA
panobinostat results in increased expression of OLFM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:205,417,962...205,640,479
Ensembl chr 2:205,598,959...205,640,479 		JBrowse link
G Olfml3 olfactomedin-like 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA
panobinostat results in increased expression of OLFML3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:193,932,665...193,935,494
Ensembl chr 2:193,932,665...193,935,494 		JBrowse link
G Olig3 oligodendrocyte transcription factor 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA CTD PMID:27188386 NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274 		JBrowse link
G Onecut2 one cut homeobox 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of ONECUT2 mRNA CTD PMID:21791302 NCBI chr18:60,101,967...60,161,095
Ensembl chr18:60,102,126...60,107,668 		JBrowse link
G Opcml opioid binding protein/cell adhesion molecule-like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA
panobinostat results in increased expression of OPCML mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:34,451,629...35,562,897
Ensembl chr 8:34,451,500...35,558,966 		JBrowse link
G Oprk1 opioid receptor, kappa 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA
panobinostat results in decreased expression of OPRK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671 		JBrowse link
G Orm1 orosomucoid 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA
panobinostat results in decreased expression of ORM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667 		JBrowse link
G Osbpl10 oxysterol binding protein-like 10 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA
panobinostat results in increased expression of OSBPL10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:123,536,818...123,796,822
Ensembl chr 8:123,539,235...123,796,822 		JBrowse link
G Otx2 orthodenticle homeobox 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA CTD PMID:27188386 NCBI chr15:24,422,876...24,432,709
Ensembl chr15:24,422,876...24,432,472 		JBrowse link
G Ovol1 ovo like transcriptional repressor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA
panobinostat results in increased expression of OVOL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:212,284,601...212,296,106
Ensembl chr 1:212,284,605...212,296,106 		JBrowse link
G Ovol2 ovo-like zinc finger 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA CTD PMID:27188386 NCBI chr 3:152,130,767...152,160,487
Ensembl chr 3:152,130,767...152,160,487 		JBrowse link
G Pabpc4l poly(A) binding protein, cytoplasmic 4-like increases expression
multiple interactions 		ISO panobinostat results in increased expression of PABPC4L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:129,807,755...129,809,745
Ensembl chr 2:131,740,252...131,746,176 		JBrowse link
G Pabpc5 poly A binding protein, cytoplasmic 5 increases expression ISO panobinostat results in increased expression of PABPC5 mRNA CTD PMID:26272509 NCBI chr  X:85,637,763...85,641,235
Ensembl chr  X:89,858,427...89,860,487 		JBrowse link
G Pak3 p21 (RAC1) activated kinase 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA
panobinostat results in decreased expression of PAK3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:111,912,967...112,171,037
Ensembl chr  X:111,913,059...112,165,035 		JBrowse link
G Pamr1 peptidase domain containing associated with muscle regeneration 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA
panobinostat results in decreased expression of PAMR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:109,340,411...109,443,595
Ensembl chr 3:109,341,476...109,443,585 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [resveratrol co-treated with panobinostat] results in increased cleavage of PARP1 protein CTD PMID:22923501 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Patj PATJ, crumbs cell polarity complex component multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA CTD PMID:27188386 NCBI chr 5:118,177,557...118,480,301
Ensembl chr 5:118,177,565...118,480,301 		JBrowse link
G Pax2 paired box 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA
panobinostat results in increased expression of PAX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:253,555,447...253,646,623
Ensembl chr 1:253,555,418...253,645,438 		JBrowse link
G Pax3 paired box 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA
panobinostat results in increased expression of PAX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141 		JBrowse link
G Pax6 paired box 6 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of PAX6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763 		JBrowse link
G Pax7 paired box 7 increases expression
multiple interactions 		ISO panobinostat results in increased expression of PAX7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:157,279,623...157,381,188
Ensembl chr 5:157,279,623...157,381,121 		JBrowse link
G Pbx2 PBX homeobox 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of PBX2 mRNA CTD PMID:21791302 NCBI chr20:4,156,107...4,161,503
Ensembl chr20:4,156,107...4,161,827 		JBrowse link
G Pcdh10 protocadherin 10 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA
panobinostat results in increased expression of PCDH10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:130,553,425...130,613,407 		JBrowse link
G Pcdh20 protocadherin 20 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA
panobinostat results in increased expression of PCDH20 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:70,834,042...70,840,298
Ensembl chr15:70,834,042...70,840,298 		JBrowse link
G Pcdh7 protocadherin 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA
panobinostat results in increased expression of PCDH7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:56,684,817...57,114,976
Ensembl chr14:56,687,725...57,112,665 		JBrowse link
G Pcdh8 protocadherin 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA
panobinostat results in increased expression of PCDH8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:61,607,521...61,612,090
Ensembl chr15:61,607,521...61,612,097 		JBrowse link
G Pcdhb20 protocadherin beta 20 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA
panobinostat results in decreased expression of PCDHB14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:29,211,878...29,215,272
Ensembl chr18:29,454,999...29,489,427 		JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA CTD PMID:27188386 NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561 		JBrowse link
G Pcm1 pericentriolar material 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA CTD PMID:27188386 NCBI chr16:57,711,833...57,808,842
Ensembl chr16:57,711,833...57,808,599 		JBrowse link
G Pcmtd1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA CTD PMID:27188386 NCBI chr 5:17,071,629...17,143,803
Ensembl chr 5:17,071,629...17,142,010 		JBrowse link
G Pcolce procollagen C-endopeptidase enhancer multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA CTD PMID:27188386 NCBI chr12:24,720,972...24,727,287
Ensembl chr12:24,720,936...24,727,287 		JBrowse link
G Pcolce2 procollagen C-endopeptidase enhancer 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA
panobinostat results in increased expression of PCOLCE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:105,073,086...105,130,725
Ensembl chr 8:105,073,086...105,145,160 		JBrowse link
G Pcp4l1 Purkinje cell protein 4-like 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA CTD PMID:27188386 NCBI chr13:86,121,463...86,145,097
Ensembl chr13:86,121,464...86,144,899 		JBrowse link
G Pde10a phosphodiesterase 10A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA
panobinostat results in decreased expression of PDE10A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:54,313,343...54,765,668
Ensembl chr 1:54,317,732...54,764,051 		JBrowse link
G Pde11a phosphodiesterase 11A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA CTD PMID:27188386 NCBI chr 3:81,320,822...81,704,397
Ensembl chr 3:81,320,822...81,680,612 		JBrowse link
G Pde3a phosphodiesterase 3A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA
panobinostat results in increased expression of PDE3A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:175,904,077...176,169,270 		JBrowse link
G Pde4c phosphodiesterase 4C multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of PDE4C mRNA CTD PMID:21791302 NCBI chr16:18,724,703...18,745,528
Ensembl chr16:18,725,674...18,744,037 		JBrowse link
G Pde4d phosphodiesterase 4D multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA
panobinostat results in increased expression of PDE4D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:41,748,337...43,262,567
Ensembl chr 2:42,110,838...43,262,569 		JBrowse link
G Pde4dip phosphodiesterase 4D interacting protein multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA
panobinostat results in increased expression of PDE4DIP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:187,982,002...188,178,937
Ensembl chr 2:187,981,878...188,178,869 		JBrowse link
G Pdgfa platelet derived growth factor subunit A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA
panobinostat results in increased expression of PDGFA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:20,759,366...20,780,337
Ensembl chr12:20,754,208...20,780,322 		JBrowse link
G Pdgfc platelet derived growth factor C increases expression
multiple interactions 		ISO panobinostat results in increased expression of PDGFC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:168,613,409...168,791,575
Ensembl chr 2:168,614,353...168,791,573 		JBrowse link
G Pdgfra platelet derived growth factor receptor alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA
panobinostat results in increased expression of PDGFRA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,360,028...33,408,516 		JBrowse link
G Pdia5 protein disulfide isomerase family A, member 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA
panobinostat results in increased expression of PDIA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:78,777,436...78,892,370
Ensembl chr11:78,777,419...78,864,329 		JBrowse link
G Pdlim1 PDZ and LIM domain 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA
panobinostat results in increased expression of PDLIM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:248,991,818...249,040,409
Ensembl chr 1:248,991,818...249,047,379 		JBrowse link
G Pdpn podoplanin increases expression
multiple interactions 		ISO panobinostat results in increased expression of PDPN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:160,884,995...160,919,112
Ensembl chr 5:160,884,993...160,925,637 		JBrowse link
G Pdyn prodynorphin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA
panobinostat results in increased expression of PDYN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:137,354,161...137,366,503
Ensembl chr 3:137,354,161...137,366,503 		JBrowse link
G Pfkp phosphofructokinase, platelet increases expression
multiple interactions 		ISO panobinostat results in increased expression of PFKP mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:68,639,749...68,704,055
Ensembl chr17:68,639,481...68,705,752 		JBrowse link
G Pgcka1 PDCD10 and GCKIII kinases associated 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGCKA1 mRNA CTD PMID:27188386 NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,740,972...44,831,613 		JBrowse link
G Pgm1 phosphoglucomutase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA
panobinostat results in increased expression of PGM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:119,710,734...119,770,159
Ensembl chr 5:119,710,737...119,770,159 		JBrowse link
G Phip pleckstrin homology domain interacting protein multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA
panobinostat results in decreased expression of PHIP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:92,656,890...92,771,098
Ensembl chr 8:92,656,890...92,771,021 		JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA
panobinostat results in increased expression of PHLDA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542 		JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of PHLDA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920 		JBrowse link
G Phtf2 putative homeodomain transcription factor 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA CTD PMID:27188386 NCBI chr 4:15,107,341...15,222,683
Ensembl chr 4:15,107,373...15,222,692 		JBrowse link
G Pid1 phosphotyrosine interaction domain containing 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA CTD PMID:27188386 NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:92,734,214...92,750,070 		JBrowse link
G Piezo2 piezo-type mechanosensitive ion channel component 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA CTD PMID:27188386 NCBI chr18:58,738,734...59,115,252
Ensembl chr18:58,738,740...59,115,215 		JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase increases expression
multiple interactions 		ISO panobinostat results in increased expression of PIM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764 		JBrowse link
G Pipox pipecolic acid and sarcosine oxidase increases expression
multiple interactions 		ISO panobinostat results in increased expression of PIPOX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:63,267,946...63,281,556
Ensembl chr10:63,267,972...63,282,273 		JBrowse link
G Pitx2 paired-like homeodomain 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA
panobinostat results in increased expression of PITX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:220,391,417...220,411,588
Ensembl chr 2:220,391,888...220,411,591 		JBrowse link
G Pkdcc protein kinase domain containing, cytoplasmic increases expression
multiple interactions 		ISO panobinostat results in increased expression of PKDCC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:17,208,171...17,217,488
Ensembl chr 6:17,208,171...17,218,042 		JBrowse link
G Pkm pyruvate kinase M1/2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of PKM mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396 		JBrowse link
G Pknox2 PBX/knotted 1 homeobox 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA
panobinostat results in increased expression of PKNOX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:44,789,464...45,051,933
Ensembl chr 8:44,789,467...44,979,754 		JBrowse link
G Pla2g2a phospholipase A2 group IIA multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA
panobinostat results in increased expression of PLA2G2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:156,359,725...156,362,297 		JBrowse link
G Pla2g4a phospholipase A2 group 4A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA
panobinostat results in increased expression of PLA2G4A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641 		JBrowse link
G Pla2g7 phospholipase A2 group VII multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA
panobinostat results in increased expression of PLA2G7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:24,859,502...24,901,747 		JBrowse link
G Plaat5 phospholipase A and acyltransferase 5 increases expression
multiple interactions 		ISO Panobinostat results in increased expression of PLAAT5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:204,847,600...204,878,456
Ensembl chr 1:214,277,044...214,307,598 		JBrowse link
G Plat plasminogen activator, tissue type multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA
panobinostat results in increased expression of PLAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA
panobinostat results in increased expression of PLAU mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030 		JBrowse link
G Plbd1 phospholipase B domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA
panobinostat results in increased expression of PLBD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,204,198...171,260,488
Ensembl chr 4:171,204,198...171,260,488 		JBrowse link
G Plce1 phospholipase C, epsilon 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA
panobinostat results in increased expression of PLCE1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:245,655,855...245,964,966
Ensembl chr 1:245,657,080...245,963,828 		JBrowse link
G Plekha2 pleckstrin homology domain containing A2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA CTD PMID:27188386 NCBI chr16:73,641,338...73,704,068
Ensembl chr16:73,641,344...73,703,087 		JBrowse link
G Plekhm3 pleckstrin homology domain containing M3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA CTD PMID:27188386 NCBI chr 9:73,659,998...73,819,079
Ensembl chr 9:73,664,817...73,799,503 		JBrowse link
G Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA
panobinostat results in increased expression of PLOD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022 		JBrowse link
G Plp1 proteolipid protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA
panobinostat results in increased expression of PLP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:104,933,921...104,993,317
Ensembl chr  X:104,975,780...104,993,314 		JBrowse link
G Plscr1 phospholipid scramblase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA
panobinostat results in increased expression of PLSCR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:101,662,512...101,684,474
Ensembl chr 8:101,664,056...101,684,614 		JBrowse link
G Plxna2 plexin A2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA
panobinostat results in increased expression of PLXNA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453 		JBrowse link
G Plxnc1 plexin C1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA
panobinostat results in decreased expression of PLXNC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:31,276,978...31,430,823
Ensembl chr 7:31,276,978...31,431,092 		JBrowse link
G Pmepa1 prostate transmembrane protein, androgen induced 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA
panobinostat results in increased expression of PMEPA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:182,430,193...182,478,649
Ensembl chr 3:182,430,193...182,478,649 		JBrowse link
G Pnmt phenylethanolamine-N-methyltransferase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of PNMT mRNA CTD PMID:21791302 NCBI chr10:83,881,211...83,882,849
Ensembl chr10:83,881,185...83,882,849 		JBrowse link
G Pnp purine nucleoside phosphorylase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA
panobinostat results in increased expression of PNP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:26,644,147...26,651,808
Ensembl chr15:26,643,858...26,678,162 		JBrowse link
G Podxl podocalyxin-like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA
panobinostat results in increased expression of PODXL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:61,102,434...61,149,131
Ensembl chr 4:61,102,419...61,149,789 		JBrowse link
G Poli DNA polymerase iota multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA
panobinostat results in decreased expression of POLI mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:66,389,214...66,409,734
Ensembl chr18:66,364,236...66,409,819 		JBrowse link
G Polr2a RNA polymerase II subunit A multiple interactions
decreases phosphorylation 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased phosphorylation of POLR2A protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of POLR2A protein]
panobinostat results in decreased phosphorylation of POLR2A protein 		CTD PMID:24435446 NCBI chr10:54,951,162...54,977,179
Ensembl chr10:54,951,162...54,977,179 		JBrowse link
G Polr3e RNA polymerase III subunit E multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of POLR3E mRNA CTD PMID:21791302 NCBI chr 1:175,466,091...175,494,679
Ensembl chr 1:184,897,426...184,926,534 		JBrowse link
G Polr3g RNA polymerase III subunit G multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA
panobinostat results in increased expression of POLR3G mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:13,680,893...13,721,802
Ensembl chr 2:13,680,895...13,721,802 		JBrowse link
G Pon1 paraoxonase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA
panobinostat results in decreased expression of PON1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924 		JBrowse link
G Popdc2 popeye domain cAMP effector 2 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of POPDC2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of POPDC2 mRNA] CTD PMID:26733615 NCBI chr11:75,850,068...75,897,094
Ensembl chr11:75,880,274...75,896,269 		JBrowse link
G Popdc3 popeye domain cAMP effector 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA
panobinostat results in decreased expression of POPDC3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:50,354,775...50,383,050
Ensembl chr20:50,354,767...50,385,674 		JBrowse link
G Pou3f1 POU class 3 homeobox 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA
panobinostat results in decreased expression of POU3F1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:142,195,090...142,198,070
Ensembl chr 5:142,194,066...142,202,704 		JBrowse link
G Pou3f3 POU class 3 homeobox 3 increases expression ISO panobinostat results in increased expression of POU3F3 mRNA CTD PMID:26272509 NCBI chr 9:52,438,026...52,441,152
Ensembl chr 9:52,435,625...52,454,705 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO panobinostat results in increased expression of POU5F1 mRNA CTD PMID:26272509 NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598 		JBrowse link
G Ppargc1b PPARG coactivator 1 beta multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA
panobinostat results in increased expression of PPARGC1B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:57,029,264...57,131,466
Ensembl chr18:57,029,275...57,131,466 		JBrowse link
G Ppib peptidylprolyl isomerase B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA
panobinostat results in increased expression of PPIB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:75,498,966...75,504,823
Ensembl chr 8:75,498,797...75,504,847 		JBrowse link
G Ppic peptidylprolyl isomerase C multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA
panobinostat results in increased expression of PPIC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:49,040,690...49,053,296
Ensembl chr18:49,040,692...49,053,466 		JBrowse link
G Ppl periplakin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA
panobinostat results in increased expression of PPL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:10,957,388...11,003,035
Ensembl chr10:10,957,341...11,003,658 		JBrowse link
G Ppm1a protein phosphatase, Mg2+/Mn2+ dependent, 1A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA CTD PMID:27188386 NCBI chr 6:97,174,955...97,216,585
Ensembl chr 6:97,174,916...97,216,574 		JBrowse link
G Ppm1j protein phosphatase, Mg2+/Mn2+ dependent, 1J multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA
panobinostat results in increased expression of PPM1J mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:194,966,854...194,972,228
Ensembl chr 2:194,966,950...194,972,227 		JBrowse link
G Ppm1k protein phosphatase, Mg2+/Mn2+ dependent, 1K multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA
panobinostat results in increased expression of PPM1K mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:87,612,198...87,638,993
Ensembl chr 4:88,942,386...88,969,136 		JBrowse link
G Ppox protoporphyrinogen oxidase multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA
panobinostat results in decreased expression of PPOX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:86,230,111...86,235,028
Ensembl chr13:86,230,111...86,234,246 		JBrowse link
G Ppp1r13l protein phosphatase 1, regulatory subunit 13 like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA
panobinostat results in increased expression of PPP1R13L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:88,139,000...88,158,714
Ensembl chr 1:88,140,532...88,158,714 		JBrowse link
G Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA
panobinostat results in increased expression of PPP1R1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:136,533,031...136,540,687
Ensembl chr 7:136,523,604...136,540,683 		JBrowse link
G Ppp1r3b protein phosphatase 1, regulatory subunit 3B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA
panobinostat results in increased expression of PPP1R3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:63,533,318...63,545,683
Ensembl chr16:63,532,842...63,549,997 		JBrowse link
G Ppp1r3d protein phosphatase 1, regulatory subunit 3D multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA
panobinostat results in increased expression of PPP1R3D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:185,880,087...185,883,158
Ensembl chr 3:185,876,709...185,883,703 		JBrowse link
G Ppp1r9a protein phosphatase 1, regulatory subunit 9A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA
panobinostat results in decreased expression of PPP1R9A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:33,936,949...34,258,927
Ensembl chr 4:33,988,827...34,258,927 		JBrowse link
G Ppp2r2b protein phosphatase 2, regulatory subunit B, beta multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA
panobinostat results in decreased expression of PPP2R2B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:34,904,686...35,357,299
Ensembl chr18:34,904,686...35,356,977 		JBrowse link
G Prag1 PEAK1 related kinase activating pseudokinase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA
panobinostat results in increased expression of PRAG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:62,791,249...62,844,532
Ensembl chr16:62,786,329...62,844,532 		JBrowse link
G Prdm1 PR/SET domain 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA
panobinostat results in increased expression of PRDM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:49,542,465...49,564,088
Ensembl chr20:49,542,465...49,564,088 		JBrowse link
G Prdm14 PR/SET domain 14 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA
panobinostat results in increased expression of PRDM14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:10,864,137...10,876,666
Ensembl chr 5:10,864,137...10,876,666 		JBrowse link
G Prdm16 PR/SET domain 16 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA CTD PMID:27188386 NCBI chr 5:170,162,275...170,486,371
Ensembl chr 5:170,162,275...170,485,804 		JBrowse link
G Prelp proline and arginine rich end leucine rich repeat protein multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA CTD PMID:27188386 NCBI chr13:47,920,480...47,943,547
Ensembl chr13:47,922,590...47,932,324 		JBrowse link
G Prex1 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA
panobinostat results in increased expression of PREX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:175,724,939...175,875,764
Ensembl chr 3:175,726,012...175,875,764 		JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA
panobinostat results in increased expression of PRKACA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:41,059,843...41,083,189
Ensembl chr19:41,059,843...41,086,494 		JBrowse link
G Prkca protein kinase C, alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA
panobinostat results in increased expression of PRKCA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572 		JBrowse link
G Prkcb protein kinase C, beta multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA
panobinostat results in increased expression of PRKCB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740 		JBrowse link
G Prkch protein kinase C, eta multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA
panobinostat results in increased expression of PRKCH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:98,027,830...98,226,486
Ensembl chr 6:98,027,646...98,226,477 		JBrowse link
G Prnp prion protein multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA
panobinostat results in increased expression of PRNP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:139,639,076...139,654,420
Ensembl chr 3:139,630,144...139,658,436 		JBrowse link
G Prodh proline dehydrogenase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA
panobinostat results in increased expression of PRODH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:96,414,275...96,431,604
Ensembl chr11:96,414,224...96,433,418 		JBrowse link
G Prok2 prokineticin 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA
panobinostat results in decreased expression of PROK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:133,903,210...133,918,126
Ensembl chr 4:133,903,210...133,917,933 		JBrowse link
G Prr15 proline rich 15 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA
panobinostat results in increased expression of PRR15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:84,762,357...84,765,403
Ensembl chr 4:84,761,523...84,768,442 		JBrowse link
G Prr16 proline rich 16 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA
panobinostat results in increased expression of PRR16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:44,424,348...44,764,796
Ensembl chr18:46,623,058...46,830,385 		JBrowse link
G Prrg1 proline rich and Gla domain 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA
panobinostat results in increased expression of PRRG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:46,381,329...46,493,677
Ensembl chr  X:46,383,967...46,493,700 		JBrowse link
G Prrx1 paired related homeobox 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA
panobinostat results in increased expression of PRRX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:78,136,783...78,205,379
Ensembl chr13:78,136,783...78,204,058 		JBrowse link
G Prss12 serine protease 12 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA
panobinostat results in increased expression of PRSS12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:214,308,774...214,369,941 		JBrowse link
G Prss23 serine protease 23 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA
panobinostat results in decreased expression of PRSS23 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:152,813,670...152,947,871 		JBrowse link
G Prss8 serine protease 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA
panobinostat results in increased expression of PRSS8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:191,966,701...191,971,271
Ensembl chr 1:191,966,701...191,971,193 		JBrowse link
G Prune2 prune homolog 2 with BCH domain multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA
panobinostat results in decreased expression of PRUNE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592 		JBrowse link
G Ptchd1 patched domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA
panobinostat results in increased expression of PTCHD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:43,496,907...43,548,413
Ensembl chr  X:43,496,907...43,548,544 		JBrowse link
G Ptger4 prostaglandin E receptor 4 increases expression ISO panobinostat results in increased expression of PTGER4 mRNA CTD PMID:26272509 NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:56,062,890...56,074,135 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA
panobinostat results in decreased expression of PTGS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990 		JBrowse link
G Ptpn5 protein tyrosine phosphatase, non-receptor type 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA
panobinostat results in decreased expression of PTPN5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:106,756,896...106,817,369
Ensembl chr 1:106,756,896...106,816,828 		JBrowse link
G Ptpn9 protein tyrosine phosphatase, non-receptor type 9 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of PTPN9 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of PTPN9 mRNA] CTD PMID:26733615 NCBI chr 8:66,286,771...66,368,306
Ensembl chr 8:66,287,284...66,368,294 		JBrowse link
G Ptprf protein tyrosine phosphatase, receptor type, F multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of PTPRF mRNA CTD PMID:21791302 NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426 		JBrowse link
G Ptprn2 protein tyrosine phosphatase, receptor type N2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA
panobinostat results in decreased expression of PTPRN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:143,582,568...144,334,573
Ensembl chr 6:143,582,547...144,336,744 		JBrowse link
G Ptpro protein tyrosine phosphatase, receptor type, O multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA
panobinostat results in decreased expression of PTPRO mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903 		JBrowse link
G Purg purine-rich element binding protein G multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA
panobinostat results in decreased expression of PURG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:65,435,371...65,466,437
Ensembl chr16:65,412,238...65,466,185 		JBrowse link
G Pwwp2b PWWP domain containing 2B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA CTD PMID:27188386 NCBI chr 1:203,470,172...203,489,575
Ensembl chr 1:203,470,928...203,489,549 		JBrowse link
G Pxdc1 PX domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA
panobinostat results in increased expression of PXDC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:30,481,336...30,510,330
Ensembl chr17:30,481,373...30,510,331 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA
panobinostat results in increased expression of PYCARD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419 		JBrowse link
G Pym1 PYM homolog 1, exon junction complex associated factor decreases expression ISO Panobinostat results in decreased expression of PYM1 mRNA CTD PMID:33770205 NCBI chr 7:1,177,746...1,200,899
Ensembl chr 7:1,759,110...1,783,948 		JBrowse link
G Rab11fip1 RAB11 family interacting protein 1 increases expression ISO Panobinostat results in increased expression of RAB11FIP1 mRNA CTD PMID:33770205 NCBI chr16:71,589,753...71,620,341
Ensembl chr16:71,589,753...71,620,341 		JBrowse link
G Rab11fip4 RAB11 family interacting protein 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA
panobinostat results in increased expression of RAB11FIP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:65,048,070...65,156,086
Ensembl chr10:65,048,140...65,152,722 		JBrowse link
G Rab17 RAB17, member RAS oncogene family multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA
panobinostat results in increased expression of RAB17 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:99,001,044...99,014,340
Ensembl chr 9:99,001,045...99,014,032 		JBrowse link
G Rab20 RAB20, member RAS oncogene family multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA
panobinostat results in increased expression of RAB20 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:84,721,427...84,745,610
Ensembl chr16:84,721,427...84,745,610 		JBrowse link
G Rab31 RAB31, member RAS oncogene family multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA
panobinostat results in increased expression of RAB31 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:112,693,597...112,828,092 		JBrowse link
G Rab33a RAB33A, member RAS oncogene family multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA
panobinostat results in decreased expression of RAB33A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:132,572,133...132,584,255
Ensembl chr  X:132,572,148...132,584,254 		JBrowse link
G Rab3c RAB3C, member RAS oncogene family multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA
panobinostat results in increased expression of RAB3C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:41,627,720...41,843,541
Ensembl chr 2:43,361,093...43,577,022 		JBrowse link
G Rab3ip RAB3A interacting protein multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA
panobinostat results in decreased expression of RAB3IP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:54,417,418...54,461,253
Ensembl chr 7:54,418,358...54,447,000 		JBrowse link
G Rab7b Rab7b, member RAS oncogene family multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA
panobinostat results in increased expression of RAB7B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:45,673,396...45,699,798
Ensembl chr13:45,673,416...45,709,933 		JBrowse link
G Rabgap1l RAB GTPase activating protein 1-like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA
panobinostat results in increased expression of RABGAP1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:74,997,542...75,593,240
Ensembl chr13:74,997,542...75,533,816 		JBrowse link
G Rac2 Rac family small GTPase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA
panobinostat results in increased expression of RAC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:111,996,742...112,009,267 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein CTD PMID:18445700 NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813 		JBrowse link
G Ralgdsl1 ral guanine nucleotide dissociation stimulator like 1 increases expression ISO Panobinostat results in increased expression of RGL1 mRNA CTD PMID:33770205 NCBI chr13:67,184,402...67,454,019
Ensembl chr13:67,184,402...67,454,019 		JBrowse link
G Rarb retinoic acid receptor, beta multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA
panobinostat results in increased expression of RARB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040 		JBrowse link
G Rarres2 retinoic acid receptor responder 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA
panobinostat results in increased expression of RARRES2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457 		JBrowse link
G Rasa2 RAS p21 protein activator 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA
panobinostat results in decreased expression of RASA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:105,996,797...106,116,285
Ensembl chr 8:106,000,002...106,116,206 		JBrowse link
G Rasef RAS and EF hand domain containing multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA
panobinostat results in increased expression of RASEF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:92,595,148...92,665,526
Ensembl chr 5:92,595,148...92,666,117 		JBrowse link
G Rasgrp2 RAS guanyl releasing protein 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA CTD PMID:27188386 NCBI chr 1:213,135,034...213,152,246
Ensembl chr 1:213,136,015...213,151,884 		JBrowse link
G Rassf1 Ras association domain family member 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of RASSF1 mRNA CTD PMID:21791302 NCBI chr 8:117,103,665...117,114,805
Ensembl chr 8:117,103,362...117,114,805 		JBrowse link
G Rassf10 Ras association domain family member 10 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA
panobinostat results in decreased expression of RASSF10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:167,058,277...167,063,591
Ensembl chr 1:176,492,839...176,495,758 		JBrowse link
G Rassf3 Ras association domain family member 3 increases expression ISO panobinostat results in increased expression of RASSF3 mRNA CTD PMID:26272509 NCBI chr 7:58,821,360...58,886,020
Ensembl chr 7:58,821,360...58,886,020 		JBrowse link
G Rassf6 Ras association domain family member 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA CTD PMID:27188386 NCBI chr14:17,433,328...17,473,565
Ensembl chr14:17,717,567...17,760,378 		JBrowse link
G Rax retina and anterior neural fold homeobox multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA
panobinostat results in decreased expression of RAX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:61,733,322...61,737,444
Ensembl chr18:61,733,322...61,737,444 		JBrowse link
G Rbfox1 RNA binding fox-1 homolog 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA
panobinostat results in increased expression of RBFOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:8,658,809...10,754,648
Ensembl chr10:8,658,809...10,754,706 		JBrowse link
G Rbfox3 RNA binding fox-1 homolog 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA
panobinostat results in decreased expression of RBFOX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:104,218,940...104,655,863
Ensembl chr10:104,218,940...104,551,945 		JBrowse link
G Rbm22 RNA binding motif protein 22 decreases expression ISO Panobinostat results in decreased expression of RBM22 mRNA CTD PMID:33770205 NCBI chr18:56,283,807...56,294,615
Ensembl chr18:56,283,770...56,295,073 		JBrowse link
G Rbm24 RNA binding motif protein 24 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA
panobinostat results in decreased expression of RBM24 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:18,481,893...18,494,440
Ensembl chr17:18,481,900...18,494,604 		JBrowse link
G Rbm43 RNA binding motif protein 43 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA
panobinostat results in increased expression of RBM43 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:56,802,384...56,821,371
Ensembl chr 3:56,803,593...56,811,350 		JBrowse link
G Rbm47 RNA binding motif protein 47 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA CTD PMID:27188386 NCBI chr14:42,407,226...42,545,304
Ensembl chr14:42,466,335...42,543,163 		JBrowse link
G Rbms3 RNA binding motif, single stranded interacting protein 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA CTD PMID:27188386 NCBI chr 8:125,183,311...125,970,239
Ensembl chr 8:125,183,315...126,503,586 		JBrowse link
G Rbp1 retinol binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA
panobinostat results in increased expression of RBP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:107,904,589...107,926,109
Ensembl chr 8:107,887,417...107,983,847 		JBrowse link
G Rbpms2 RNA binding protein, mRNA processing factor 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA
panobinostat results in increased expression of RBPMS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:75,048,159...75,079,393
Ensembl chr 8:75,048,263...75,079,396 		JBrowse link
G Rcan1 regulator of calcineurin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA
panobinostat results in increased expression of RCAN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:45,108,123...45,188,065
Ensembl chr11:45,108,124...45,118,236 		JBrowse link
G Rdm1 RAD52 motif containing 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA CTD PMID:27188386 NCBI chr10:86,562,871...86,573,034
Ensembl chr10:87,039,940...87,073,273 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO panobinostat results in increased activity of and results in decreased acetylation of RELA protein; resveratrol inhibits the reaction [panobinostat results in increased activity of and results in decreased acetylation of RELA protein] CTD PMID:22923501 NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Reln reelin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA
panobinostat results in increased expression of RELN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:13,628,440...14,055,201
Ensembl chr 4:13,628,399...14,055,162 		JBrowse link
G Rest RE1-silencing transcription factor multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA
panobinostat results in increased expression of REST mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:31,213,415...31,233,451
Ensembl chr14:31,213,415...31,248,662 		JBrowse link
G Rftn2 raftlin family member 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA
panobinostat results in increased expression of RFTN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:64,146,062...64,202,342
Ensembl chr 9:64,124,865...64,215,186 		JBrowse link
G Rfx3 regulatory factor X3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA CTD PMID:27188386 NCBI chr 1:234,863,462...235,122,989
Ensembl chr 1:234,863,462...235,122,536 		JBrowse link
G Rfx4 regulatory factor X4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA
panobinostat results in increased expression of RFX4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:20,740,760...20,903,355
Ensembl chr 7:20,741,079...20,902,851 		JBrowse link
G RGD1359108 similar to RIKEN cDNA 3110043O21 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of C9ORF72 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:54,562,570...54,587,649
Ensembl chr 5:54,562,570...54,587,637 		JBrowse link
G Rgma repulsive guidance molecule BMP co-receptor a multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA
panobinostat results in decreased expression of RGMA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:136,538,782...136,582,763
Ensembl chr 1:136,538,759...136,582,763 		JBrowse link
G Rgs5 regulator of G-protein signaling 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA
panobinostat results in increased expression of RGS5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:84,381,077...84,417,875
Ensembl chr13:84,380,910...84,421,352 		JBrowse link
G Rhob ras homolog family member B increases expression
multiple interactions 		ISO panobinostat results in increased expression of RHOB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772 		JBrowse link
G Rhobtb3 Rho-related BTB domain containing 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA
panobinostat results in increased expression of RHOBTB3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:7,094,972...7,201,507
Ensembl chr 2:7,095,253...7,150,906 		JBrowse link
G Rhoh ras homolog family member H multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA CTD PMID:27188386 NCBI chr14:42,694,860...42,725,690
Ensembl chr14:42,693,413...42,749,967 		JBrowse link
G Rims1 regulating synaptic membrane exocytosis 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA
panobinostat results in increased expression of RIMS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:32,193,352...32,692,998
Ensembl chr 9:32,193,352...32,692,772 		JBrowse link
G Ripk4 receptor-interacting serine-threonine kinase 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA
panobinostat results in increased expression of RIPK4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:50,591,926...50,614,169
Ensembl chr11:50,591,936...50,614,169 		JBrowse link
G Rnd3 Rho family GTPase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA
panobinostat results in increased expression of RND3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:55,981,142...55,998,494
Ensembl chr 3:55,980,355...55,998,536 		JBrowse link
G Rnf144b ring finger protein 144B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA
panobinostat results in increased expression of RNF144B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,639,079...17,769,037 		JBrowse link
G Rnf150 ring finger protein 150 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA
panobinostat results in increased expression of RNF150 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:25,006,978...25,229,273
Ensembl chr19:41,912,276...42,133,217 		JBrowse link
G Rnf182 ring finger protein 182 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA
panobinostat results in decreased expression of RNF182 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:21,026,110...21,081,760
Ensembl chr17:21,232,084...21,299,723 		JBrowse link
G Rnf217 ring finger protein 217 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA
panobinostat results in increased expression of RNF217 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:26,016,668...26,108,736
Ensembl chr 1:27,835,148...27,928,044 		JBrowse link
G Rnf24 ring finger protein 24 increases expression ISO Panobinostat results in increased expression of RNF24 mRNA CTD PMID:33770205 NCBI chr 3:138,973,492...138,987,354
Ensembl chr 3:138,973,492...139,028,177 		JBrowse link
G Rnf43 ring finger protein 43 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA
panobinostat results in increased expression of RNF43 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:72,958,744...73,034,540
Ensembl chr10:72,961,641...73,034,551 		JBrowse link
G Robo2 roundabout guidance receptor 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA CTD PMID:27188386 NCBI chr11:26,015,919...27,583,750
Ensembl chr11:26,015,919...26,876,185 		JBrowse link
G Ror1 receptor tyrosine kinase-like orphan receptor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA
panobinostat results in increased expression of ROR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:119,859,744...120,203,573
Ensembl chr 5:119,859,970...120,205,801 		JBrowse link
G Rpl31 ribosomal protein L31 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA
panobinostat results in decreased expression of RPL31 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:49,143,044...49,147,155
Ensembl chr 9:49,142,955...49,147,155 		JBrowse link
G Rpp25 ribonuclease P and MRP subunit p25 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA
panobinostat results in increased expression of RPP25 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:66,803,262...66,804,642
Ensembl chr 8:66,803,212...66,810,550 		JBrowse link
G Rprm reprimo, TP53 dependent G2 arrest mediator homolog multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA
panobinostat results in increased expression of RPRM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:58,948,618...58,950,035
Ensembl chr 3:58,799,866...58,950,542 		JBrowse link
G Rprml reprimo-like multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA
panobinostat results in increased expression of RPRML mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:89,060,280...89,061,284
Ensembl chr10:89,059,522...89,063,831 		JBrowse link
G Rps24 ribosomal protein S24 increases expression ISO panobinostat results in increased expression of RPS24 mRNA CTD PMID:26272509 NCBI chr16:95,429...101,146
Ensembl chr16:96,484...101,144 		JBrowse link
G Rps6ka6 ribosomal protein S6 kinase A6 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA
panobinostat results in decreased expression of RPS6KA6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:80,537,723...80,638,910
Ensembl chr  X:80,537,723...80,692,148 		JBrowse link
G Rragd Ras-related GTP binding D multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA
panobinostat results in decreased expression of RRAGD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:52,170,234...52,205,700
Ensembl chr 5:52,169,783...52,209,000 		JBrowse link
G Rreb1 ras responsive element binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA
panobinostat results in increased expression of RREB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:27,082,217...27,208,061
Ensembl chr17:27,082,227...27,208,061 		JBrowse link
G Rspo2 R-spondin 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA
panobinostat results in decreased expression of RSPO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:75,987,217...76,123,984
Ensembl chr 7:75,987,817...76,123,654 		JBrowse link
G Rspo3 R-spondin 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA
panobinostat results in increased expression of RSPO3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:30,112,529...30,197,267
Ensembl chr 1:30,112,114...30,197,938 		JBrowse link
G RT1-Bb RT1 class II, locus Bb multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA CTD PMID:27188386 NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118 		JBrowse link
G RT1-DMa RT1 class II, locus DMa multiple interactions
increases expression 		ISO [Cisplatin co-treated with Panobinostat] affects the expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA
panobinostat results in increased expression of HLA-DMA mRNA 		CTD PMID:21791302 PMID:26272509 PMID:27188386 NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,708,933...4,712,335 		JBrowse link
G RT1-DMb RT1 class II, locus DMb multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of HLA-DMB mRNA CTD PMID:21791302 NCBI chr20:4,695,009...4,702,560
Ensembl chr20:4,695,010...4,702,246 		JBrowse link
G RT1-Ha RT1 class II, locus Ha multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of HLA-DPA1 mRNA CTD PMID:21791302 NCBI chr20:4,762,425...4,772,439
Ensembl chr20:4,763,033...4,772,141 		JBrowse link
G Rtn1 reticulon 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA
panobinostat results in decreased expression of RTN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:96,499,137...96,719,340
Ensembl chr 6:96,499,134...96,719,340 		JBrowse link
G Rtp1 receptor (chemosensory) transporter protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA CTD PMID:27188386 NCBI chr11:90,927,633...90,930,149
Ensembl chr11:90,927,633...90,930,149 		JBrowse link
G Runx1t1 RUNX1 partner transcriptional co-repressor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA
panobinostat results in increased expression of RUNX1T1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:31,984,946...32,136,878
Ensembl chr 5:31,984,855...32,132,855 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA CTD PMID:27188386 NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027 		JBrowse link
G Runx3 RUNX family transcription factor 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA
panobinostat results in increased expression of RUNX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:152,644,270...152,702,835 		JBrowse link
G Ryr3 ryanodine receptor 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA
panobinostat results in decreased expression of RYR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:119,886,129...120,433,465
Ensembl chr 3:119,885,878...120,433,677 		JBrowse link
G S100a10 S100 calcium binding protein A10 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA
panobinostat results in increased expression of S100A10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103 		JBrowse link
G S100a11 S100 calcium binding protein A11 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA
panobinostat results in increased expression of S100A11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:181,875,130...181,880,541 		JBrowse link
G S100a4 S100 calcium-binding protein A4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA
panobinostat results in increased expression of S100A4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837 		JBrowse link
G S100a6 S100 calcium binding protein A6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA
panobinostat results in increased expression of S100A6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762 		JBrowse link
G S100b S100 calcium binding protein B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA
panobinostat results in increased expression of S100B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081 		JBrowse link
G S1pr3 sphingosine-1-phosphate receptor 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA
panobinostat results in decreased expression of S1PR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:13,932,773...13,946,213
Ensembl chr17:13,928,444...13,947,197 		JBrowse link
G S1pr5 sphingosine-1-phosphate receptor 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA
panobinostat results in increased expression of S1PR5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:28,062,841...28,068,013
Ensembl chr 8:28,061,752...28,068,389 		JBrowse link
G Sall2 spalt-like transcription factor 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA
panobinostat results in decreased expression of SALL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:27,494,831...27,512,402
Ensembl chr15:27,494,589...27,512,402 		JBrowse link
G Sall3 spalt-like transcription factor 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA
panobinostat results in decreased expression of SALL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:76,680,997...76,700,905
Ensembl chr18:76,681,005...76,700,905 		JBrowse link
G Sat1 spermidine/spermine N1-acetyl transferase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA
panobinostat results in increased expression of SAT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:44,008,089...44,011,376
Ensembl chr  X:44,006,781...44,011,374 		JBrowse link
G Sbf2 SET binding factor 2 increases expression ISO panobinostat results in increased expression of SBF2 mRNA CTD PMID:26272509 NCBI chr 1:173,787,638...174,154,589
Ensembl chr 1:173,788,187...174,154,522 		JBrowse link
G Sccpdh saccharopine dehydrogenase (putative) decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of SCCPDH mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:93,932,086...93,953,840
Ensembl chr13:93,912,395...93,954,192 		JBrowse link
G Scg3 secretogranin III multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA
panobinostat results in increased expression of SCG3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,280,253...85,322,484
Ensembl chr 8:85,280,253...85,361,874 		JBrowse link
G Scgb3a2 secretoglobin, family 3A, member 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA
panobinostat results in increased expression of SCGB3A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:36,183,745...36,186,667
Ensembl chr18:36,183,698...36,186,742 		JBrowse link
G Scgn secretagogin, EF-hand calcium binding protein multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA CTD PMID:27188386 NCBI chr17:41,534,558...41,576,525
Ensembl chr17:41,534,497...41,576,522 		JBrowse link
G Scml1 Scm polycomb group protein like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA
panobinostat results in increased expression of SCML1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:36,526,068...36,543,336
Ensembl chr  X:36,526,068...36,544,450 		JBrowse link
G Scn2b sodium voltage-gated channel beta subunit 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of SCN2B mRNA CTD PMID:21791302 NCBI chr 8:54,322,383...54,334,519
Ensembl chr 8:54,322,383...54,334,519 		JBrowse link
G Scn4b sodium voltage-gated channel beta subunit 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA
panobinostat results in increased expression of SCN4B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:54,343,873...54,359,046
Ensembl chr 8:54,334,548...54,359,047 		JBrowse link
G Scn7a sodium voltage-gated channel alpha subunit 7 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA
panobinostat results in decreased expression of SCN7A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:71,743,873...71,846,454
Ensembl chr 3:71,743,873...71,846,284 		JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA
panobinostat results in increased expression of SCNN1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405 		JBrowse link
G Scnn1g sodium channel epithelial 1 subunit gamma multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA
panobinostat results in increased expression of SCNN1G mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097 		JBrowse link
G Scrg1 stimulator of chondrogenesis 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA
panobinostat results in increased expression of SCRG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:32,760,028...32,788,299
Ensembl chr16:37,770,739...37,799,010 		JBrowse link
G Scube2 signal peptide, CUB domain and EGF like domain containing 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA
panobinostat results in decreased expression of SCUBE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:173,264,862...173,341,323
Ensembl chr 1:173,264,865...173,334,372 		JBrowse link
G Sdc4 syndecan 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA
panobinostat results in increased expression of SDC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670 		JBrowse link
G Sec24d SEC24 homolog D, COPII coat complex component multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA
panobinostat results in increased expression of SEC24D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:214,103,138...214,211,155
Ensembl chr 2:214,103,190...214,211,144 		JBrowse link
G Selenoi selenoprotein I multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA
panobinostat results in increased expression of SELENOI mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:26,073,127...26,111,326
Ensembl chr 6:31,792,973...31,831,523 		JBrowse link
G Selenop selenoprotein P multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA
panobinostat results in increased expression of SELENOP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:54,225,152...54,236,019 		JBrowse link
G Sema3c semaphorin 3C multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA
panobinostat results in increased expression of SEMA3C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:18,538,454...18,701,740 		JBrowse link
G Sema3e semaphorin 3E multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA
panobinostat results in increased expression of SEMA3E mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:21,252,686...21,510,449
Ensembl chr 4:21,210,734...21,510,374 		JBrowse link
G Sema5a semaphorin 5A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA
panobinostat results in decreased expression of SEMA5A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:85,020,724...85,451,938
Ensembl chr 2:85,020,724...85,451,938 		JBrowse link
G Sema6d semaphorin 6D multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA
panobinostat results in decreased expression of SEMA6D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:131,801,680...132,394,578
Ensembl chr 3:132,337,343...132,394,584 		JBrowse link
G Senp6 SUMO specific peptidase 6 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of SENP6 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of SENP6 mRNA] CTD PMID:26733615 NCBI chr 8:89,868,115...89,951,803
Ensembl chr 8:89,868,867...89,948,062 		JBrowse link
G Septin6 septin 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA
Panobinostat results in increased expression of SEPTIN6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:121,018,951...121,157,677
Ensembl chr  X:121,018,944...121,095,792 		JBrowse link
G Serpinb9 serpin family B member 9 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA
panobinostat results in increased expression of SERPINB9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974 		JBrowse link
G Serpinf1 serpin family F member 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA
panobinostat results in decreased expression of SERPINF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:60,748,504...60,760,898
Ensembl chr10:60,748,506...60,760,898 		JBrowse link
G Sestd1 SEC14 and spectrin domain containing 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA
panobinostat results in decreased expression of SESTD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:82,530,796...82,627,960
Ensembl chr 3:82,537,092...82,588,078 		JBrowse link
G Sez6 seizure related 6 homolog multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA
panobinostat results in increased expression of SEZ6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:63,317,065...63,366,733
Ensembl chr10:63,316,953...63,366,723 		JBrowse link
G Sfmbt1 Scm-like with four mbt domains 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA
panobinostat results in decreased expression of SFMBT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:5,889,046...6,009,860
Ensembl chr16:5,897,187...6,011,934 		JBrowse link
G Sfmbt2 Scm-like with four mbt domains 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA
panobinostat results in increased expression of SFMBT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:72,844,037...73,038,599
Ensembl chr17:72,845,708...73,032,172 		JBrowse link
G Sfn stratifin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA
panobinostat results in increased expression of SFN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995 		JBrowse link
G Sfrp1 secreted frizzled-related protein 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA
panobinostat results in decreased expression of SFRP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:75,278,325...75,316,736
Ensembl chr16:75,278,325...75,316,736 		JBrowse link
G Sfrp2 secreted frizzled-related protein 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA
panobinostat results in decreased expression of SFRP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079 		JBrowse link
G Sgk3 serum/glucocorticoid regulated kinase family, member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA
panobinostat results in increased expression of SGK3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:14,128,628...14,255,099
Ensembl chr 5:14,126,257...14,198,331 		JBrowse link
G Sgpp1 sphingosine-1-phosphate phosphatase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA
panobinostat results in increased expression of SGPP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,161,024...100,182,214
Ensembl chr 6:100,161,024...100,182,259 		JBrowse link
G Sgpp2 sphingosine-1-phosphate phosphatase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA
panobinostat results in increased expression of SGPP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:87,211,155...87,331,787
Ensembl chr 9:87,211,717...87,333,132 		JBrowse link
G Sh3kbp1 SH3 domain-containing kinase-binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA
panobinostat results in increased expression of SH3KBP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:38,686,530...39,031,658
Ensembl chr  X:38,686,530...39,031,393 		JBrowse link
G Shb SH2 domain containing adaptor protein B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA
panobinostat results in increased expression of SHB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:64,473,694...64,581,072
Ensembl chr 5:64,473,694...64,581,072 		JBrowse link
G Shc3 SHC adaptor protein 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA CTD PMID:27188386 NCBI chr17:13,803,980...13,924,433
Ensembl chr17:13,803,781...13,924,433 		JBrowse link
G Shisa2 shisa family member 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA CTD PMID:27188386 NCBI chr15:37,982,913...37,987,211
Ensembl chr15:37,982,169...37,988,535 		JBrowse link
G Shisa6 shisa family member 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA CTD PMID:27188386 NCBI chr10:51,396,806...51,691,156
Ensembl chr10:51,396,806...51,691,156 		JBrowse link
G Sik1 salt-inducible kinase 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA CTD PMID:27188386 NCBI chr20:9,947,104...9,958,729
Ensembl chr20:9,947,105...9,958,698 		JBrowse link
G Six1 SIX homeobox 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA
panobinostat results in increased expression of SIX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:97,482,617...97,487,853
Ensembl chr 6:97,482,617...97,487,853 		JBrowse link
G Six3 SIX homeobox 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA
panobinostat results in decreased expression of SIX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:14,791,937...14,796,365
Ensembl chr 6:14,789,354...14,804,175 		JBrowse link
G Six6 SIX homeobox 6 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA
panobinostat results in decreased expression of SIX6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:97,357,883...97,375,415
Ensembl chr 6:97,370,435...97,375,415 		JBrowse link
G Six6os1 Six6 opposite strand transcript 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA
panobinostat results in decreased expression of C14ORF39 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:97,314,829...97,351,069
Ensembl chr 6:97,314,712...97,351,171 		JBrowse link
G Skap2 src kinase associated phosphoprotein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA
panobinostat results in increased expression of SKAP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:82,281,221...82,431,664
Ensembl chr 4:82,263,709...82,432,886 		JBrowse link
G Slc16a1 solute carrier family 16 member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA
panobinostat results in increased expression of SLC16A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:194,812,502...194,832,977 		JBrowse link
G Slc16a14 solute carrier family 16, member 14 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA
panobinostat results in decreased expression of SLC16A14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:93,558,144...93,585,396
Ensembl chr 9:93,558,144...93,585,396 		JBrowse link
G Slc16a4 solute carrier family 16, member 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA
panobinostat results in increased expression of SLC16A4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:197,593,738...197,621,569
Ensembl chr 2:197,599,295...197,621,562 		JBrowse link
G Slc17a5 solute carrier family 17 member 5 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of SLC17A5 mRNA CTD PMID:21791302 NCBI chr 8:88,274,497...88,309,734
Ensembl chr 8:88,274,721...88,309,664 		JBrowse link
G Slc18b1 solute carrier family 18 member B1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA
panobinostat results in increased expression of SLC18B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:23,447,462...23,490,043
Ensembl chr 1:23,447,462...23,489,962 		JBrowse link
G Slc19a3 solute carrier family 19 member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA
panobinostat results in increased expression of SLC19A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:91,724,718...91,754,991 		JBrowse link
G Slc1a1 solute carrier family 1 member 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of SLC1A1 mRNA CTD PMID:21791302 NCBI chr 1:235,963,455...236,043,572
Ensembl chr 1:235,963,437...236,045,469 		JBrowse link
G Slc1a3 solute carrier family 1 member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA
panobinostat results in increased expression of SLC1A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:59,482,707...59,557,808
Ensembl chr 2:59,482,709...59,557,808 		JBrowse link
G Slc24a3 solute carrier family 24 member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA
panobinostat results in increased expression of SLC24A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:153,005,418...153,504,497
Ensembl chr 3:153,004,987...153,504,497 		JBrowse link
G Slc25a12 solute carrier family 25 member 12 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA
panobinostat results in increased expression of SLC25A12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:76,504,868...76,599,536
Ensembl chr 3:76,504,868...76,599,536 		JBrowse link
G Slc25a16 solute carrier family 25 member 16 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA
panobinostat results in increased expression of SLC25A16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:25,659,847...25,717,080
Ensembl chr20:25,660,339...25,689,285
Ensembl chr20:25,660,339...25,689,285 		JBrowse link
G Slc25a25 solute carrier family 25 member 25 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of SLC25A25 mRNA CTD PMID:21791302 NCBI chr 3:36,106,448...36,139,812
Ensembl chr 3:36,106,449...36,140,011 		JBrowse link
G Slc25a53 solute carrier family 25, member 53 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA
panobinostat results in decreased expression of SLC25A53 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:105,099,191...105,111,936
Ensembl chr  X:105,099,112...105,113,009 		JBrowse link
G Slc27a2 solute carrier family 27 member 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA CTD PMID:27188386 NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581 		JBrowse link
G Slc2a3 solute carrier family 2 member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA
panobinostat results in increased expression of SLC2A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186 		JBrowse link
G Slc30a4 solute carrier family 30 member 4 increases expression ISO panobinostat results in increased expression of SLC30A4 mRNA CTD PMID:26272509 NCBI chr 3:130,206,852...130,228,888
Ensembl chr 3:130,206,852...130,228,888 		JBrowse link
G Slc35d3 solute carrier family 35, member D3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA CTD PMID:27188386 NCBI chr 1:16,389,308...16,392,780
Ensembl chr 1:16,389,308...16,392,780 		JBrowse link
G Slc35f2 solute carrier family 35, member F2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA
panobinostat results in increased expression of SLC35F2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:63,055,503...63,099,791
Ensembl chr 8:63,056,105...63,099,789 		JBrowse link
G Slc35g2 solute carrier family 35, member G2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA CTD PMID:27188386 NCBI chr 8:109,964,589...109,992,347
Ensembl chr 8:109,964,378...109,992,412 		JBrowse link
G Slc38a6 solute carrier family 38, member 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA CTD PMID:27188386 NCBI chr 6:97,723,526...97,814,394
Ensembl chr 6:97,723,471...97,785,791 		JBrowse link
G Slc39a6 solute carrier family 39 member 6 decreases expression ISO panobinostat results in decreased expression of SLC39A6 mRNA CTD PMID:26272509 NCBI chr18:16,139,621...16,160,163
Ensembl chr18:16,135,008...16,160,163 		JBrowse link
G Slc39a7 solute carrier family 39 member 7 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of SLC39A7 mRNA CTD PMID:21791302 NCBI chr20:4,824,967...4,828,431
Ensembl chr20:4,824,688...4,828,430 		JBrowse link
G Slc39a8 solute carrier family 39 member 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA
panobinostat results in increased expression of SLC39A8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:226,929,644...226,992,667 		JBrowse link
G Slc40a1 solute carrier family 40 member 1 multiple interactions
increases expression 		ISO [Cisplatin co-treated with Panobinostat] affects the expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA
panobinostat results in increased expression of SLC40A1 mRNA 		CTD PMID:21791302 PMID:26272509 PMID:27188386 NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460 		JBrowse link
G Slc43a1 solute carrier family 43 member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA
panobinostat results in increased expression of SLC43A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:90,327,250...90,353,438
Ensembl chr 3:90,327,149...90,353,438 		JBrowse link
G Slc52a3 solute carrier family 52 member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA
panobinostat results in increased expression of SLC52A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:160,959,233...160,976,170
Ensembl chr 3:160,965,302...160,974,692 		JBrowse link
G Slc6a8 solute carrier family 6 member 8 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA
panobinostat results in decreased expression of SLC6A8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:156,536,017...156,545,321
Ensembl chr  X:156,536,017...156,545,321 		JBrowse link
G Slc7a10 solute carrier family 7 member 10 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA
panobinostat results in increased expression of SLC7A10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:96,966,030...96,982,020
Ensembl chr 1:96,966,076...96,982,018 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA
panobinostat results in increased expression of SLC7A11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
G Slc7a5 solute carrier family 7 member 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA
panobinostat results in increased expression of SLC7A5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412 		JBrowse link
G Slc9b2 solute carrier family 9 member B2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA
panobinostat results in decreased expression of SLC9B2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:226,400,358...226,435,039
Ensembl chr 2:226,410,263...226,435,030 		JBrowse link
G Slco4c1 solute carrier organic anion transporter family, member 4C1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA
panobinostat results in increased expression of SLCO4C1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:104,624,802...104,676,462
Ensembl chr 9:104,624,802...104,676,462 		JBrowse link
G Slfn5 schlafen family member 5 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA CTD PMID:27188386 NCBI chr10:68,378,440...68,392,515
Ensembl chr10:68,378,449...68,392,544 		JBrowse link
G Slit1 slit guidance ligand 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA
panobinostat results in increased expression of SLIT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:250,358,917...250,507,476
Ensembl chr 1:250,358,919...250,507,476 		JBrowse link
G Slit2 slit guidance ligand 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA
panobinostat results in increased expression of SLIT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:66,829,661...67,168,517
Ensembl chr14:66,829,661...67,167,146 		JBrowse link
G Slit3 slit guidance ligand 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA
panobinostat results in increased expression of SLIT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:20,075,929...20,660,704
Ensembl chr10:20,076,021...20,660,704 		JBrowse link
G Slitrk6 SLIT and NTRK-like family, member 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA
panobinostat results in increased expression of SLITRK6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:93,977,812...93,984,431
Ensembl chr15:93,969,038...93,984,526 		JBrowse link
G Smad2 SMAD family member 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA
panobinostat results in decreased expression of SMAD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388 		JBrowse link
G Smarca2 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA
panobinostat results in increased expression of SMARCA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:233,617,277...233,784,908
Ensembl chr 1:233,617,366...233,784,869 		JBrowse link
G Smim14 small integral membrane protein 14 increases expression ISO Panobinostat results in increased expression of SMIM14 mRNA CTD PMID:33770205 NCBI chr14:42,783,361...42,829,762
Ensembl chr14:43,136,867...43,183,416 		JBrowse link
G Smoc1 SPARC related modular calcium binding 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA
panobinostat results in decreased expression of SMOC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:106,432,592...106,593,956
Ensembl chr 6:106,432,603...106,593,956 		JBrowse link
G Smoc2 SPARC related modular calcium binding 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA CTD PMID:27188386 NCBI chr 1:63,935,627...64,064,952
Ensembl chr 1:63,935,647...64,064,955 		JBrowse link
G Smpdl3a sphingomyelin phosphodiesterase, acid-like 3A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA CTD PMID:27188386 NCBI chr20:37,679,004...37,701,979
Ensembl chr20:37,678,964...37,704,260 		JBrowse link
G Smyd2 SET and MYND domain containing 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA
panobinostat results in increased expression of SMYD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:103,956,470...103,997,774
Ensembl chr13:103,956,473...103,997,774 		JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA
panobinostat results in increased expression of SNAI2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349 		JBrowse link
G Snap25 synaptosome associated protein 25 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA
panobinostat results in increased expression of SNAP25 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448 		JBrowse link
G Snrk SNF related kinase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of SNRK mRNA CTD PMID:21791302 NCBI chr 8:130,657,204...130,711,461
Ensembl chr 8:130,657,266...130,711,457 		JBrowse link
G Snx25 sorting nexin 25 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA
panobinostat results in decreased expression of SNX25 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:52,867,102...52,971,028
Ensembl chr16:52,858,532...52,971,008 		JBrowse link
G Socs1 suppressor of cytokine signaling 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA
panobinostat results in increased expression of SOCS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:5,389,574...5,391,265
Ensembl chr10:5,389,334...5,391,847 		JBrowse link
G Socs2 suppressor of cytokine signaling 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA
panobinostat results in increased expression of SOCS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA
panobinostat results in decreased expression of SOCS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825 		JBrowse link
G Sorcs2 sortilin-related VPS10 domain containing receptor 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA
panobinostat results in decreased expression of SORCS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:78,592,290...78,960,582
Ensembl chr14:78,596,087...78,960,582 		JBrowse link
G Sord sorbitol dehydrogenase multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA
panobinostat results in decreased expression of SORD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100 		JBrowse link
G Sost sclerostin multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA CTD PMID:27188386 NCBI chr10:87,412,722...87,415,766
Ensembl chr10:87,411,721...87,415,766 		JBrowse link
G Sox10 SRY-box transcription factor 10 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA
panobinostat results in increased expression of SOX10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:112,605,721...112,615,097
Ensembl chr 7:112,605,721...112,615,990 		JBrowse link
G Sox11 SRY-box transcription factor 11 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA
panobinostat results in decreased expression of SOX11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:49,736,773...49,738,794
Ensembl chr 6:49,736,304...49,738,691 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA
panobinostat results in decreased expression of SOX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350 		JBrowse link
G Sox3 SRY-box transcription factor 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA
panobinostat results in decreased expression of SOX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:144,344,892...144,346,971
Ensembl chr  X:144,344,892...144,346,987 		JBrowse link
G Sox8 SRY-box transcription factor 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA
panobinostat results in increased expression of SOX8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:15,089,357...15,094,345
Ensembl chr10:15,089,357...15,094,345 		JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA
panobinostat results in increased expression of SOX9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250 		JBrowse link
G Sp5 Sp5 transcription factor multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA
panobinostat results in increased expression of SP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:75,682,677...75,685,479
Ensembl chr 3:75,682,677...75,685,479 		JBrowse link
G Sp6 Sp6 transcription factor multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA
panobinostat results in increased expression of SP6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:82,501,957...82,506,138
Ensembl chr10:82,501,726...82,508,887 		JBrowse link
G Sp8 Sp8 transcription factor decreases expression ISO panobinostat results in decreased expression of SP8 mRNA CTD PMID:26272509 NCBI chr 6:145,959,219...145,961,824
Ensembl chr 6:145,959,097...145,964,845 		JBrowse link
G Spag1 sperm associated antigen 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA CTD PMID:27188386 NCBI chr 7:69,246,301...69,306,483
Ensembl chr 7:69,246,582...69,306,482 		JBrowse link
G Spag9 sperm associated antigen 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA CTD PMID:27188386 NCBI chr10:79,440,311...79,574,709
Ensembl chr10:79,440,377...79,575,258 		JBrowse link
G Sphk1 sphingosine kinase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA
panobinostat results in increased expression of SPHK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082 		JBrowse link
G Spink1 serine peptidase inhibitor, Kazal type 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA
panobinostat results in increased expression of SPINK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:36,121,626...36,133,596
Ensembl chr18:36,076,399...36,133,545 		JBrowse link
G Spink2 serine peptidase inhibitor, Kazal type 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA
panobinostat results in increased expression of SPINK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:31,321,976...31,328,622
Ensembl chr14:31,322,010...31,328,622 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA
panobinostat results in increased expression of SPP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Spry1 sprouty RTK signaling antagonist 1 decreases expression ISO panobinostat results in decreased expression of SPRY1 mRNA CTD PMID:26272509 NCBI chr 2:122,484,995...122,490,008
Ensembl chr 2:122,484,355...122,492,956 		JBrowse link
G Spsb4 splA/ryanodine receptor domain and SOCS box containing 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA
panobinostat results in increased expression of SPSB4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:106,416,039...106,489,271
Ensembl chr 8:106,416,040...106,489,271 		JBrowse link
G Sqor sulfide quinone oxidoreductase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA
panobinostat results in increased expression of SQOR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:130,294,783...130,341,655
Ensembl chr 3:130,292,814...130,340,799 		JBrowse link
G Srcin1 SRC kinase signaling inhibitor 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA
panobinostat results in decreased expression of SRCIN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:82,999,295...83,066,359
Ensembl chr10:82,991,033...83,067,419 		JBrowse link
G Ssbp2 single-stranded DNA binding protein 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA
panobinostat results in decreased expression of SSBP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:24,385,494...24,673,768
Ensembl chr 2:24,385,687...24,673,768 		JBrowse link
G Sst somatostatin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA
panobinostat results in increased expression of SST mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:90,461,546...90,462,823
Ensembl chr11:90,461,546...90,462,823 		JBrowse link
G St14 ST14 transmembrane serine protease matriptase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA CTD PMID:27188386 NCBI chr 8:37,798,994...37,839,881
Ensembl chr 8:37,798,995...37,855,652 		JBrowse link
G St3gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA
panobinostat results in increased expression of ST3GAL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:100,734,300...100,745,242 		JBrowse link
G St3gal5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 increases expression ISO Panobinostat results in increased expression of ST3GAL5 mRNA CTD PMID:33770205 NCBI chr 4:105,692,840...105,750,774
Ensembl chr 4:105,692,840...105,750,775 		JBrowse link
G St6galnac2 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA CTD PMID:27188386 NCBI chr10:102,409,048...102,427,299
Ensembl chr10:102,409,048...102,427,137 		JBrowse link
G St6galnac5 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA
panobinostat results in decreased expression of ST6GALNAC5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:244,398,604...244,571,100
Ensembl chr 2:244,402,589...244,571,097 		JBrowse link
G St8sia2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ST8SIA2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA2 mRNA] CTD PMID:26733615 NCBI chr 1:137,172,354...137,247,796
Ensembl chr 1:137,172,354...137,247,792 		JBrowse link
G St8sia3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of ST8SIA3 mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA3 mRNA]
panobinostat affects the expression of ST8SIA3 mRNA 		CTD PMID:26733615 NCBI chr18:60,024,555...60,031,050
Ensembl chr18:60,024,236...60,032,473 		JBrowse link
G Stam2 signal transducing adaptor molecule 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA CTD PMID:27188386 NCBI chr 3:57,597,557...57,643,915
Ensembl chr 3:57,597,559...57,643,915 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
increases acetylation 		ISO Panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; Panobinostat promotes the reaction [Resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; Panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]
Panobinostat results in increased acetylation of STAT3 protein 		CTD PMID:23681230 PMID:26775640 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359 		JBrowse link
G Stat6 signal transducer and activator of transcription 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA
panobinostat results in increased expression of STAT6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,365,505...65,382,825
Ensembl chr 7:65,365,306...65,383,795 		JBrowse link
G Stc1 stanniocalcin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA
panobinostat results in increased expression of STC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:50,709,439...50,720,093
Ensembl chr15:50,709,415...50,720,082 		JBrowse link
G Steap1 STEAP family member 1 multiple interactions ISO [Cisplatin co-treated with Panobinostat] affects the expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA CTD PMID:21791302 PMID:27188386 NCBI chr 4:29,231,809...29,242,317
Ensembl chr 4:29,231,753...29,242,317 		JBrowse link
G Steap3 STEAP3 metalloreductase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA
panobinostat results in increased expression of STEAP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:33,904,710...33,950,100
Ensembl chr13:33,904,710...33,950,080 		JBrowse link
G Stimate STIM activating enhancer increases expression ISO Panobinostat results in increased expression of STIMATE-MUSTN1 mRNA CTD PMID:26272509 NCBI chr16:6,019,788...6,077,272
Ensembl chr16:6,019,793...6,079,110 		JBrowse link
G Stk32a serine/threonine kinase 32A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA
panobinostat results in decreased expression of STK32A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:35,509,791...35,620,421
Ensembl chr18:35,509,982...35,628,985 		JBrowse link
G Stmn2 stathmin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA
panobinostat results in increased expression of STMN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335 		JBrowse link
G Stom stomatin multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA CTD PMID:27188386 NCBI chr 3:39,042,503...39,064,818
Ensembl chr 3:39,042,503...39,064,818 		JBrowse link
G Ston1 stonin 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of STON1 mRNA CTD PMID:21791302 NCBI chr 6:11,596,726...11,646,098
Ensembl chr 6:11,572,905...11,615,635 		JBrowse link
G Stox1 storkhead box 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA CTD PMID:27188386 NCBI chr20:31,140,993...31,209,126
Ensembl chr20:31,140,993...31,208,877 		JBrowse link
G Stra6 signaling receptor and transporter of retinol STRA6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA
panobinostat results in increased expression of STRA6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:67,444,757...67,464,719
Ensembl chr 8:67,444,742...67,464,720 		JBrowse link
G Styk1 serine/threonine/tyrosine kinase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA
panobinostat results in increased expression of STYK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:165,047,613...165,097,890
Ensembl chr 4:166,779,040...166,827,738 		JBrowse link
G Sulf2 sulfatase 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of SULF2 mRNA CTD PMID:21791302 NCBI chr 3:175,241,322...175,323,808
Ensembl chr 3:175,241,322...175,323,651 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA CTD PMID:27188386 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Sult1c2a sulfotransferase family 1C member 2A increases expression
multiple interactions 		ISO panobinostat results in increased expression of SULT1C2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:7,075,873...7,103,316
Ensembl chr 9:7,066,905...7,244,132 		JBrowse link
G Susd2 sushi domain containing 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA
panobinostat results in increased expression of SUSD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:13,016,960...13,024,264
Ensembl chr20:13,016,907...13,024,264 		JBrowse link
G Susd3 sushi domain containing 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA
panobinostat results in increased expression of SUSD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:15,607,259...15,623,322
Ensembl chr17:15,606,906...15,624,262 		JBrowse link
G Sv2c synaptic vesicle glycoprotein 2c multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA
panobinostat results in increased expression of SV2C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,967,631...29,163,168
Ensembl chr 2:28,964,582...29,163,168 		JBrowse link
G Syk spleen associated tyrosine kinase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA
panobinostat results in increased expression of SYK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,756,493...12,813,278 		JBrowse link
G Syncrip synaptotagmin binding, cytoplasmic RNA interacting protein multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA CTD PMID:27188386 NCBI chr 8:98,282,358...98,315,412
Ensembl chr 8:98,282,358...98,315,386 		JBrowse link
G Syne1 spectrin repeat containing nuclear envelope protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA
panobinostat results in increased expression of SYNE1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:43,895,994...44,388,721 		JBrowse link
G Syne3 spectrin repeat containing, nuclear envelope family member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA
panobinostat results in increased expression of SYNE3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:129,637,644...129,729,542
Ensembl chr 6:129,641,123...129,729,509 		JBrowse link
G Syngr1 synaptogyrin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA
panobinostat results in increased expression of SYNGR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:113,516,246...113,542,918
Ensembl chr 7:113,516,265...113,542,917 		JBrowse link
G Synpr synaptoporin multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA
panobinostat results in increased expression of SYNPR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:14,003,861...14,330,808
Ensembl chr15:14,004,715...14,330,848 		JBrowse link
G Syt11 synaptotagmin 11 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA
panobinostat results in decreased expression of SYT11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:176,503,845...176,530,354
Ensembl chr 2:176,503,845...176,529,775 		JBrowse link
G Syt4 synaptotagmin 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA
panobinostat results in increased expression of SYT4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:23,311,454...23,320,863
Ensembl chr18:23,312,859...23,320,815 		JBrowse link
G Syt7 synaptotagmin 7 increases expression
multiple interactions 		ISO panobinostat results in increased expression of SYT7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:216,456,148...216,518,718
Ensembl chr 1:216,456,259...216,518,718 		JBrowse link
G Sytl2 synaptotagmin-like 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA CTD PMID:27188386 NCBI chr 1:153,685,403...153,791,758
Ensembl chr 1:153,665,327...153,791,756 		JBrowse link
G Sytl4 synaptotagmin-like 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA CTD PMID:27188386 NCBI chr  X:101,428,785...101,479,207
Ensembl chr  X:101,428,785...101,479,151 		JBrowse link
G Tac1 tachykinin, precursor 1 increases expression ISO panobinostat results in increased expression of TAC1 mRNA CTD PMID:26272509 NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546 		JBrowse link
G Tacc1 transforming, acidic coiled-coil containing protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA
panobinostat results in increased expression of TACC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:66,812,232...66,895,736
Ensembl chr16:73,514,889...73,598,394 		JBrowse link
G Tacstd2 tumor-associated calcium signal transducer 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
panobinostat results in increased expression of TACSTD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:98,033,251...98,039,323 		JBrowse link
G Tagln2 transgelin 2 increases expression
multiple interactions 		ISO panobinostat results in increased expression of TAGLN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:87,499,350...87,506,328
Ensembl chr13:87,499,394...87,506,330 		JBrowse link
G Tanc1 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA
panobinostat results in increased expression of TANC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:64,508,037...64,741,826
Ensembl chr 3:64,508,085...64,741,825 		JBrowse link
G Tars1 threonyl-tRNA synthetase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA
Panobinostat results in increased expression of TARS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:62,095,978...62,114,802
Ensembl chr 2:62,087,763...62,114,802 		JBrowse link
G Tbc1d16 TBC1 domain family, member 16 increases expression ISO Panobinostat results in increased expression of TBC1D16 mRNA CTD PMID:33770205 NCBI chr10:104,899,507...104,985,233
Ensembl chr10:104,899,507...104,985,216 		JBrowse link
G Tbc1d30 TBC1 domain family, member 30 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA
panobinostat results in decreased expression of TBC1D30 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:58,665,054...58,754,427
Ensembl chr 7:58,665,054...58,754,614 		JBrowse link
G Tbc1d8 TBC1 domain family, member 8 decreases expression ISO panobinostat results in decreased expression of TBC1D8 mRNA CTD PMID:26272509 NCBI chr 9:49,147,109...49,257,140
Ensembl chr 9:49,147,109...49,257,118 		JBrowse link
G Tbl1xr1 TBL1X/Y related 1 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBL1XR1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBL1XR1 mRNA] CTD PMID:26733615 NCBI chr 2:106,718,811...106,857,989
Ensembl chr 2:106,730,665...106,857,989 		JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBX3 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBX3 mRNA] CTD PMID:26733615 NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171 		JBrowse link
G Tc2n tandem C2 domains, nuclear multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA CTD PMID:27188386 NCBI chr 6:126,526,006...126,622,163
Ensembl chr 6:126,526,009...126,614,215 		JBrowse link
G Tdrkh tudor and KH domain containing multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA
panobinostat results in decreased expression of TDRKH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:184,736,255...184,760,534
Ensembl chr 2:184,737,591...184,762,052 		JBrowse link
G Tdrp testis development related protein multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA
panobinostat results in increased expression of TDRP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:82,326,837...82,354,861
Ensembl chr16:82,314,220...82,354,861 		JBrowse link
G Tenm2 teneurin transmembrane protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA
panobinostat results in increased expression of TENM2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:20,984,710...22,121,001
Ensembl chr10:20,985,902...22,447,611 		JBrowse link
G Tent5b terminal nucleotidyltransferase 5B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA
panobinostat results in increased expression of TENT5B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:150,979,238...150,986,548
Ensembl chr11:27,212,316...27,214,238
Ensembl chr 5:27,212,316...27,214,238 		JBrowse link
G Tep1 telomerase associated protein 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of TEP1 mRNA CTD PMID:21791302 NCBI chr15:26,519,429...26,567,073
Ensembl chr15:26,519,431...26,567,073 		JBrowse link
G Tes testin LIM domain protein multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA
panobinostat results in increased expression of TES mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:46,331,257...46,369,782
Ensembl chr 4:46,331,257...46,369,780 		JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA
panobinostat results in increased expression of TFAP2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219 		JBrowse link
G Tfap2b transcription factor AP-2 beta multiple interactions
affects expression
increases expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of TFAP2B mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TFAP2B mRNA]
panobinostat affects the expression of TFAP2B mRNA
panobinostat results in increased expression of TFAP2B mRNA 		CTD PMID:26272509 PMID:26733615 PMID:27188386 NCBI chr 9:29,282,703...29,312,568
Ensembl chr 9:29,282,825...29,312,568 		JBrowse link
G Tfap2c transcription factor AP-2 gamma multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA
panobinostat results in increased expression of TFAP2C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:181,733,524...181,742,412
Ensembl chr 3:181,733,419...181,741,404 		JBrowse link
G Tfcp2l1 transcription factor CP2-like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA
panobinostat results in increased expression of TFCP2L1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:32,286,643...32,346,671
Ensembl chr13:32,286,643...32,346,671 		JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA
panobinostat results in increased expression of TFPI mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:89,939,862...89,989,253
Ensembl chr 3:89,939,868...89,980,742 		JBrowse link
G Tfpi2 tissue factor pathway inhibitor 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA
panobinostat results in increased expression of TFPI2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:32,936,462...32,941,385
Ensembl chr 4:32,936,854...32,941,426 		JBrowse link
G Tgfb1i1 transforming growth factor beta 1 induced transcript 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA
panobinostat results in increased expression of TGFB1I1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:192,258,598...192,265,903 		JBrowse link
G Tgfbi transforming growth factor, beta induced multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA CTD PMID:27188386 NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471 		JBrowse link
G Tgfbrap1 transforming growth factor, beta receptor associated protein 1 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TGFBRAP1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TGFBRAP1 mRNA] CTD PMID:26733615 NCBI chr 9:52,813,087...52,863,441
Ensembl chr 9:52,813,087...52,863,441 		JBrowse link
G Thap2 THAP domain containing 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA CTD PMID:27188386 NCBI chr 7:52,879,011...52,893,680
Ensembl chr 7:52,879,011...52,891,932 		JBrowse link
G Thbs2 thrombospondin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA
panobinostat results in increased expression of THBS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:64,343,523...64,372,918
Ensembl chr 1:64,343,523...64,372,918 		JBrowse link
G Thrb thyroid hormone receptor beta multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA
panobinostat results in increased expression of THRB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:10,115,954...10,465,231
Ensembl chr15:10,115,954...10,313,680 		JBrowse link
G Tktl1 transketolase-like 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA CTD PMID:27188386 NCBI chr  X:157,105,455...157,138,510
Ensembl chr  X:157,105,495...157,138,503 		JBrowse link
G Tle4 TLE family member 4, transcriptional corepressor multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA
panobinostat results in decreased expression of TLE4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:221,086,250...221,222,826
Ensembl chr 1:221,086,253...221,222,826 		JBrowse link
G Tmc5 transmembrane channel-like 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA
panobinostat results in increased expression of TMC5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:182,349,102...182,433,679
Ensembl chr 1:182,355,473...182,433,679 		JBrowse link
G Tmcc2 transmembrane and coiled-coil domain family 2 increases expression ISO Panobinostat results in increased expression of TMCC2 mRNA CTD PMID:33770205 NCBI chr13:43,794,029...43,831,716
Ensembl chr13:46,346,177...46,383,862 		JBrowse link
G Tmed5 transmembrane p24 trafficking protein 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA
panobinostat results in increased expression of TMED5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:1,752,857...1,763,990
Ensembl chr14:1,752,745...1,773,389 		JBrowse link
G Tmem125 transmembrane protein 125 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA
panobinostat results in increased expression of TMEM125 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:137,348,545...137,349,949
Ensembl chr 5:137,345,202...137,351,952 		JBrowse link
G Tmem144 transmembrane protein 144 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA
panobinostat results in increased expression of TMEM144 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:164,960,649...164,993,562
Ensembl chr 2:167,258,789...167,290,902 		JBrowse link
G Tmem154 transmembrane protein 154 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA
panobinostat results in increased expression of TMEM154 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:172,313,290...172,352,939
Ensembl chr 2:172,313,240...172,361,723 		JBrowse link
G Tmem163 transmembrane protein 163 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA
panobinostat results in decreased expression of TMEM163 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:41,520,595...41,693,938
Ensembl chr13:41,520,359...41,693,938 		JBrowse link
G Tmem169 transmembrane protein 169 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA
panobinostat results in decreased expression of TMEM169 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:81,375,854...81,399,970 JBrowse link
G Tmem170b transmembrane protein 170B multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA
panobinostat results in decreased expression of TMEM170B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:23,336,914...23,375,707
Ensembl chr17:23,343,017...23,375,519 		JBrowse link
G Tmem178a transmembrane protein 178A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA
panobinostat results in decreased expression of TMEM178A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:19,756,919...19,815,961
Ensembl chr 6:19,756,920...19,815,839 		JBrowse link
G Tmem18 transmembrane protein 18 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA
panobinostat results in decreased expression of TMEM18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:52,934,419...52,941,868
Ensembl chr 6:52,934,419...52,941,866 		JBrowse link
G Tmem218 transmembrane protein 218 decreases expression ISO panobinostat results in decreased expression of TMEM218 mRNA CTD PMID:26272509 NCBI chr 8:45,113,368...45,128,739
Ensembl chr 8:45,113,427...45,129,152 		JBrowse link
G Tmem30b transmembrane protein 30B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA
panobinostat results in increased expression of TMEM30B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:97,987,471...97,990,546
Ensembl chr 6:97,987,130...97,991,170 		JBrowse link
G Tmem64 transmembrane protein 64 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA
panobinostat results in increased expression of TMEM64 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:33,495,992...33,542,390
Ensembl chr 5:33,496,032...33,542,389 		JBrowse link
G Tmem74 transmembrane protein 74 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA
panobinostat results in decreased expression of TMEM74 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:76,814,000...76,822,633
Ensembl chr 7:76,813,212...76,822,925 		JBrowse link
G Tmem88 transmembrane protein 88 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA
panobinostat results in decreased expression of TMEM88 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:54,617,554...54,619,309
Ensembl chr10:54,617,630...54,619,438 		JBrowse link
G Tmod2 tropomodulin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA
panobinostat results in increased expression of TMOD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,197,222...85,250,627
Ensembl chr 8:85,196,226...85,246,371 		JBrowse link
G Tmprss11e transmembrane serine protease 11E multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA CTD PMID:27188386 NCBI chr14:21,638,418...21,683,029
Ensembl chr14:21,638,418...21,683,029 		JBrowse link
G Tmt1a thiol methyltransferase 1A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA CTD PMID:27188386 NCBI chr 7:133,330,141...133,377,172
Ensembl chr 7:133,330,447...133,338,959 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of TNFAIP3 mRNA CTD PMID:21791302 NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979 		JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA
panobinostat results in increased expression of TNFRSF11B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075 		JBrowse link
G Tnfrsf12a TNF receptor superfamily member 12A multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA
panobinostat results in increased expression of TNFRSF12A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704 		JBrowse link
G Tnfrsf19 TNF receptor superfamily member 19 increases expression ISO Panobinostat results in increased expression of TNFRSF19 mRNA CTD PMID:33770205 NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of TNFSF10 mRNA CTD PMID:21791302 NCBI chr 2:112,136,550...112,155,903 JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA
panobinostat results in increased expression of TNFSF11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479 		JBrowse link
G Tnfsf9 TNF superfamily member 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA CTD PMID:27188386 NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:2,030,953...2,033,339 		JBrowse link
G Tnik TRAF2 and NCK interacting kinase multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA
panobinostat results in increased expression of TNIK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:113,112,937...113,511,341
Ensembl chr 2:113,112,938...113,511,339 		JBrowse link
G Tnn tenascin N multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA
panobinostat results in increased expression of TNN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:74,852,586...74,919,789
Ensembl chr13:74,852,586...74,919,789 		JBrowse link
G Tnrc6b trinucleotide repeat containing adaptor 6B multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of TNRC6B mRNA CTD PMID:21791302 NCBI chr 7:114,132,574...114,350,010
Ensembl chr 7:114,132,573...114,342,973 		JBrowse link
G Tox thymocyte selection-associated high mobility group box multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA
panobinostat results in increased expression of TOX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:24,672,487...24,968,754
Ensembl chr 5:24,672,487...24,968,754 		JBrowse link
G Tox2 TOX high mobility group box family member 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA
panobinostat results in decreased expression of TOX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:172,272,718...172,400,235
Ensembl chr 3:172,272,736...172,400,233 		JBrowse link
G Tox3 TOX high mobility group box family member 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA
panobinostat results in decreased expression of TOX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:32,820,957...32,929,776
Ensembl chr19:32,820,977...32,929,776 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases acetylation 		ISO [panobinostat co-treated with SRT2183] results in increased acetylation of TP53 protein
panobinostat results in increased acetylation of TP53 protein 		CTD PMID:23681230 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tp63 tumor protein p63 increases expression ISO panobinostat results in increased expression of TP63 protein alternative form CTD PMID:20043870 NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177 		JBrowse link
G Tpbg trophoblast glycoprotein multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA CTD PMID:27188386 NCBI chr 8:95,673,993...95,677,364
Ensembl chr 8:95,629,267...95,678,394 		JBrowse link
G Tpd52l1 TPD52 like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA
panobinostat results in increased expression of TPD52L1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:27,991,114...28,109,767
Ensembl chr 1:27,991,131...28,110,158 		JBrowse link
G Trabd2b TraB domain containing 2B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA
panobinostat results in increased expression of TRABD2B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:133,178,014...133,395,740
Ensembl chr 5:133,178,302...133,441,812 		JBrowse link
G Trim14 tripartite motif-containing 14 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA
panobinostat results in increased expression of TRIM14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:65,596,149...65,620,434
Ensembl chr 5:65,596,149...65,620,434 		JBrowse link
G Trim38 tripartite motif containing 38 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA
panobinostat results in increased expression of TRIM38 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:41,774,419...41,787,709 JBrowse link
G Trim6 tripartite motif containing 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA
panobinostat results in increased expression of TRIM6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:168,095,619...168,108,809
Ensembl chr 1:168,095,564...168,109,719 		JBrowse link
G Trim69 tripartite motif-containing 69 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA
panobinostat results in increased expression of TRIM69 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:129,565,060...129,585,629
Ensembl chr 3:129,564,934...129,585,629 		JBrowse link
G Trim8 tripartite motif-containing 8 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TRIM8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TRIM8 mRNA] CTD PMID:26733615 NCBI chr 1:255,311,039...255,325,937
Ensembl chr 1:255,310,457...255,325,937 		JBrowse link
G Trim9 tripartite motif-containing 9 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA
panobinostat results in increased expression of TRIM9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:94,492,789...94,592,597
Ensembl chr 6:94,493,268...94,592,551 		JBrowse link
G Trnp1 TMF1-regulated nuclear protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA
panobinostat results in increased expression of TRNP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:150,990,312...150,997,148
Ensembl chr 5:150,989,973...150,997,277 		JBrowse link
G Trpc2 transient receptor potential cation channel subfamily C member 2 multiple interactions ISO [Cisplatin co-treated with Panobinostat] affects the expression of TRPC2 mRNA CTD PMID:21791302 NCBI chr 1:165,871,991...165,885,339
Ensembl chr 1:165,857,557...165,885,055 		JBrowse link
G Trpc4 transient receptor potential cation channel, subfamily C, member 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA
panobinostat results in decreased expression of TRPC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:140,457,841...140,629,556
Ensembl chr 2:140,458,296...140,626,969 		JBrowse link
G Trpc6 transient receptor potential cation channel, subfamily C, member 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA
panobinostat results in increased expression of TRPC6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304 		JBrowse link
G Trps1 transcriptional repressor GATA binding 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA
panobinostat results in increased expression of TRPS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:83,806,121...84,032,609
Ensembl chr 7:83,811,497...84,031,786 		JBrowse link
G Tshz2 teashirt zinc finger homeobox 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA CTD PMID:27188386 NCBI chr 3:178,824,221...179,271,151
Ensembl chr 3:178,824,994...179,269,641 		JBrowse link
G Tspo translocator protein multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA
panobinostat results in increased expression of TSPO mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:116,600,214...116,610,461
Ensembl chr 7:116,600,210...116,610,460 		JBrowse link
G Tspoap1 TSPO associated protein 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of TSPOAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:73,053,414...73,083,640
Ensembl chr10:73,058,354...73,083,640 		JBrowse link
G Ttc29 tetratricopeptide repeat domain 29 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA
panobinostat results in increased expression of TTC29 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:46,436,526...46,654,891
Ensembl chr19:46,424,935...46,654,870 		JBrowse link
G Ttll6 tubulin tyrosine ligase like 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA CTD PMID:27188386 NCBI chr10:81,081,985...81,118,009
Ensembl chr10:81,579,178...81,623,919 		JBrowse link
G Tuba1a tubulin, alpha 1A decreases expression ISO panobinostat results in decreased expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:131,968,770...131,996,035 		JBrowse link
G Tubb2a tubulin, beta 2A class IIa multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA
panobinostat results in increased expression of TUBB2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,983,387...31,006,838 		JBrowse link
G Tulp4 TUB like protein 4 increases expression ISO Panobinostat results in increased expression of TULP4 mRNA CTD PMID:33770205 NCBI chr 1:49,082,492...49,218,262
Ensembl chr 1:49,087,886...49,218,250 		JBrowse link
G Tvp23a trans-golgi network vesicle protein 23 homolog A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA CTD PMID:27188386 NCBI chr10:5,227,198...5,263,185
Ensembl chr10:5,734,100...5,769,998 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA
panobinostat results in increased expression of TWIST1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965 		JBrowse link
G Ugt2b34l1 UDP glucuronosyltransferase 2 family, polypeptide B34 like 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA CTD PMID:27188386 NCBI chr14:21,500,948...21,524,095
Ensembl chr14:21,501,091...21,522,265 		JBrowse link
G Ugt3a1 UDP glycosyltransferase family 3 member A1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA CTD PMID:27188386 NCBI chr 2:60,062,257...60,077,354
Ensembl chr 2:60,061,775...60,077,354 		JBrowse link
G Ugt8 UDP glycosyltransferase 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA
panobinostat results in increased expression of UGT8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:216,938,884...217,007,167
Ensembl chr 2:216,938,990...217,007,167 		JBrowse link
G Unc5a unc-5 netrin receptor A decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of UNC5A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:9,614,841...9,670,558
Ensembl chr17:9,620,005...9,676,140 		JBrowse link
G Unc5c unc-5 netrin receptor C multiple interactions
affects expression
increases expression 		ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of UNC5C mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of UNC5C mRNA]
panobinostat affects the expression of UNC5C mRNA
panobinostat results in increased expression of UNC5C mRNA 		CTD PMID:26272509 PMID:26733615 PMID:27188386 NCBI chr 2:232,854,352...233,208,482
Ensembl chr 2:232,846,262...233,208,482 		JBrowse link
G Uqcc2 ubiquinol-cytochrome c reductase complex assembly factor 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA
panobinostat results in decreased expression of UQCC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:5,204,682...5,217,080
Ensembl chr17:12,088,037...12,088,606
Ensembl chr20:12,088,037...12,088,606 		JBrowse link
G Usp28 ubiquitin specific peptidase 28 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA
panobinostat results in increased expression of USP28 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:58,222,258...58,282,711
Ensembl chr 8:58,222,220...58,282,750 		JBrowse link
G Usp43 ubiquitin specific peptidase 43 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA CTD PMID:27188386 NCBI chr10:53,047,368...53,110,099
Ensembl chr10:53,048,158...53,110,180 		JBrowse link
G Usp49 ubiquitin specific peptidase 49 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA
panobinostat results in decreased expression of USP49 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:20,803,177...20,867,681
Ensembl chr 9:20,804,921...20,863,667 		JBrowse link
G Ust uronyl-2-sulfotransferase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of UST mRNA CTD PMID:21791302 NCBI chr 1:4,487,316...4,782,579
Ensembl chr 1:4,489,925...4,782,356 		JBrowse link
G Utf1 undifferentiated embryonic cell transcription factor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA
panobinostat results in increased expression of UTF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:194,740,339...194,741,465
Ensembl chr 1:204,169,954...204,171,080 		JBrowse link
G Vamp7 vesicle-associated membrane protein 7 increases expression
multiple interactions 		ISO panobinostat results in increased expression of VAMP7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:21,842,206...21,958,556
Ensembl chr12:21,842,228...21,958,552 		JBrowse link
G Vamp8 vesicle-associated membrane protein 8 increases expression
multiple interactions 		ISO panobinostat results in increased expression of VAMP8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:106,000,570...106,011,081
Ensembl chr 4:106,000,570...106,011,073 		JBrowse link
G Vapa VAMP associated protein A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA
panobinostat results in decreased expression of VAPA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:112,624,791...112,654,731
Ensembl chr 9:112,624,794...112,654,731 		JBrowse link
G Vash2 vasohibin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA
panobinostat results in increased expression of VASH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:105,060,857...105,092,325
Ensembl chr13:105,060,857...105,092,275 		JBrowse link
G Ventx VENT homeobox increases expression
multiple interactions 		ISO Panobinostat results in increased expression of VENTX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:90,707,273...90,708,315
Ensembl chr  X:90,706,748...90,708,555 		JBrowse link
G Veph1 ventricular zone expressed PH domain-containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA
panobinostat results in increased expression of VEPH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:150,291,379...150,537,491
Ensembl chr 2:152,601,680...152,847,318 		JBrowse link
G Vgll1 vestigial-like family member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA
panobinostat results in increased expression of VGLL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:140,016,938...140,036,348 JBrowse link
G Vgll3 vestigial-like family member 3 increases expression
multiple interactions 		ISO panobinostat results in increased expression of VGLL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:3,642,993...3,692,590
Ensembl chr11:17,089,597...17,138,937 		JBrowse link
G Wdr72 WD repeat domain 72 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA
panobinostat results in increased expression of WDR72 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:83,718,897...83,902,128
Ensembl chr 8:83,718,914...83,900,286 		JBrowse link
G Wfdc17 WAP four-disulfide core domain 17 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA
panobinostat results in decreased expression of KAL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:69,059,451...69,060,298 JBrowse link
G Wfdc2 WAP four-disulfide core domain 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA
panobinostat results in increased expression of WFDC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:173,706,091...173,735,055
Ensembl chr 3:173,706,460...173,712,161 		JBrowse link
G Wls Wnt ligand secretion mediator multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA CTD PMID:27188386 NCBI chr 2:251,590,653...251,705,991
Ensembl chr 2:251,590,614...251,706,380 		JBrowse link
G Wnt10b Wnt family member 10B multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA
panobinostat results in increased expression of WNT10B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:131,801,046...131,806,850
Ensembl chr 7:131,801,046...131,806,850 		JBrowse link
G Wnt3 Wnt family member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA
Panobinostat results in increased expression of WNT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:89,180,224...89,224,195
Ensembl chr10:89,216,801...89,224,195 		JBrowse link
G Wnt4 Wnt family member 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA
panobinostat results in increased expression of WNT4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128 		JBrowse link
G Wnt5a Wnt family member 5A multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA
panobinostat results in decreased expression of WNT5A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860 		JBrowse link
G Wnt5b Wnt family member 5B multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA
panobinostat results in decreased expression of WNT5B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:154,281,852...154,406,081
Ensembl chr 4:154,281,852...154,405,681 		JBrowse link
G Wnt6 Wnt family member 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA CTD PMID:27188386 NCBI chr 9:83,778,552...83,792,186
Ensembl chr 9:83,778,552...83,792,186 		JBrowse link
G Wnt8a Wnt family member 8A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA CTD PMID:27188386 NCBI chr18:26,411,833...26,417,426
Ensembl chr18:26,411,833...26,417,426 		JBrowse link
G Wwc1 WW and C2 domain containing 1 increases expression
multiple interactions 		ISO panobinostat results in increased expression of WWC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:20,804,173...20,958,437
Ensembl chr10:20,799,237...20,958,437 		JBrowse link
G Xcl1 X-C motif chemokine ligand 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of XCL1 mRNA CTD PMID:21791302 NCBI chr13:79,781,784...79,785,440
Ensembl chr13:79,781,784...79,785,440 		JBrowse link
G Xkr4 XK related 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA CTD PMID:27188386 NCBI chr 5:20,694,433...21,095,350
Ensembl chr 5:20,693,966...21,080,579 		JBrowse link
G Xkrx XK related, X-linked multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA CTD PMID:27188386 NCBI chr  X:101,634,438...101,733,814
Ensembl chr  X:101,635,283...101,646,461 		JBrowse link
G Yap1 Yes1 associated transcriptional regulator increases expression
multiple interactions 		ISO panobinostat results in increased expression of YAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:13,380,551...13,451,437 		JBrowse link
G Ypel1 yippee-like 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA CTD PMID:27188386 NCBI chr11:97,426,012...97,440,646 JBrowse link
G Zbtb1 zinc finger and BTB domain containing 1 decreases expression ISO Panobinostat results in decreased expression of ZBTB1 mRNA CTD PMID:33770205 NCBI chr 6:100,832,506...100,864,019
Ensembl chr 6:100,838,714...100,852,643 		JBrowse link
G Zbtb16 zinc finger and BTB domain containing 16 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA
panobinostat results in decreased expression of ZBTB16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:57,885,886...58,073,507
Ensembl chr 8:57,891,081...58,073,507 		JBrowse link
G Zc3h12c zinc finger CCCH type containing 12C decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ZC3H12C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:61,340,446...61,404,932
Ensembl chr 8:61,345,271...61,400,610 		JBrowse link
G Zc3h6 zinc finger CCCH type containing 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA CTD PMID:27188386 NCBI chr 3:116,203,466...116,254,186
Ensembl chr 3:136,657,414...136,706,504 		JBrowse link
G Zeb1 zinc finger E-box binding homeobox 1 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ZEB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745 		JBrowse link
G Zfp14 ZFP14 zinc finger protein multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA
panobinostat results in decreased expression of ZFP14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:94,396,055...94,413,338
Ensembl chr 1:94,396,057...94,413,534 		JBrowse link
G Zfp2 zinc finger protein 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA CTD PMID:27188386 NCBI chr10:35,701,303...35,729,861
Ensembl chr10:35,702,151...35,730,108 		JBrowse link
G Zfp280c zinc finger protein 280C increases expression ISO Panobinostat results in increased expression of ZNF280C mRNA CTD PMID:33770205 NCBI chr  X:132,594,279...132,685,548
Ensembl chr  X:132,594,292...132,685,841 		JBrowse link
G Zfp287 zinc finger protein 287 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA CTD PMID:27188386 NCBI chr10:47,896,517...47,914,860
Ensembl chr10:47,896,517...47,914,950 		JBrowse link
G Zfp36l2 zinc finger protein 36, C3H type-like 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA
panobinostat results in increased expression of ZFP36L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:16,242,610...16,246,653 		JBrowse link
G Zfp385b zinc finger protein 385B multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA
panobinostat results in decreased expression of ZNF385B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:82,762,387...83,140,856
Ensembl chr 3:82,762,387...83,084,615 		JBrowse link
G Zfp385d zinc finger protein 385D multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA
panobinostat results in decreased expression of ZNF385D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:7,473,431...7,854,364
Ensembl chr15:7,473,435...8,504,582 		JBrowse link
G Zfp386 zinc finger protein 386 (Kruppel-like) multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA
panobinostat results in decreased expression of ZNF519 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:143,109,563...143,124,266
Ensembl chr 6:143,109,610...143,127,027 		JBrowse link
G Zfp42 zinc finger protein 42 increases expression
multiple interactions 		ISO panobinostat results in increased expression of ZFP42 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:55,568,903...55,577,883
Ensembl chr16:55,568,093...55,578,170
Ensembl chr 4:55,568,093...55,578,170 		JBrowse link
G Zfp46 zinc finger protein 46 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA
panobinostat results in decreased expression of ZNF436 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:153,802,887...153,813,388
Ensembl chr 5:153,802,834...153,812,941 		JBrowse link
G Zfp462 zinc finger protein 462 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF462 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF462 mRNA] CTD PMID:26733615 NCBI chr 5:74,465,383...74,606,020
Ensembl chr 5:74,468,643...74,606,020 		JBrowse link
G Zfp483 zinc finger protein 483 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA
panobinostat results in decreased expression of ZNF483 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:73,763,201...73,780,511
Ensembl chr 5:78,558,304...78,575,552 		JBrowse link
G Zfp503 zinc finger protein 503 multiple interactions
decreases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA
panobinostat results in decreased expression of ZNF503 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:2,362,450...2,366,238
Ensembl chr15:2,362,427...2,366,238 		JBrowse link
G Zfp521 zinc finger protein 521 decreases expression
multiple interactions 		ISO panobinostat results in decreased expression of ZNF521 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:5,050,297...5,343,188
Ensembl chr18:5,056,236...5,343,054 		JBrowse link
G Zfp804a zinc finger protein 804A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA CTD PMID:27188386 NCBI chr 3:87,440,496...87,670,872
Ensembl chr 3:87,197,582...87,670,869 		JBrowse link
G Zfp827 zinc finger protein 827 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF827 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF827 mRNA] CTD PMID:26733615 NCBI chr19:45,624,849...45,791,739
Ensembl chr19:45,614,604...45,844,430 		JBrowse link
G Zic1 Zic family member 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of ZIC1 mRNA CTD PMID:21791302 NCBI chr 8:100,785,282...100,797,716
Ensembl chr 8:100,787,789...100,792,427 		JBrowse link
G Zic3 Zic family member 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA
panobinostat results in increased expression of ZIC3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:141,159,623...141,165,587
Ensembl chr  X:141,149,594...141,170,464 		JBrowse link
G Zmym2 zinc finger MYM-type containing 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA CTD PMID:27188386 NCBI chr15:35,151,356...35,224,528
Ensembl chr15:35,127,994...35,224,941 		JBrowse link
G Zmynd8 zinc finger, MYND-type containing 8 multiple interactions
affects expression 		ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZMYND8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZMYND8 mRNA] CTD PMID:26733615 NCBI chr 3:174,948,162...175,061,382
Ensembl chr 3:174,948,537...175,061,571 		JBrowse link
G Znf750 zinc finger protein 750 multiple interactions
increases expression 		ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA
panobinostat results in increased expression of ZNF750 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:107,270,926...107,279,904
Ensembl chr10:107,270,763...107,279,300 		JBrowse link
G Zranb3 zinc finger RANBP2-type containing 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA CTD PMID:27188386 NCBI chr13:41,993,110...42,148,298
Ensembl chr13:41,992,922...42,148,274 		JBrowse link
G Zyg11a zyg-11 family member A, cell cycle regulator increases expression
multiple interactions 		ISO panobinostat results in increased expression of ZYG11A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:128,163,732...128,202,462
Ensembl chr 5:128,164,884...128,202,481 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20862
    role 20820
      application 20621
        pharmaceutical 20416
          drug 20416
            antineoplastic agent 18066
              panobinostat 1295
Path 2
Term Annotations click to browse term
  CHEBI ontology 20862
    subatomic particle 20860
      composite particle 20860
        hadron 20860
          baryon 20860
            nucleon 20860
              atomic nucleus 20860
                atom 20860
                  main group element atom 20781
                    p-block element atom 20781
                      carbon group element atom 20715
                        carbon atom 20710
                          organic molecular entity 20710
                            heteroorganic entity 20219
                              organochalcogen compound 19904
                                organooxygen compound 19806
                                  carbon oxoacid 19155
                                    carboxylic acid 19152
                                      carboacyl group 18085
                                        univalent carboacyl group 18085
                                          carbamoyl group 17921
                                            carboxamide 17921
                                              alpha,beta-unsaturated carboxylic acid amide 7298
                                                enamide 7298
                                                  cinnamamides 1355
                                                    panobinostat 1295
paths to the root